Reaxys
PubChem
eMolecules
Reactions (368)
Substances (168)
Structure
Citations (3449)
Structure/Compound Data Chemical Name: methamphetamin Reaxys Registry Number: 1072499
CAS Registry Number: 7632-10-2 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C6H5CH2CH(NHCH3)CH3
Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N
1
N° of preparations All Preps | All Reactions
Available Data
N° of ref.
60 prep out of 139 reactions.
Identification Physical Data (50) Spectra (31) Bioactivity (108) Other Data (15)
1289
55 prep out of 101 reactions.
Identification Physical Data (46) Spectra (32) Bioactivity (283) Other Data (72)
640
Synthesize | Show Details Find similar Chemical Name: Methamphetamin Reaxys Registry Number: 2207147
CAS Registry Number: 537-46-2 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-VIFPVBQESA-N
2
Synthesize | Show Details Find similar
Chemical Name: (R)-2-methylamino-1-phenylpropane Reaxys Registry Number: 3081879
CAS Registry Number: 33817-09-3 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-SECBINFHSA-N
3
40 prep out of 59 reactions.
Identification Physical Data (21) Spectra (13) Bioactivity (47) Other Data (3)
74
1 prep out of 1 reactions.
Identification Physical Data (1) Bioactivity (3)
5
Synthesize | Show Details Find similar Chemical Name: (+)-N-methylamphetamine Reaxys Registry Number: 5248384
CAS Registry Number: 537-46-2, 4846-07-5, 7632-10-2, 33817-09-3 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N
4
Synthesize | Hide Details Find similar Chemical Names and Synonyms (+)-N-methylamphetamine, (+)-methamphetamine, d-Methamphetamine, (+)-2-methylamino-1-phenyl-propane Identification Substance Label (3) Label
Reference
(+)-13
Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.
Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details
(+)-II/III
Acs, Maria; Kozma, David; Fogassy, Elemer
ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details
6i
Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian
Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details
Derivative (1) Comment (Derivative)
Reference
By formation of salt/complex with dilituric acid. Additional data: optical crystallographic properties
Julian; Plein
Journal of Pharmaceutical Sciences, 1981 , vol. 70, # 6 p. 704 - 707 Title/Abstract Full Text View citing articles Show Details
Purification (1) Purification (method)
Reference
via salt with sodium-hydrogen-R,R-tartrate
Acs, Maria; Kozma, David; Fogassy, Elemer
ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details
Physical Data Optical Rotatory Power (1) Type (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
[alpha]
neat (no solvent)
3.32 deg
589 nm
Reference Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian
Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (3) 1 of 3
2 of 3
3 of 3
Comment (Pharmacological Data)
Bioactivities present
Reference
Drabowicz, Jozef; Legedz, Slawomir; Mikolajczik, Marian
Tetrahedron, 1988 , vol. 44, # 16 p. 5243 - 5252 Title/Abstract Full Text View citing articles Show Details
Kaufmann; Hofmann; Kreiskott
Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 2 p. 335 - 337 Title/Abstract Full Text View citing articles Show Details
Julian; Plein
Journal of Pharmaceutical Sciences, 1981 , vol. 70, # 6 p. 704 - 707 Title/Abstract Full Text View citing articles Show Details
Acs, Maria; Kozma, David; Fogassy, Elemer
ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details
Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.
Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
locomotor stimulant
Species or TestSystem (Pharmacological Data)
albino ICR mice
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.5 - 2 mg/kg
Kind of Dosing (Pharmacological Data)
0.5, 1.0, and 2.0 mg/kg
Exposure Period (Pharmacological Data)
10 - 40 min
Method (Pharmacological Data)
mouse weight 25-30 g; acclimated for 30 min before treatment; experiments performed between 8.00 and 17.00 h; multiple doses; locomotor activity measured as distance traversed (in cm), recorded by computerized video tracking behavior recognition system
Results
dose-related increase in locomotor stimulation, 2 mg/kg produced 625 percent increase over saline-treated controls
Reference
Malmusi, Luca; Dukat, Malgorzata; Young, Richard; Teitler, Milt; Darmani, Nissar A.; Ahmad, Bashir; Smith, Carol; Glennon, Richard A.
Medicinal Chemistry Research, 1996 , vol. 6, # 6 p. 400 - 411 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
anorexigenic effect; reduces food intake from 9 to 0 g/h (0.5 - 2 mg/kg, rat)
Reference
Kaufmann; Hofmann; Kreiskott
Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 2 p. 335 - 337 Title/Abstract Full Text View citing articles Show Details
Chemical Name: methamphetamine
no reactions.
Reaxys Registry Number: 6269621
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N
Physical Data (4) Bioactivity (3)
5
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine, Methamphetamin Physical Data Dissociation Exponent (1) Type (Dissociation Exponent)
Reference
b1/apparent
Muller
Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details
Electrochemical Behaviour (1) Description (Electrochemical Behaviour)
Reference
Electrolytic dissociation / protonation equilibrium
Muller
Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details
Liquid/Liquid Systems (MCS) (2) Description (Liquid/Liquid Systems (MCS))
Partner (Liquid/Liquid Systems (MCS))
Reference
Distribution between solvent 1 + 2
1) aqueous buffer solution 2) ether
Muller
Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details
Distribution between solvent 1 + 2
1) aqueous buffer solution 2) CHCl3
Muller
Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (3) 1 of 3
Comment (Pharmacological Data)
Bioactivities present
Reference
Wollweber; Hiltman; Stoepel; Kroneberg
European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 111 - 117 Title/Abstract Full Text View citing articles Show Details
Bekemeier; Wenzel
Pharmazie, 1989 , vol. 44, # 11 p. 781 - 783 Title/Abstract Full Text View citing articles Show Details
Teschendorf; Kretzschmar; Kreiskott; Weifenbach
Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 9 A p. 1580 - 1588 Title/Abstract Full Text View citing articles Show Details
Muller
Pharmazie, 1983 , vol. 38, # 9 p. 596 - 597 Title/Abstract Full Text View citing articles Show Details
Little; Rees
Journal of Pharmacy and Pharmacology, 1980 , vol. 32, # 11 p. 751 - 756 Title/Abstract Full Text View citing articles Show Details
Testa; Salvesen
23
Journal of Pharmaceutical Sciences, 1980 , vol. 69, # 5 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
Comai; Sullivan
Journal of Pharmaceutical Sciences, 1982 , vol. 71, # 4 p. 418 - 421 Title/Abstract Full Text View citing articles Show Details
Kita, Taizo; Philbert, Martin A.; Wagner, George C.; Huang, Jian; Lowndes, Herbert E.
Pharmacology and Toxicology, 1998 , vol. 83, # 1 p. 36 - 39 Title/Abstract Full Text View citing articles Show Details
Seager
Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 4 p. 375 - 382 Title/Abstract Full Text View citing articles Show Details
Nakahara, Yuji; Kikura, Ruri
Archives of Toxicology, 1996 , vol. 70, # 12 p. 841 - 849 Title/Abstract Full Text View citing articles Show Details
Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek
Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details
Nakahara, Yuji; Kikura, Ruri
Biological and Pharmaceutical Bulletin, 1997 , vol. 20, # 9 p. 969 - 972 Title/Abstract Full Text View citing articles Show Details
Sekine; Nagao; Nakahara
Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details
Kita, Taizo; Takahashi, Masahiro; Kubo, Kaoru; Wagner, George C.; Nakashima, Toshikatsu
Pharmacology and Toxicology, 1999 , vol. 85, # 3 p. 133 - 137 Title/Abstract Full Text View citing articles Show Details
Fleckenstein, Annette E.; Metzger, Ryan R.; Wilkins, Diana G.; Gibb, James W.; Hanson, Glen R.
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 282, # 2 p. 834 - 838 Title/Abstract Full Text View citing articles Show Details
Jozwiak, Krzysztof; Ravichandran, Sarangan; Collins, Jack R.; Wainer, Irving W.
Journal of Medicinal Chemistry, 2004 , vol. 47, # 16 p. 4008 - 4021 Title/Abstract Full Text View citing articles Show Details
Partilla, John S.; Dempsey, Allison G.; Nagpal, Ameet S.; Blough, Bruce E.; Baumann, Michael H.; Rothman, Richard B.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 237 - 246 Title/Abstract Full Text View citing articles Show Details
Mendelson, John; Uemura, Naoto; Harris, Debra; Nath, Rajneesh P.; Fernandez, Emilio; Jacob III, Peyton; Everhart, E. Thomas; Jones, Reese T.
Clinical Pharmacology and Therapeutics, 2006 , vol. 80, # 4 p. 403 - 420 Title/Abstract Full Text View citing articles Show Details
Banks, Matthew L.; Blough, Bruce E.; Negus, S. Stevens
Behavioural Pharmacology, 2011 , vol. 22, # 8 p. 824 - 836 Title/Abstract Full Text View citing articles Show Details
D'Almeida; Camarini; Azzalis; Mattei; Junqueira; Carlini
Toxicology Letters, 1995 , vol. 81, # 2-3 p. 101 - 105 Title/Abstract Full Text Show Details
2 of 3
Comment (Pharmacological Data)
Bioactivities present
Reference
Roberts; Harbison; Westhouse; James
Toxicology Letters, 1995 , vol. 76, # 1 p. 77 - 83 Title/Abstract Full Text Show Details
Chu; Nordeen; Hardy; Swanson; Giardina; Pernet; Plattner
Journal of Medicinal Chemistry, 1991 , vol. 34, # 1 p. 168 - 174 Title/Abstract Full Text Show Details
PIKULEVA, Irina, A.; MAST, Natalia, V.
Patent: WO2008/153722 A1, 2008 ; Title/Abstract Full Text Show Details
3 of 3
Comment (Pharmacological Data)
mortality after 2h, 4h and 24 h (female NMRI mice, 21.5 mg/kg p.o.): 5/10, 8/10, 9/10 (in groups); 0/10, 0/10, 1/10 (single)
Reference
Teschendorf; Kretzschmar; Kreiskott; Weifenbach
Arzneimittel-Forschung/Drug Research, 1981 , vol. 31, # 9 A p. 1580 - 1588 Title/Abstract Full Text View citing articles Show Details
Reaxys Registry Number: 7410286
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N
6
1 prep out of 1 reactions.
Identification
1
Synthesize | Hide Details Find similar
Identification Substance Label (1) Label
Reference
(-)-II/III
Acs, Maria; Kozma, David; Fogassy, Elemer
ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details
Purification (1) Purification (method)
Reference
via salt with sodium-hydrogen-R,R-tartrate
Acs, Maria; Kozma, David; Fogassy, Elemer
ACH - Models in Chemistry, 1995 , vol. 132, # 3 p. 475 - 478 Title/Abstract Full Text Show Details
Chemical Name: L-methamphetamine
no reactions.
Reaxys Registry Number: 9387147
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H15N Molecular Weight: 149.236
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-N 7
Synthesize | Hide Details Find similar Chemical Names and Synonyms L-methamphetamine Identification Substance Label (1) Label
Reference
L-MAMP
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (5) 1 of 5
2 of 5
Comment (Pharmacological Data)
Bioactivities present
Reference
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
nicotine metabolism, examination of
Species or TestSystem (Pharmacological Data)
CYP2A6 of mouse
Identification Bioactivity (5)
1
3 of 5
4 of 5
5 of 5
Concentration (Pharmacological Data)
10 - 100 μmol/l
Method (Pharmacological Data)
CYP2A6 (20 pM P450/ml plus reductase and cc b5) incubated (15 min, 37 deg C) with mixture, containing title comp., 1 mM NADPH and 100 μM nicotine; reaction stopped with 4percent Na2CO3; samples prepared and analyzed for nicotine and metabolites by HPLC
Further Details (Pharmacological Data)
control: vehicle; internal control: 70 μg 5-methylcotinine; cotinine: product of nicotine oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine; cc: cytochrome
Comment (Pharmacological Data)
No effect
Reference
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
nicotine metabolism, inhibition of
Species or TestSystem (Pharmacological Data)
CYP2A5 of mouse
Concentration (Pharmacological Data)
10 - 100 μmol/l
Method (Pharmacological Data)
CYP2A5 (60 pM P450/ml, reductase and cc b5) incubated (15 min, 37 deg C) with mixture, containing title comp., 1 mM NADPH and 60 μM nicotine; reaction stopped with 4percent Na2CO3; samples prepared and analyzed for nicotine and metabolites by HPLC system
Further Details (Pharmacological Data)
control: vehicle; internal control: 70 μg 5-methylcotinine; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine; cc: cytochrome
Results
title comp. dose-dep. inhibited nicotine metabolism (formation of cotinine) of CYP2A5; at 100 μM title comp.inhibited nicotine metabolism by ca. 45percent; fig.
Reference
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
nicotine metabolism, inhibition of
Species or TestSystem (Pharmacological Data)
liver microsomes of DBA/2 mouse
Concentration (Pharmacological Data)
10 - 100 μmol/l
Method (Pharmacological Data)
MLMs (0.5 mg/ml protein) incubated for 15 min at 37 deg C with mixture, containing title comp., 1 mM NADPH and 10 μM nicotine; reaction stopped with 4percent Na2CO3; then samples prepared and analyzed for nicotine and metabolites by HPLC system
Further Details (Pharmacological Data)
control: vehicle; internal control: 5-methylcotinine; MLMs: mouse liver microsomes; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine
Results
title comp. dose-dep. inhibited nicotine metabolism (formation of cotinine); at 100 μM inhibition was ca. 45percent; fig.
Reference
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
nicotine metabolism, examination of
Species or TestSystem (Pharmacological Data)
liver microsomes of human
Concentration (Pharmacological Data)
10 - 100 μmol/l
Method (Pharmacological Data)
HLMs (0.5 mg/ml protein) incubated for 20 min at 37 deg C with mixture, containing title comp., 1 mM NADPH and 20 μM nicotine; reaction stopped with 4percent Na2CO3; then samples prepared and analyzed for nicotine and metabolites by HPLC system
Further Details (Pharmacological Data)
control: vehicle; internal control: 5-methylcotinine; HLMs: human liver microsomes; cotinine: product of nicotine C-oxidation; HPLC: high performance liquid chromatography; limits of quantification: 5 ng/ml for nicotine and 12.5 ng/ml for cotinine
Comment (Pharmacological Data)
No effect
Reference
Siu, Eric C. K.; Tyndale, Rachel F.
Journal of Pharmacology and Experimental Therapeutics, 2008 , vol. 324, # 3 p. 992 - 999 Title/Abstract Full Text View citing articles Show Details
Chemical Name: (1R,2S)-2-(Methylamino)-1-deuterio-1-phenylpropane
2 prep out of 2 reactions.
Reaxys Registry Number: 6920257
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H14DN Molecular Weight: 150.228
InChI Key: MYWUZJCMWCOHBA-KENKBMNRSA-N
Identification Physical Data (2) Spectra (6)
1
8
Synthesize | Hide Details Find similar Chemical Names and Synonyms (1R,2S)-2-(Methylamino)-1-deuterio-1-phenylpropane Identification Substance Label (1) Label
Reference
12b
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Physical Data Boiling Point (1) Boiling Point
Pressure (Boiling Point)
Reference
37 - 41 °C
0.1 Torr
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
2.07 g/100ml
CH2Cl2
2.61 deg
589 nm
25 °C
Spectra NMR Spectroscopy (4)
Reference Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
Comment (NMR Spectroscopy)
Chemical shifts
1H
CDCl3
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
CDCl3
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Reference
Spin-spin coupling constants
CDCl3
1H-1H
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Spin-spin coupling constants
CDCl3
2D-13C.
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
IR Spectroscopy (1) Description (IR Spectroscopy)
Solvent (IR Spectroscopy)
Comment (IR Spectroscopy)
Reference
Bands
neat (no solvent)
3300 cm**(-1)
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Mass Spectrometry (1) Description (Mass Spectrometry)
Reference
spectrum
Almena, Juan; Foubelo, Francisco; Yus, Miguel
Journal of Organic Chemistry, 1994 , vol. 59, # 11 p. 3210 - 3215 Title/Abstract Full Text View citing articles Show Details
Chemical Name: D, methamphetamine
no reactions.
2
3 prep out of 10 reactions.
1
Reaxys Registry Number: 29823490
Molecular Formula: C10H15N Linear Structure Formula: C10H14(2)HN
Molecular Weight: 150.228
InChI Key: MYWUZJCMWCOHBA-VMNATFBRSA-N
9
Synthesize | Hide Details Find similar Chemical Names and Synonyms D, methamphetamine, methamphetamine-D Reaxys Registry Number: 3943810
Type of Substance: isocyclic Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)
Molecular Weight: 150.244
InChI Key: MYWUZJCMWCOHBA-UHFFFAOYSA-O
10
Synthesize Find similar Reaxys Registry Number: 26132956
Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)
no reactions.
Bioactivity (1)
1
no reactions.
Bioactivity (1)
1
Molecular Weight: 150.244
InChI Key: MYWUZJCMWCOHBA-SECBINFHSA-O
11
Synthesize | Hide Details Find similar
Bioactivity Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Reference
Magyar; Palfi; Tabi; Kalasz; Szende; Szoeko
Current Medicinal Chemistry, 2004 , vol. 11, # 15 p. 2017 - 2031 Title/Abstract Full Text View citing articles Show Details
Reaxys Registry Number: 26132957
CAS Registry Number: 1551249-69-4 Molecular Formula: C10H15N*H Linear Structure Formula: C10H15N*H(1+)
Molecular Weight: 150.244
InChI Key: MYWUZJCMWCOHBA-VIFPVBQESA-O
12
Synthesize | Hide Details Find similar
Bioactivity Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Magyar; Palfi; Tabi; Kalasz; Szende; Szoeko
Current Medicinal Chemistry, 2004 , vol. 11, # 15 p. 2017 - 2031 Title/Abstract Full Text View citing articles Show Details
Reference
Chemical Name: (13)C,(15)N-methamphetamine Reaxys Registry Number: 12690028
Molecular Formula: C10H15N Linear Structure Formula: C9(13)CH15(15)N
1 prep out of 1 reactions.
Identification
1
1 prep out of 1 reactions.
1
1 prep out of 1 reactions.
1
Molecular Weight: 151.218
InChI Key: MYWUZJCMWCOHBA-OMUUITEASA-N
13
Synthesize | Hide Details Find similar Chemical Names and Synonyms (13)C,(15)N-methamphetamine Identification Substance Label (1) Label
Reference
a-19
DR PHARMA NOVA, LLC
Patent: WO2006/91885 A2, 2006 ; Title/Abstract Full Text Show Details
Patent-Specific Data (1) Related Markush Structure (RN)
Reference
12690024
DR PHARMA NOVA, LLC
Patent: WO2006/91885 A2, 2006 ; Title/Abstract Full Text Show Details
Chemical Name: S-(+)-[2H2]methamphetamine Reaxys Registry Number: 9758471
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H13D2N Molecular Weight: 151.22
InChI Key: MYWUZJCMWCOHBA-FPCJZCRGSA-N
14
Synthesize | Hide Details Find similar Chemical Names and Synonyms S-(+)-[2H2]methamphetamine Chemical Name: d-methamphetamine-d3
Reaxys Registry Number: 9758470
Type of Substance: isocyclic Molecular Formula: C H N
10 15
Linear Structure Formula: C10H12D3N Molecular Weight: 152.212
InChI Key: MYWUZJCMWCOHBA-XYFUXNRQSA-N
15
Synthesize | Hide Details Find similar Chemical Names and Synonyms d-methamphetamine-d3, S-(+)-[2H3]methamphetamine Chemical Name: (R)-N-d3-methyl-1-phenylpropan-2-amine
1 prep out of 2 reactions.
Reaxys Registry Number: 20920682
CAS Registry Number: 1254494-15-9 Molecular Formula: C10H15N Linear Structure Formula: C10H12(2)H3N
Physical Data (1) Spectra (2)
1
Molecular Weight: 152.212
InChI Key: MYWUZJCMWCOHBA-NNKNZJFPSA-N
16
Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-N-d3-methyl-1-phenylpropan-2-amine Physical Data Crystal Property Description (1) Colour & Other Properties
Location
Reference
colorless
Page/Page column 11
AUSPEX PHARMACEUTICALS, INC.
Patent: US2010/286124 A1, 2010 ; Title/Abstract Full Text Show Details
Spectra NMR Spectroscopy (1) Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
1H
chloroform-d1
Original Text (NMR Spectroscopy)
Location
1H-NMR
Page/Page column 11
(CDCl3): δ1.05 (d, J=6.9 Hz, 3H), 1.40 (br s, 1H), 2.61
(m, 1H), 2.70 (m, 1H), 2.78 (m, 1H), 7.10-7.32 (m, 5H)
Comment (NMR Spectroscopy) Signals given
Reference AUSPEX PHARMACEUTICALS, INC.
Patent: US2010/286124 A1, 2010 ; Title/Abstract Full Text Show Details
Mass Spectrometry (1) Location
Reference
AUSPEX PHARMACEUTICALS, INC.
Patent: US2010/286124 A1, 2010 ;
Page/Page column 11
Title/Abstract Full Text Show Details
Chemical Name: (S)-[2',6'-(3)H2]methamphetamine Reaxys Registry Number: 20382968
CAS Registry Number: 1207183-39-8 Molecular Formula: C10H15N Linear Structure Formula: C10H13(3)H2N
1 prep out of 1 reactions.
1
1 prep out of 2 reactions.
Identification Physical Data (1) Spectra (2)
4
Molecular Weight: 153.22
InChI Key: MYWUZJCMWCOHBA-CJTMEMAZSA-N
17
Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-[2',6'-(3)H2]methamphetamine Chemical Name: 1-phenyl-2-methyl-d3-aminopropane-1,2-d2 Reaxys Registry Number: 2975553
CAS Registry Number: 60124-88-1 Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H10D5N Molecular Weight: 154.196
InChI Key: MYWUZJCMWCOHBA-CXVYKYTNSA-N
18
Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methyl-d3-aminopropane-1,2-d2, methamphetamine-D5, Methamphetamine-d5 Identification Substance Label (1) Label
Reference
I
Fentiman; Foltz
Journal of Labelled Compounds and Radiopharmaceuticals, 1976 , vol. 12, p. 69,74 Full Text Show Details
Derivative (1)
Comment (Derivative)
Reference
Hydrochlorid; F: 133-134grad
Fentiman; Foltz
Journal of Labelled Compounds and Radiopharmaceuticals, 1976 , vol. 12, p. 69,74 Full Text Show Details
Physical Data Chromatographic Data (1) Chromatographic data
Reference
Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman
Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details
LC (Liquid chromatography)
Spectra Mass Spectrometry (2) Description (Mass Spectrometry)
Reference
tandem mass spectrometry electrospray ionisation (ESI) high resolution mass spectrometry (HRMS) spectrum
Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman
Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details
electrospray ionisation (ESI) high resolution mass spectrometry (HRMS) spectrum
Fedorova, Ganna; Randak, Tomas; Lindberg, Richard H.; Grabic, Roman
Rapid Communications in Mass Spectrometry, 2013 , vol. 27, # 15 p. 1751 - 1762 Title/Abstract Full Text View citing articles Show Details
Chemical Name: methamphetamine-d5
no reactions.
Identification Spectra (1)
1
Reaxys Registry Number: 30060469
Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N
Molecular Weight: 154.196
InChI Key: MYWUZJCMWCOHBA-FIJCCKCHSA-N
19
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-d5
Identification Substance Label (1) Label
Reference
MAd5
Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil
Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details
Spectra Mass Spectrometry (1) Description (Mass Spectrometry) electrospray ionisation (ESI) liquid chromatography mass spectrometry (LCMS) tandem mass spectrometry spectrum
Location
Reference
supporting information
Earla, Ravinder; Kumar, Santosh; Wang, Lei; Bosinger, Steven; Li, Junhao; Shah, Ankit; Gangwani, Mohitkumar; Nookala, Anantha; Liu, Xun; Cao, Lu; Jackson, Austin; Silverstein, Peter S.; Fox, Howard S.; Li, Weihua; Kumar, Anil
Drug Metabolism and Disposition, 2014 , vol. 42, # 12 p. 2097 - 2108 Title/Abstract Full Text Show Details
Chemical Name: methamphetamine-D5 Reaxys Registry Number: 30195335
Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N
no reactions.
6
Molecular Weight: 154.196
InChI Key: MYWUZJCMWCOHBA-QIYJHHKOSA-N
20
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-D5 Chemical Name: methamphetamine-d5
no reactions.
Spectra (1)
1
Reaxys Registry Number: 30549854
Molecular Formula: C10H15N Linear Structure Formula: C10H10(2)H5N
Molecular Weight: 154.196
InChI Key: MYWUZJCMWCOHBA-DKFMXDSJSA-N
21
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-d5 Spectra Mass Spectrometry (1) Description (Mass Spectrometry) electrospray ionisation (ESI) spectrum
Reference Paíga, Paula; Rodrigues, Manuela J.E.; Correia, Manuela; Amaral, Joana S.; Oliveira, M. Beatriz P.P.; Delerue-Matos, Cristina
European Journal of Pharmaceutical Sciences, 2017 , vol. 99, p. 219 - 227 Title/Abstract Full Text Show Details
Chemical Name: DL-[13C6]-methamphetamine Reaxys Registry Number: 26969029
Molecular Formula: C10H15N Linear Structure Formula: C4(13)C6H15N
Molecular Weight: 155.17
InChI Key: MYWUZJCMWCOHBA-RKQYQYHUSA-N
22
Synthesize | Hide Details Find similar
1 prep out of 2 reactions.
Identification
1
Chemical Names and Synonyms DL-[13C6]-methamphetamine Identification Patent-Specific Data (1) Related Markush Structure (RN)
Reference
30665511
CHIRON AS; Johansen, Jon Eigill; Liu, Huiling; Karlsen, Morten
Patent: US9435816 B2, 2016 ; Title/Abstract Full Text Show Details
Chemical Name: 1-phenyl-2-methylaminopropane-1,1,2,3,3,3-d6 Reaxys Registry Number: 7532918
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H9D6N Molecular Weight: 155.188
InChI Key: MYWUZJCMWCOHBA-KLJQIKPOSA-N
23
0 prep out of 2 reactions.
1
0 prep out of 2 reactions.
1
no reactions.
1
Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methylaminopropane-1,1,2,3,3,3-d6 Chemical Name: 1-phenyl-2-methyl-d3-aminopropane-1,2,3,3,3-d5 Reaxys Registry Number: 7535408
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H7D8N Molecular Weight: 157.172
InChI Key: MYWUZJCMWCOHBA-URFKORASSA-N
24
Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-2-methyl-d3-aminopropane-1,2,3,3,3-d5 Chemical Name: methamphetamine-D9
Reaxys Registry Number: 30638606
Molecular Formula: C10H15N Linear Structure Formula: C10H6(2)H9N
25
Molecular Weight: 158.164
InChI Key: MYWUZJCMWCOHBA-FUUWYYHRSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine-D9
Chemical Name: 1-phenyl-d5-2-methyl-d3-aminopropane-3,3,3-d3 Reaxys Registry Number: 7539213
Type of Substance: isocyclic Molecular Formula: C10H15N Linear Structure Formula: C10H4D11N Molecular Weight: 160.148
InChI Key: MYWUZJCMWCOHBA-JFZRXOORSA-N
26
0 prep out of 2 reactions.
1
no reactions.
19
no reactions.
10
Synthesize | Hide Details Find similar Chemical Names and Synonyms 1-phenyl-d5-2-methyl-d3-aminopropane-3,3,3-d3 Chemical Name: methane ice Reaxys Registry Number: 30156167
Molecular Formula: CH4*C10H15N Linear Structure Formula: CH4*C10H15N Molecular Weight: 165.279
InChI Key: JPKWQXJAZOTHAQ-FVGYRXGTSA-N
27
Synthesize | Hide Details Find similar Chemical Names and Synonyms methane ice Chemical Name: ammonia ice Reaxys Registry Number: 30204741
Molecular Formula: C10H15N*H3N Linear Structure Formula: C10H15N*H3N Molecular Weight: 166.266
InChI Key: YJWVKGVRRKFJIZ-FVGYRXGTSA-N
28
Synthesize | Hide Details Find similar Chemical Names and Synonyms ammonia ice
Chemical Name: (2S)-N-methyl-1-phenylpropan-2-amine hydrate Reaxys Registry Number: 13191660
Molecular Formula: C10H15N*H2O Linear Structure Formula: C10H15N*H2O Molecular Weight: 167.251
InChI Key: JEPOEABJTIMMHD-FVGYRXGTSA-N
29
1 prep out of 8 reactions.
1251
no reactions.
Identification Bioactivity (3)
1
Synthesize | Hide Details Find similar Chemical Names and Synonyms (2S)-N-methyl-1-phenylpropan-2-amine hydrate, ice+water, ice +water, Ice water, Ice H2O Chemical Name: sodium salt of methamphetamine Reaxys Registry Number: 8164135
Type of Substance: isocyclic Molecular Formula: C10H14N*Na Linear Structure Formula: C10H14N(1-)*Na(1+)
Molecular Weight: 171.218
InChI Key: DOEOAPQAINWNIB-UHFFFAOYSA-N
30
Synthesize | Hide Details Find similar Chemical Names and Synonyms sodium salt of methamphetamine Identification Substance Label (1) Label
Reference
MNa
Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek
Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (3) 1 of 3
2 of 3
Comment (Pharmacological Data)
Bioactivities present
Reference
Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek
Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
analgesic, other
Species or TestSystem (Pharmacological Data)
white Wistar rat
Sex
male and female
3 of 3
Route of Application
epicutaneous
Concentration (Pharmacological Data)
18 mg/kg
Kind of Dosing (Pharmacological Data)
test comp. appl. as a paste
Exposure Period (Pharmacological Data)
24 h
Method (Pharmacological Data)
rats weigh. 180-220 g; edema induced by burning of hind paws (60 deg C for 5 sec); decrease in pain sensitivity threshold of inflammed extremities
Further Details (Pharmacological Data)
test comp. applied onto burned surface 2 h after thermal irritation when edema reached 210-215 percent of initial paw volume
Results
23.8-48.1 percent reduction of pain sensitivity threshold
Reference
Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek
Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
antiinflammatory
Species or TestSystem (Pharmacological Data)
white Wistar rat
Sex
male and female
Route of Application
epicutaneous
Concentration (Pharmacological Data)
18 mg/kg
Kind of Dosing (Pharmacological Data)
test comp. appl. as a paste
Exposure Period (Pharmacological Data)
24 h
Method (Pharmacological Data)
rats weigh. 180-220 g; edema induced by burning of hind paws (60 deg C for 5 sec)
Further Details (Pharmacological Data)
test comp. applied onto burned surface 2 h after thermal irritation when edema reached 210-215 percent of initial paw volume
Results
13.5-39.3 percent edema inhibition
Reference
Grigor'eva; Vorotyntsev; Konakhovich; Mokhort; Kirichek
Pharmaceutical Chemistry Journal, 1997 , vol. 31, # 4 p. 170 - 172 Title/Abstract Full Text View citing articles Show Details
Chemical Name: carbon monoxide ice Reaxys Registry Number: 30636987
Molecular Formula: CO*C10H15N Linear Structure Formula: CO*C10H15N Molecular Weight: 177.246
InChI Key: VAQJAOMKVIEPJH-FVGYRXGTSA-N
31
Synthesize | Hide Details
no reactions.
2
Find similar Chemical Names and Synonyms carbon monoxide ice Chemical Name: ethylene ice
no reactions.
no reactions.
1
no reactions.
1
no reactions.
4
Reaxys Registry Number: 30842693
Molecular Formula: C2H4*C10H15N Linear Structure Formula: C2H4*C10H15N Molecular Weight: 177.29
InChI Key: VMFZMCDVULWGCK-FVGYRXGTSA-N
32
Synthesize | Hide Details Find similar Chemical Names and Synonyms ethylene ice Chemical Name: aluminum ice Reaxys Registry Number: 30842761
Molecular Formula: AlH3*C10H15N Linear Structure Formula: AlH3*C10H15N Molecular Weight: 179.241
InChI Key: QZEOTIOXDXGEKT-ZWACTXNCSA-N
33
Synthesize | Hide Details Find similar Chemical Names and Synonyms aluminum ice Chemical Name: formaldehyde ice Reaxys Registry Number: 30786718
Molecular Formula: CH2O*C10H15N Linear Structure Formula: CH2O*C10H15N Molecular Weight: 179.262
InChI Key: SZXXRURPJQVWLY-FVGYRXGTSA-N
34
Synthesize | Hide Details Find similar Chemical Names and Synonyms formaldehyde ice Chemical Name:
ethane ice Reaxys Registry Number: 30159202
Molecular Formula: C2H6*C10H15N Linear Structure Formula: C2H6*C10H15N Molecular Weight: 179.305
InChI Key: RFIMPHSGLJKTCZ-FVGYRXGTSA-N
35
Synthesize | Hide Details Find similar Chemical Names and Synonyms ethane ice Chemical Name: ice methanol
no reactions.
14
no reactions.
Bioactivity (1)
2
Reaxys Registry Number: 29866147
Molecular Formula: CH4O*C10H15N Linear Structure Formula: CH4O*C10H15N Molecular Weight: 181.278
InChI Key: IKIQMUFOYPAWCN-FVGYRXGTSA-N
36
Synthesize | Hide Details Find similar Chemical Names and Synonyms ice methanol, methanol ice Chemical Name: (-)-Metamphetamine phosphate Reaxys Registry Number: 24296479
Molecular Formula: C10H15N*0H3O4P Linear Structure Formula: C10H15N*0.33H3O4P Molecular Weight: 181.574
InChI Key: LERYZJIMAXSLFC-SBSPUUFOSA-N
37
Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-Metamphetamine phosphate Bioactivity Pharmacological Data (1) 1 of 1
Comment (Pharmacological Data)
Bioactivities present
Reference
Campbell; Patil; LaPidus; Campbell; Tye
Title/Abstract Full Text Show Details
LaPidus; Patil; LaPidus; Tye
Title/Abstract Full Text Show Details
Chemical Name: methamphetamine hydroxylamine
no reactions.
1
no reactions.
1
2 prep out of 6 reactions.
Identification Physical Data (21) Spectra (7) Bioactivity (40) Other Data (2)
60
Reaxys Registry Number: 30249430
Molecular Formula: C10H15N*H3NO Linear Structure Formula: C10H15N*H3NO Molecular Weight: 182.266
InChI Key: QSHWSGSYMIEDMV-UHFFFAOYSA-N
38
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine hydroxylamine Chemical Name: ammonia hydrate ice Reaxys Registry Number: 30428298
Molecular Formula: C10H15N*H2O*H3N Linear Structure Formula: C10H15N*H2O*H3N Molecular Weight: 184.282
InChI Key: XFSDUYCHTDEMIL-WWPIYYJJSA-N
39
Synthesize | Hide Details Find similar Chemical Names and Synonyms ammonia hydrate ice Chemical Name: D-methamphetamine hydrochloride Reaxys Registry Number: 4155698
CAS Registry Number: 300-42-5 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697
InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N
40
Synthesize | Hide Details Find similar Chemical Names and Synonyms D-methamphetamine hydrochloride, d-Methamphetamine hydrochloride, Amphedroxyn, methamphetamine hydrochloride, (+/-)-methamphetamine hydrochloride, (+)-methamphetamine hydrochloride, (+-)-methyl-(1-methyl-2-phenyl-ethyl)-amine; hydrochloride
Identification Substance Label (4) Label
Reference
METH
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details
Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon
Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details
MPA*HCl
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Meth
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
MAHCl
Sekine; Nagao; Nakahara
Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details
Patent-Specific Data (1) Location in Patent
Reference
Claim
Alza Corporation
Patent: US3968245 A1, 1976 ; Title/Abstract Full Text Show Details
Men, Tewa; Men, Yangyang
Patent: EP1232748 A1, 2002 ; Title/Abstract Full Text Show Details
Nippon Shinyaju Co., Ltd.
Patent: US5811547 A1, 1998 ; Title/Abstract Full Text Show Details
Cascade Development, Inc.
Patent: US6312728 B1, 2001 ; Title/Abstract Full Text Show Details
Cascade Development, Inc. a subsidiary of Cardinal Health, Inc.
Patent: US5968554 A1, 1999 ; Title/Abstract Full Text Show Details
General Mills, Inc.
Patent: US2002/44968 A1, 2002 ; Title/Abstract Full Text Show Details
Alza Corporation
Patent: US5023088 A1, 1991 ; Title/Abstract Full Text Show Details
Physical Data Melting Point (6)
Melting Point
Solvent (Melting Point)
Reference
129 - 134 °C
de Sarlo,F. et al.
Tetrahedron, 1966 , vol. 22, p. 2989 - 2994 Full Text View citing articles Show Details
135 - 136 °C
acetone
Nishimura; Takamatsu
Yakugaku Zasshi, 1964 , vol. 84, p. 938,943 Chem.Abstr., 1965 , vol. 62, # 2731 Full Text Show Details
134 - 135 °C
Shiho
Nippon Kagaku Kaishi, 1944 , vol. 65, p. 237 Chem.Abstr., 1947 , p. 3800 Full Text Show Details
135 - 136 °C
ethanol diethyl ether
Woodruff; Lambooy; Burt
Journal of the American Chemical Society, 1940 , vol. 62, p. 922 Full Text View citing articles Show Details
133 - 135 °C
ethanol diethyl ether
Novelli
Anales de la Asociacion Quimica Argentina (1921-2001), 1939 , vol. 27, p. 162,164 Chem.Abstr., 1940 , p. 1695 Full Text Show Details
134 - 135 °C
ethanol
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Adsorption (MCS) (1) Description (Adsorption (MCS))
Reference
Adsorption isotherm
Sengling; Guth
Journal of Pharmaceutical Sciences, 1961 , vol. 50, p. 929 Full Text View citing articles Show Details
Association (MCS) (11) Partner (Association (MCS))
Solvent (Association (MCS))
Comment (Association (MCS))
Formation constant of a complex
2,4,6-trinitrotoluene
CHCl3
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Formation constant of a complex
2,3-dicyano-5,6-dichloro-pbenzoquinone
CHCl3
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Formation constant of a complex
bromocresol green
CHCl3
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Formation constant of a complex
chlorophenol red
CHCl3
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Formation constant of a complex
bromcresol purple
CHCl3
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
UV/VIS spectrum of the complex
2,4,6-trinitrotoluene
CHCl3
concentration dependence
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular
Description (Association (MCS))
Reference
Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
UV/VIS spectrum of the complex
2,3-dicyano-5,6-dichloro-pbenzoquinone
CHCl3
concentration dependence
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
UV/VIS spectrum of the complex
bromocresol green
CHCl3
concentration dependence
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
UV/VIS spectrum of the complex
chlorophenol red
CHCl3
concentration dependence
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
UV/VIS spectrum of the complex
bromcresol purple
CHCl3
concentration dependence
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Further physical properties of the complex
3,7-dihydro-1,3,7-trimethyl-1H-purine2,6-dione; sodium benzoate
solid
Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty
Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details
Crystal Property Description (2) Colour & Other Properties
Reference
white
Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.
Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details
Tafeln
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Optics (1) Description (Optics)
Reference
Crystal refractive indices
Keenan
Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details
Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
Frequency (NMR Spectroscopy)
Chemical shifts
1H
water-d2
400 MHz
Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.
Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
water-d2
100 MHz
Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.
Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details
IR Spectroscopy (2) Description (IR Spectroscopy)
Solvent (IR Spectroscopy)
Comment (IR Spectroscopy)
Reference
Reference
Bands
potassium bromide
Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.
Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details
Spectrum
3500 - 500 cm**(-1)
Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty
Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details
UV/VIS Spectroscopy (1) Description (UV/VIS Spectroscopy)
Solvent (UV/VIS Spectroscopy)
Spectrum
CHCl3
Reference Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Raman Spectroscopy (2) Description (Raman Spectroscopy)
Comment (Raman Spectroscopy)
Reference
Spectrum
H2O
Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty
Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details
Spectrum
neat (no solvent, solid phase)
Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty
Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (40) 1 of 40
Comment (Pharmacological Data)
Bioactivities present
Reference
Alza Corporation
Patent: US3968245 A1, 1976 ; Title/Abstract Full Text Show Details
Men, Tewa; Men, Yangyang
Patent: EP1232748 A1, 2002 ; Title/Abstract Full Text Show Details
de Sarlo,F. et al.
Tetrahedron, 1966 , vol. 22, p. 2989 - 2994 Full Text View citing articles Show Details
Nippon Shinyaju Co., Ltd.
Patent: US5811547 A1, 1998 ; Title/Abstract Full Text Show Details
Cascade Development, Inc.
Patent: US6312728 B1, 2001 ; Title/Abstract Full Text Show Details
Cascade Development, Inc. a subsidiary of Cardinal Health, Inc.
Patent: US5968554 A1, 1999 ; Title/Abstract Full Text Show Details
General Mills, Inc.
Patent: US2002/44968 A1, 2002 ; Title/Abstract Full Text Show Details
Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng
Patent: US2005/118206 A1, 2005 ; Title/Abstract Full Text Show Details
Novelli
Anales de la Asociacion Quimica Argentina (1921-2001), 1939 , vol. 27, p. 162,164 Chem.Abstr., 1940 , p. 1695 Full Text Show Details
Keenan
Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Shiho
Nippon Kagaku Kaishi, 1944 , vol. 65, p. 237 Chem.Abstr., 1947 , p. 3800 Full Text Show Details
Woodruff; Lambooy; Burt
Journal of the American Chemical Society, 1940 , vol. 62, p. 922 Full Text View citing articles Show Details
Nishimura; Takamatsu
Yakugaku Zasshi, 1964 , vol. 84, p. 938,943 Chem.Abstr., 1965 , vol. 62, # 2731 Full Text Show Details
Sengling; Guth
Journal of Pharmaceutical Sciences, 1961 , vol. 50, p. 929 Full Text View citing articles Show Details
Herraez-Hernandez, Rosa; Campins-Falco, Pilar; Sevillano-Cabeza, Adela
Analytical Chemistry, 1996 , vol. 68, # 5 p. 734 - 739 Title/Abstract Full Text View citing articles Show Details
Tsuchihashi; Katagi; Nishikawa; Tatsuno; Nishioka; Nara; Nishio; Petty
Applied Spectroscopy, 1997 , vol. 51, # 12 p. 1796 - 1799 Title/Abstract Full Text View citing articles Show Details
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Ohno; Watanabe
European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details
Kuribara, Hisashi
Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 3 p. 303 - 309 Title/Abstract Full Text View citing articles Show Details
2 of 40
Comment (Pharmacological Data)
Bioactivities present
Reference
Sekine; Nagao; Nakahara
Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details
Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Morton-Norwich Products, Inc.
Patent: US4097500 A1, 1978 ; Title/Abstract Full Text Show Details
Alza Corporation
Patent: US5023088 A1, 1991 ; Title/Abstract Full Text Show Details
Shahdousti, Parvin; Aghamohammadi, Mohammad; Alizadeh, Naader
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2008 , vol. 69, # 4 p. 1195 - 1200 Title/Abstract Full Text View citing articles Show Details
Kunalan, Vanitha; Daeid, Niamh Nic; Kerr, William J.; Buchanan, Hilary A. S.; McPherson, Allan R.
Analytical Chemistry, 2009 , vol. 81, # 17 p. 7342 - 7348 Title/Abstract Full Text View citing articles Show Details
David, Gabrielle E.; Hibbert, D. Brynn; Frew, Russell D.; Hayman, Alan R.
Australian Journal of Chemistry, 2010 , vol. 63, # 1 p. 22 - 29 Title/Abstract Full Text View citing articles Show Details
Coote, Steven J.; Davies, Stephen G.; Fletcher, Ai M.; Roberts, Paul M.; Thomson, James E.
Chemistry - An Asian Journal, 2010 , vol. 5, # 3 p. 589 - 604 Title/Abstract Full Text View citing articles Show Details
Daly; Creveling; Witkop
Journal of medicinal chemistry, 1966 , vol. 9, # 3 p. 273 - 280 Title/Abstract Full Text Show Details
Zhu, Binling; Meng, Liang; Zheng, Kefang
Forensic Science International, 2014 , vol. 242, p. e44 - e47 Title/Abstract Full Text View citing articles Show Details
Shen, Ying-Ling; Chen, Shao-Tsu; Chan, Tzu-Yi; Hung, Tsai-Wei; Tao, Pao-Luh; Liao, Ruey-Ming; Chan, Ming-Huan; Chen, Hwei-Hsien
Neurobiology of Learning and Memory, 2016 , vol. 128, p. 56 - 64 Title/Abstract Full Text View citing articles Show Details
Nawata, Yoko; Kitaichi, Kiyoyuki; Yamamoto, Tsuneyuki
Drug and Alcohol Dependence, 2016 , vol. 160, p. 76 - 81 Title/Abstract Full Text View citing articles Show Details
Mori, Tomohisa; Iwase, Yoshiyuki; Murata, Asami; Iwata, Noriyuki; Suzuki, Tsutomu
Behavioural Brain Research, 2016 , vol. 306, p. 64 - 70 Title/Abstract Full Text View citing articles Show Details
Irii, Toshiaki; Maebashi, Kyoko; Fukui, Kenji; Sohma, Ryoko; Matsumoto, Sari; Takasu, Shojiro; Iwadate, Kimiharu
Legal Medicine, 2016 , vol. 20, p. 53 - 60 Title/Abstract Full Text View citing articles Show Details
3 of 40
Comment (Pharmacological Data)
Bioactivities present
Reference
Fernandes, Nicole C.; Sriram, Uma; Gofman, Larisa; Cenna, Jonathan M.; Ramirez, Servio H.; Potula, Raghava
Journal of Neuroinflammation, 2016 , vol. 13, # 1 art. no. 91 Title/Abstract Full Text View citing articles Show Details
Marks, Katherine R.; Lile, Joshua A.; Stoops, William W.; Glaser, Paul E. A.; Hays, Lon R.; Rush, Craig R.
Journal of Clinical Psychopharmacology, 2016 , vol. 36, # 3 p. 213 - 221 Title/Abstract Full Text View citing articles Show Details
Manning, Elizabeth E.; Halberstadt, Adam L.; Van Den Buuse, Maarten
International Journal of Neuropsychopharmacology, 2016 , vol. 19, # 4 art. no. PYV116 Title/Abstract Full Text View citing articles Show Details
Hopkins, Adam J.; Cooper, Justin L.; Profeta, Luisa T.M.; Ford, Alan R.
Applied Spectroscopy, 2016 , vol. 70, # 5 p. 861 - 873 Title/Abstract Full Text View citing articles Show Details
Hikichi, Hirohiko; Hiyoshi, Tetsuaki; Marumo, Toshiyuki; Tomishima, Yasumitsu; Kaku, Ayaka; Iida, Izumi; Urabe, Hiroki; Tamita, Tomoko; Yasuhara, Akito; Karasawa, Jun-ichi; Chaki, Shigeyuki
Journal of pharmacological sciences, 2015 , vol. 127, # 3 p. 352 - 361 Title/Abstract Full Text Show Details
Collins, Gregory T.; Abbott, Megan; Galindo, Kayla; Rush, Elise L.; Rice, Kenner C.; France, Charles P.
Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 1 p. 1 - 10 Title/Abstract Full Text Show Details
Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon
Behavioural Brain Research, 2017 , vol. 317, p. 494 - 501 Title/Abstract Full Text Show Details
Murphy, Brian L.
Environmental Forensics, 2016 , vol. 17, # 4 p. 282 - 293 Title/Abstract Full Text Show Details
Murphy, Brian L.
Environmental Forensics, 2016 , vol. 17, # 4 p. 282 - 293 Title/Abstract Full Text Show Details
Zhu, Rui; Yang, Tianjiao; Kobeissy, Firas; Mouhieddine, Tarek H.; Raad, Mohamad; Nokkari, Amaly; Gold, Mark S.; Wang, Kevin K.; Mechref, Yehia
PLoS ONE, 2016 , vol. 11, # 4 art. no. 0151034 Title/Abstract Full Text Show Details
Li, Zhi; Zhang, Shuaihua; Cai, Yi; Wu, Qiuhua; Chen, Hao
Analytical Methods, 2016 , vol. 8, # 43 p. 7800 - 7807 Title/Abstract Full Text Show Details
Gerak, Lisa R.; Collins, Gregory T.; France, Charles P.
Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 3 p. 383 - 391 Title/Abstract Full Text Show Details
Alcamán, Katherinne; Duffau, Boris Ettienne; Morales, Daniela
Journal of Planar Chromatography - Modern TLC, 2016 , vol. 29, # 6 p. 474 - 476 Title/Abstract Full Text Show Details
Bahmanabadi; Akhgari; Jokar; Sadeghi
Human and Experimental Toxicology, 2017 , vol. 36, # 2 p. 195 - 202 Title/Abstract Full Text Show Details
Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon
Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details
Jafari Giv, Mahsa
Cardiovascular Toxicology, 2017 , vol. 17, # 1 p. 13 - 24 Title/Abstract Full Text Show Details
Abbasian, Maryam; Balali-Mood, Mahdi; Salar Amoli, Hossein; Masoumi, Akram
Journal of Sol-Gel Science and Technology, 2017 , vol. 81, # 1 p. 247 - 260 Title/Abstract Full Text Show Details
Jalewa, Jaishree; Sharma, Mohit Kumar; Gengler, Simon; Hölscher, Christian
Neuropharmacology, 2017 , vol. 117, p. 238 - 248 Title/Abstract Full Text Show Details
Hassanzadeh, Javad; Khataee, Alireza; Lotfi, Roya
Microchemical Journal, 2017 , vol. 132, p. 371 - 377 Title/Abstract Full Text Show Details
Graniczkowska, Kinga; Pütz, Michael; Hauser, Frank M.; De Saeger, Sarah; Beloglazova, Natalia V.
Biosensors and Bioelectronics, 2017 , vol. 92, p. 741 - 747
Title/Abstract Full Text Show Details
4 of 40
5 of 40
6 of 40
7 of 40
8 of 40
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Botanas, Chrislean Jun; Yoon, Seong Shoon; de la Peña, June Bryan; dela Peña, Irene Joy; Kim, Mikyung; Woo, Taeseon; Seo, Joung-Wook; Jang, Choon-Gon; Park, Kyung-Tae; Lee, Young Hun; Lee, Yong Sup; Kim, Hee Jin; Cheong, Jae Hoon
Pharmacology Biochemistry and Behavior, 2017 , vol. 153, p. 160 - 167 Title/Abstract Full Text Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Gerak, Lisa R.; Collins, Gregory T.; France, Charles P.
Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 3 p. 383 - 391 Title/Abstract Full Text Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Collins, Gregory T.; Abbott, Megan; Galindo, Kayla; Rush, Elise L.; Rice, Kenner C.; France, Charles P.
Journal of Pharmacology and Experimental Therapeutics, 2016 , vol. 359, # 1 p. 1 - 10 Title/Abstract Full Text Show Details
Effect (Pharmacological Data)
tolerance; induction of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval
Method (Pharmacological Data)
pretreatment and challenge with title comp.; 22 h after the last dose dopamine and serotonin (5-HT) concentration in striatum and 5-HT concentration in frontal cortex and hippocampus were determined using high-performance liquid chromatography
Further Details (Pharmacological Data)
controls: pretreatment and/or challenge with saline
Results
title comp. pretreatment induced tolerance against monoamine level reduction by title comp. challenge when given 24 h - 7 d, but not 14 31 d prior to challenge; tolerance was noted for striatum and frontal cortex levels, but not in hippocampus
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
tolerance; induction of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 14 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval
Method (Pharmacological Data)
pretreatment and challenge with title comp.; core body temp. was recorded every 4 h during challenge period (9 time points)
Further Details (Pharmacological Data)
controls: pretreatment and/or challenge with saline
9 of 40
10 of 40
11 of 40
Results
title comp. pretreatment induced tolerance against body temp. increase by title comp. challenge; effect was significant at 6, 1, and 3 time points for pretreatment-challenge interval of 24 h, 7 d, and 14 d, resp.
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval
Method (Pharmacological Data)
pretreatment and challenge with title comp.; core body temp. was recorded every 4 h during challenge period (9 time points)
Further Details (Pharmacological Data)
controls: pretreatment and/or challenge with saline
Results
title comp. pretreatment enhanced body temp. increase by title comp. challenge; effect was significant at 3 time points
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; effect on
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals
Method (Pharmacological Data)
treatment with title comp.; 24 h - 31 d later challenge with saline injections during 16 h; 22 h later dopamine and serotonin (5-HT) concentrations in striatum and 5-HT concentrations in frontal cortex and hippocampus were determined using HPLC
Further Details (Pharmacological Data)
controls: saline; HPLC: high-performance liquid chromatography
Comment (Pharmacological Data)
No effect
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
body temperature; effect on
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
12 of 40
13 of 40
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals
Method (Pharmacological Data)
treatment with title comp.; 24 h - 31 d later core body temp. was recorded every 4 h during a period of 16 h
Further Details (Pharmacological Data)
controls: saline
Comment (Pharmacological Data)
No effect
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
pretreatment with 15 injections at 2.5, 5.0, and 7.5 mg/kg (5 times for each dose) at 6-h intervals; 24 h - 31 d later challenge with 5 injections at 12.5 mg/kg at 4-h interval
Method (Pharmacological Data)
pretreatment and challenge with title comp.; 2 h after the last dose title comp. and amphetamine were measured in striatum, hippocampus, frontal cortex, and plasma using liquid chromatography/tandem mass spectrometry
Further Details (Pharmacological Data)
control: pretreatment with saline
Results
title comp. and amphetamine levels in brain had no regional differences; title comp. and amphetamine levels in brain and plasma were not affected by title comp. pretreatment
Metabolite (Pharmacological Data)
2-amino-1-phenylpropane [Reaxys RN: 507867]
Reference
Danaceau, Jonathan P.; Deering, Cassandra E.; Day, Jayme E.; Smeal, Stacy J.; Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2007 , vol. 559, # 1 p. 46 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline, administered singlely in a volume of 1 ml/kg; dose referred to free base
Method (Pharmacological Data)
rats sacrificed 3 h after treatment; brains separated; number of neurons expressing ppNPY mRNA in rostral, middle and caudal striatum regions determined using in situ hybridization histochemistry ppNPY: prepro-neuropeptide Y
Further Details (Pharmacological Data)
14 of 40
15 of 40
16 of 40
Results
title comp. treatment caused significant increase in number of neurons expressing ppNPY mRNA in all regions of striatum examined compared to control (diagram)
Reference
Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and administered in a volume of 1 ml/kg as five injections at 6-h intervals; dose referred to free base
Method (Pharmacological Data)
rats sacrificed 3 h after last injection; brains separated; number of neurons expressing ppNPY and pSOM mRNA in rostral, middle and caudal striatum regions determined using in situ hybridization histochemistry
Further Details (Pharmacological Data)
ppNPY: prepro-neuropeptide Y; pSOM: prosomatostatin; further investigations on mechanisms of action in presence of dopamine D1 and D2 receptor antagonists SCH22390 and eticlopride, resp.
Results
title comp. treatment caused significant increase in number of neurons expressing ppNPY mRNA in all striatum regions but did not change number of neurons expressing pSOM mRNA; effect was suggested to depend on dopamine D1 but not D2 receptor activation
Reference
Horner, Kristen A.; Westwood, Scot C.; Hanson, Glen R.; Keefe, Kristen A.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 1 p. 414 - 421 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals
Method (Pharmacological Data)
rats treated with PCA/saline; after 7 days, administered with title comp.; sacrificed after 1 h; synaptic vesicles from hippocampus prepared; <3H>dopamine uptake evaluated by incubating synaptic vesicles at 30 deg C for 3 min in presence of <3H>dopamine
Further Details (Pharmacological Data)
control: saline; PCA: para-chloroamphetamine
Results
title comp. acutely decreased vesicular dopamine uptake; in rats pretreated with PCA, title comp. was devoid of this effect; diagram
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological
Sprague-Dawley rat
Data)
17 of 40
18 of 40
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals
Method (Pharmacological Data)
rats treated with PCA/saline; after 7 days, administered with title comp.; sacrificed after 1 h; hippocampus dissected; serotonin and norepinephrine content determined by HPLC coupled to electrochemical detector
Further Details (Pharmacological Data)
control: saline; PCA: para-chloroamphetamine
Results
title comp. acutely decreased tissue serotonin content; in rats pretreated with PCA, title comp. was devoid of this effect; table
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; effect on
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
7.5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was administered 4 times
Method (Pharmacological Data)
rats administered with title comp.; before 15 min, fluoxetine/saline administered; sacrificed after 1 h; hippocampal vesicular dopamine uptake assessed by incubating (30 deg C, 3 min) in presence of <3H>dopamine; hippocampal serotonin content assessed
Further Details (Pharmacological Data)
control: saline
Results
title comp. acutely decreased <3H>dopamine uptake and serotonin content; fluoxetine pretreatment prevented title comp. effect; diagrams
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hyperthermic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
7.5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was administered 4 times
Method (Pharmacological Data)
rats administered with title comp.; before 15 min, fluoxetine or saline administered; rectal temperatures taken every hour beginning 30 min before title comp. administration
19 of 40
20 of 40
Further Details (Pharmacological Data)
control: saline
Results
title comp. induced hyperthermia; fluoxetine pretreatment prevented title comp. effect; diagrams
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals
Method (Pharmacological Data)
rats treated with DSP-4 (50 mg/kg, i.p.)/saline 15 min after fluoxetine (10 mg/kg, i.p.)/saline pretreatment; 7 days later, treated with title comp.; sacrificed after 1 h; hippocampal vesicular dopamine uptake assessed, 30 deg C, 10 min
Further Details (Pharmacological Data)
control: saline; DSP-4: N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine
Results
title comp. acutely decreased dopamine uptake; title comp.-induced decrease in vesicular uptake occurred in rats pretreated with DSP-4; diagram
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. administered at 4 * 7.5 mg/kg/injection, 2-h intervals
Method (Pharmacological Data)
rats treated with DSP-4 (50 mg/kg, i.p.) or saline 15 min after either fluoxetine (10 mg/kg, i.p.) or saline pretreatment; 7 days later, treated with title comp.; sacrificed after 1 h; hippocampal serotonin and norepinephrine content detd. by HPLC-ED
Further Details (Pharmacological Data)
control: saline; HPLC-ED: HPLC coupled to electrochemical detector; DSP-4: N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride
Results
title comp. acutely decreased serotonin and norepinephrine content; title comp.-induced decrease occurred in rats pretreated with DSP-4; table
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological
Sprague-Dawley rat
Hide facts 21 of 40
Data)
22 of 40
23 of 40
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
7.5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. administered 4 times
Method (Pharmacological Data)
rats treated with title comp.; sacrificed after 1, 48 or 144 h; hippocampal serotonin and norepinephrine content detd. by HPLC coupled to electrochemical detector
Further Details (Pharmacological Data)
control: saline
Results
title comp. reduced levels of serotonin but not norepinephrine, 6 days after last administration; diagram
Reference
Rau, Kristi S.; Birdsall, Elisabeth; Volz, Trent J.; Riordan, James A.; Baucum II, Anthony J.; Adair, Brian P.; Bitter, Rebecca; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 676 - 682 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4-h intervals and with 40-h intervals between each dosing regimen
Method (Pharmacological Data)
2, 4 and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last pretreatment rats challenged with high dose of title comp. (8 mg/kg); 7 d after last injection striatum was dissected, and content of DA determined by HPLC
Further Details (Pharmacological Data)
control: saline pretreatment or/and challenge; DA: dopamine; HPLC: high performance liquid chromotography
Results
high-dose injections of title comp. decreased striatal DA content by 69 percent; pretreatment with increasing doses of title comp. decreased depletion effect of high-dose challenge by 51 percent; treatment with increasing doses caused only 27 percent decrease in DA content
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4-h intervals and 40-h drug-free periods between each dosing regimen
24 of 40
25 of 40
Method (Pharmacological Data)
2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last pretreatment rats challenged with high dose of title comp. (8 mg/kg); core body temperature recorded every 1 h after each title comp. injection
Further Details (Pharmacological Data)
control: saline pretreatment and/or challenge
Results
high-dose injections of title comp. induced signficant elevation of core body temperature; pretreatment with increasing doses of title comp. prior high dose injections slightly attenuated elevation of body temperature
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 2-h intervals
Method (Pharmacological Data)
rats were challenged with title comp.; core body temperature were recorded with BAT-12 model thermometer and thermocoupled rectal probe (model RET-2) every 1 h after each title comp. injection at 24 deg C and 6 deg C
Further Details (Pharmacological Data)
control: saline
Results
multiple injections of title comp. elevated core body temperature at room temperature; this effect of title comp. was blocked in rats treated with title comp. at 6 deg C
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 2-h intervals
Method (Pharmacological Data)
rats were challenged with title comp.; <3H>dopamine uptake of synaptic vesicles prepared from striatum was assessed 1 h after last injection at 24 deg C and 6 deg C
Further Details (Pharmacological Data)
control: saline
Results
multiple injections of title comp. at 24 deg C decreased vesicular dopamine uptake by 72 percent compared to saline-treated rats; at 6 deg C title comp. injections decreased vesicular dopamine uptake by 75 percent
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
26 of 40
27 of 40
28 of 40
Effect (Pharmacological Data)
transmitter uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4-h intervals and 40-h periods between each dosing regimen
Method (Pharmacological Data)
2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5, resp.; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 1 h after last injection <3H>DA uptake via plasmalemmal DAT assessed in striatal synaptosomes
Further Details (Pharmacological Data)
control: saline pretreatment and/or challenge; DAT: dopamine transporter; DA: dopamine
Results
high doses of title comp. decreased plasmalemmal DAT DA uptake by 72 percent; pretreatment with increasing doses of title comp. prior high dose challenge attenuated this effect, DA uptake was decreased only by 58 percent
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4-h intervals; 40-h drug-free intervals between each dosing regimen
Method (Pharmacological Data)
2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 2 h after last injection vesicular <3H>DA uptake was assessed in striatum
Further Details (Pharmacological Data)
control: saline pretreatment and challenge; DA: dopamine
Results
high doses title comp. decreased vesicular DA uptake by 57 percent compared to control; pretreatment with title comp. prior high dose challenge attenuated this effect by 39 percent
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein expression; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
29 of 40
30 of 40
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4 h intervals with 40 h drug-free intervals between each dosing regimen
Method (Pharmacological Data)
2, 4, and 6 mg/kg of title comp. were injected on days 1, 3, and 5; 66 h after last injection rats challenged with high dose of title comp. (8 mg/kg); 2 h after last injection Western blotting performed to determine protein level of VMAT-2
Further Details (Pharmacological Data)
VMAT-2 determined in S3, P3, P2 fractions; control: saline; VMAT-2: vesicular monoamine transporter-2; S3: nonmembrane-associated fraction; P3: membrane-associated fraction; P2: whole synaptosomal fraction pellet
Results
high doses of title comp. decreased VMAT-2 immunoreactivity in S3; pretreatment with title comp. prior high dose challenge significantly attenuated this effect; similar results obtained in P2 and P3
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 - 8 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was injected 4 times a day with 4-h intervals; 40-h drug-free periods between each dosing regimen
Method (Pharmacological Data)
2, 4, and 6 mg/kg of title comp. injected on days 1, 3 and 5, resp.; title comp. and AM conc. measured in striatum with mass spectrometer 66 h after last injection (6 mg/kg) and 0.5, 1 and 2 h after last challenge with high dose of title comp. (8 mg/kg)
Further Details (Pharmacological Data)
control: saline; AM: amphetamine
Results
66 h after pretreatment with title comp. neither title comp. nor amphetamine were detected in striatum; 0.5, 1, 2 h after high-dose challenge of title comp. its conc. elevated similarly in striatum of pretreated and nonpretreated rats
Reference
Johnson-Davis, Kamisha L.; Truong, Jannine G.; Fleckenstein, Annette E.; Wilkins, Diana G.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 309, # 2 p. 578 - 586 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
7.5 mg/kg
Kind of Dosing (Pharmacological Data)
four doses of 7.5 mg/kg at 2-h intervals; dissolved in 0.9 percent saline; doses calculated as free base
Method (Pharmacological Data)
up to 7 days pt synaptic vesicular <3H>DOPA uptake (30 deg C, 3 min) and <3H>DHTB binding (25 deg C, 10 min) measured by liquid scintillation counting, striatal DOPA levels by HPLC-ED and binding of VMAT-2 antibody in S3, P2, P3 by Western blot analysis
Further Details (Pharmacological Data)
pt: posttreatment; DOPA: dopamine; DHTB: dihydrotetrabenazine; S3: vesicular subcellular fraction; P2: whole synaptosomal fraction; P3: plasmalemmal membrane fraction; HPLC-ED: high-performance liquid chromatography with electrochemical detection
31 of 40
32 of 40
33 of 40
Results
title comp. decreased vesicular DOPA uptake and DHTB binding in striatal vesicles and VMAT-2 immunoreactivity in S3 prepared 1 h after last title comp. dose; striatal DOPA levels decreased at 7 days pt
Reference
Sandoval, Veronica; RIddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2003 , vol. 304, # 3 p. 1181 - 1187 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses
Method (Pharmacological Data)
rats pretreated with title comp. or saline on days 1, 3 and 5; 66 h after last pretreatment they were challenged with 4 injections (2-h intervals) of 10 mg/kg title comp.; animals were sacrificed 7 d later; dopamine levels in striatum determined by HPLC
Further Details (Pharmacological Data)
HPLC: high-performance liquid chromatography; HPLC coupled with electrochemical detector was used in the study; control: saline
Results
in saline-pretreated group title comp. induced a significant decrease in striatal dopamine levels; this effect was attenuated in the group pretreated with title comp.
Reference
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses
Method (Pharmacological Data)
rats pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with 4 injections (2-h intervals) of 10 mg/kg title comp.; after 7 d rats sacrificed; serotonin levels in striatum, hippocampus and frontal cortex determined by HPLC
Further Details (Pharmacological Data)
HPLC: high-performance liquid chromatography; HPLC coupled with electrochemical detector was used in the study; control: saline
Results
in saline-pretreated group title comp. induced a significant decrease of serotonin content in striatum, hippocampus and frontal cortex; this effect was attenuated in the group pretreated with title comp.
Reference
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing
during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times
34 of 40
35 of 40
(Pharmacological Data)
a day with 2-h interval between doses
Method (Pharmacological Data)
rats were pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with four injections (2-h intervals) of 10 mg/kg title comp.; rectal temperatures were measured
Further Details (Pharmacological Data)
control: saline
Results
title comp. induced an increase in core body temperature both in saline-pretreated and title comp.-pretreated groups on the day of the challenge; a trend for the stronger effect in group pretreated with title comp. was observed
Reference
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
during pretreatment the doses of title comp. were 2.5, 5.0, and 7.5 mg/kg on days 1, 3 and 5, resp.; title comp. was administered 4 times a day with 2-h interval between doses
Method (Pharmacological Data)
rats were pretreated with title comp. or saline on days 1, 3 and 5; 66 h later challenged with four injections (2-h intervals) 10 mg/kg of title comp.; the levels of title comp. in striatum, hippocampus and frontal cortex measured 7 days later by MS
Further Details (Pharmacological Data)
MS: mass spectrometry; control: saline
Results
the levels of title comp. were similar in three brain regions both in saline-pretreated group (5.7, 4.6 and 6.0 ng/mg tissue for striatum, hippocampus and frontal cortex, resp.) and in group pretreated with title comp. (5.4, 6.5 and 5.8 ng/mg)
Reference
Johnson-Davis, Kamisha L.; Fleckenstein, Annette E.; Wilkins, Diana G.
European Journal of Pharmacology, 2003 , vol. 482, # 1-3 p. 151 - 154 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 15 mg/kg
Method (Pharmacological Data)
rats admin. with title comp.; decapitated 1 or 24 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.
Further Details (Pharmacological Data)
control: saline; LSC: liquid scintillation counter; DA: dopamine; further studies with SCH23390, quinpirole (QE), cocaine (CE) and core body temperature (CBT) on title comp. effect; LT: little change
Results
title comp. (15 mg/kg) rapidly decreased VDU (25 percent); decreased Vmax with LT in Km of VDU was 607 fmol/μg of protein/min and 187 nmol/l post-dose (15 mg/kg), resp.; effect increased by QE/CE, not prevented by SCH23390, and not affected by CBT; diagrams
Reference
Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
36 of 40
37 of 40
38 of 40
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
15 mg/kg
Method (Pharmacological Data)
rats admin. with title comp.; decapitated 1 or 24 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.
Further Details (Pharmacological Data)
control: saline; LSC: liquid scintillation counter; DA: dopamine; all rats were maintained in an ambient environment of 24 deg C; further study with SCH23390 (DA D1 receptor antagonist), quinpirole (DA D2 receptor agonist) and cocaine (VDU inhibitor)
Results
decrease in vesicular <3H>DA uptake recovered by 24 h after title comp. admin.; effect of title comp. in decreasing <3H>DA uptake was not prevented by SCH23390; quinpirole and cocaine increased <3H>DA uptake by 1 h after title comp. admin.; diagrams
Reference
Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; decrease of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
15 mg/kg
Method (Pharmacological Data)
rats admin. with title comp.; decapitated 1 h later; synaptic vesicles obtained; vesicular pellet prepd.; incubated in presence of <3H>DA at 30 deg C for 3 min in assay buffer; radioactivity counted by LSC; vesicular <3H>DA uptake (VDU) detd.
Further Details (Pharmacological Data)
control: saline; LSC: liquid scintillation counter; DA: dopamine; rats were maintained in 24 or 6 deg C environment; further study with eticlopride (ET, DA D2 receptor antagonist, rats were placed in 24 or 28.5 deg C environment)
Results
attenuation of hyperthermia by rats exposed to cool environment did not prevent title comp.-induced decrease in VDU; ET attenuating title comp.-induced decrease in VDU was not reversed by restoring hyperthermia in ET + title comp.-treated rats; diagrams
Reference
Brown, Jeffrey M.; Riddle, Evan L.; Sandoval, Veronica; Weston, Raul K.; Hanson, Jarom E.; Crosby, Michael J.; Ugarte, Yvette V.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 302, # 2 p. 497 - 501 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
ddY mice
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 mg/kg
Kind of Dosing (Pharmacological
in physiological saline
Data)
39 of 40
40 of 40
Method (Pharmacological Data)
6-week-old mice; 8 groups of 10 mice: 7 times at three-day intervals treatment; placing in the activity cages for 3 h after each dosing or in the jars; circling measurement for 1 min
Further Details (Pharmacological Data)
food and water ad libitum
Results
ambulatory sensitization at placing in 20-cm diameter activity cages after each dose; inhibition of ambulatory sensitization with circling behaviour concurrently increase at small jars (6-cm diameter)
Reference
Kuribara, Hisashi
Journal of Pharmacy and Pharmacology, 1998 , vol. 50, # 3 p. 303 - 309 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
ICR SPF mice
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 - 10 mg/kg
Exposure Period (Pharmacological Data)
6 - 72 h
Method (Pharmacological Data)
mice 8 weeks old; 34-38 g; metabolic cage; urinary excretion of metabolites; urine samples were collected during 0-6, 6-12, 12-24, 24-48 and 48-72 h after injection
Results
metabolites (total excretion): amphetamine (2.6-9.1 percent), p-hydroxymethamphetamine (0.9-1.5 percent), p-hydroxyamphetamine (0.2-0.6 percent); title comp. excretion: 24.8-30.9 percent (as free base); time-course of excretion
Reference
Sekine; Nagao; Nakahara
Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
Wistar SPF rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 - 10 mg/kg
Exposure Period (Pharmacological Data)
6 - 72 h
Method (Pharmacological Data)
rats 8 weeks old; 190-205 g; metabolic cage; urinary excretion of metabolites; urine samples were collected during 0-6, 6-12, 12-24, 24-48 and 48-72 h after injection
Results
metabolites (total excretion): amphetamine (2.9-3.5 percent), p-hydroxymethamphetamine (18.4-27.2 percent), p-hydroxyamphetamine (4.3-27.2 percent); title comp. excretion: 6.1-9.7 percent (as free base); time-course of excretion
Reference
Sekine; Nagao; Nakahara
Xenobiotica, 1995 , vol. 25, # 1 p. 49 - 58 Title/Abstract Full Text View citing articles Show Details
Other Data Use (2) Use Pattern
Reference
sustained delivery of a beneficial agent
Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng
Patent: US2005/118206 A1, 2005 ; Title/Abstract Full Text Show Details
Luk, Andrew Sheung-King; Lam, Stan; Zhang, Yuanpeng
Patent: US2005/118206 A1, 2005 ;
beneficial agent
Title/Abstract Full Text Show Details
Chemical Name: S-methamphetamine hydrochloride Reaxys Registry Number: 5125268
CAS Registry Number: 51-57-0 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697
InChI Key: TWXDDNPPQUTEOV-FVGYRXGTSA-N
41
8 prep out of 31 reactions.
Synthesize | Hide Details Find similar Chemical Names and Synonyms S-methamphetamine hydrochloride, Metamphetamine hydrochloride, Desoxyn, (+)-N-α-dimethylphenethylamine hydrochloride, (S)-metamphetamine hydrochloride, d-desoxyephedrine hydrochloride, metamphetamine*HCl Identification Substance Label (17) Label
Reference
MA
Ohmori, T.; Abekawa, T.; Koyama, T.
Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details
Tsutsumi, Hiroe; Katagi, Munehiro; Nishikawa, Mayumi; Tsuchihashi, Hitoshi; Kasuya, Fumiyo; Igarashi, Kazuo
Biological and Pharmaceutical Bulletin, 2004 , vol. 27, # 10 p. 1572 - 1575 Title/Abstract Full Text View citing articles Show Details
Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details
Ishiguro, Yoshiki; Morgan, James P.
Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details
Collins, Karen C.; Schlosburg, Joel E.; Bremer, Paul T.; Janda, Kim D.
Journal of Medicinal Chemistry, 2016 , vol. 59, # 8 p. 3878 - 3885 Title/Abstract Full Text View citing articles Show Details
METH
Bronstein; Hong
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details
Albers; Sonsalla
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Farfel; Seiden
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details
Rocher; Gardier
Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.
European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details
Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.
European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details
Identification Physical Data (35) Spectra (11) Bioactivity (173) Other Data (5)
127
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Peltier; Li; Lytle; Taylor; Emmett-Oglesby
Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian
European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details
Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus
Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details
Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu
Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details
Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.
Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details
4
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
2
Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.
Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details
S-(+)-METH; + METH
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
met; M
Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details
Methamphet
Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details
methamph
Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details
MAP
Shibata; Ono; Fukuhara; Watanabe
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details
Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji
Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Merck12 6015
Kuribara, Hisashi
European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details
Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details
Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details
Merck 12: 6015
Morrow; Corrigan; Waldren
Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details
Meth
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Merck Index 6015
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
METH-HCl
Cass, Wayne A.
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details
MI 12 6015
Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu
Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details
Negwer 2038
Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton
Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details
MeAmp (Merck 6015)
Melega; Williams; Schmitz; DiStefano; Cho
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details
Patent-Specific Data (1) Location in Patent
Reference
Claim
Halikas; James A.
Patent: US5102913 A1, 1992 ; Title/Abstract Full Text Show Details
The Regents of the University of Minnesota
Patent: US5028611 A1, 1991 ; Title/Abstract Full Text Show Details
Physical Data Melting Point (14) Melting Point
Solvent (Melting Point)
Location
Reference
170 - 172 °C
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
172.4 178.4 °C
MALLINCKRODT INC.
Patent: WO2006/73547 A1, 2006 ;
170 - 175 °C
Title/Abstract Full Text Show Details
MALLINCKRODT INC.
Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
166 - 167 °C
ethanol diethyl ether
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
168 - 171 °C
Fowler
The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637
Title/Abstract Full Text View citing articles Show Details
171 - 175 °C
SINSHEIMER; SMITH
Journal of pharmaceutical sciences, 1963 , vol. 52, p. 1080 - 1085 Title/Abstract Full Text View citing articles Show Details
171 - 172 °C
ethanol
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
171 - 172 °C
acetone
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
174 - 175 °C
Adamson et al.
Journal of the Chemical Society, 1949 , p. Spl. 144, 152 Full Text Show Details
172 °C
ethanol
Rosenmund; Karg
Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details
Emde
Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details
Temmler
Patent: DE767186 ; Full Text Show Details
172 °C
CHCl3 ethyl acetate
Rosenmund; Karg
Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details
Temmler
Patent: DE767186 ; Full Text Show Details
173 °C
Hauschild
Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, 1938 , vol. 191, p. 465 Full Text View citing articles Show Details
171 - 172 °C
ethanol diethyl ether
Leithe
Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details
172 °C
acetone
Schmidt
Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details
Crystal Property Description (3) Colour & Other Properties
Location
Reference
colourless
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
white
MALLINCKRODT INC.
Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details
Staebchen
Emde
Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details
Optical Rotatory Dispersion (1) Solvent (Optical Rotatory Dispersion)
Reference
H2O
Emde
Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details
Optical Rotatory Power (16) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
4 g/100ml
water
17.56 deg
589 nm
[alpha]
1.2 g/100ml
H2O
19.3 deg
[alpha]
16.1 g/100ml
H2O
[alpha]
c=2
[alpha]
Location
Reference
25 °C
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
589 nm
23 °C
Buckley, Thomas F.; Rapoport, Henry
Journal of the American Chemical Society, 1981 , vol. 103, # 20 p. 6157 - 6163 Title/Abstract Full Text View citing articles Show Details
-12.6 deg
589 nm
25 °C
Fowler
The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637 Title/Abstract Full Text View citing articles Show Details
ethanol
-7.9 deg
589 nm
20 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
c=4
ethanol
-6 deg
589 nm
28 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=2
H2O
16.8 deg
589 nm
20 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=4
H2O
16 deg
589 nm
28 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=4
H2O
17.5 deg
589 nm
18 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=10
H2O
16 deg
589 nm
21.5 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=0.2
acetone
-13.9 deg
589 nm
22 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=0.9
methanol
1.62 deg
589 nm
23 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
c=1.8
methanol
0.39 deg
589 nm
24 °C
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
[alpha]
H2O
21.6 deg
589 nm
Freudenberg; Nikolai
Justus Liebigs Annalen der Chemie, 1934 , vol. 510, p. 223,227 Full Text Show Details
[alpha]
c=7
H2O
15.7 deg
589 nm
15 °C
Leithe
Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details
[alpha]
c=2.8
H2O
17.9 deg
589 nm
20 °C
Emde
Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details
[alpha]
c=1.1
H2O
17.8 deg
589 nm
17.5 °C
Schmidt
Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details
Optics (1) Description (Optics)
Reference
Crystal refractive indices
Keenan
Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details
Spectra NMR Spectroscopy (5) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
Temperature (NMR Spectroscopy)
Frequency (NMR Spectroscopy)
Chemical shifts Spectrum
1H
water-d2
Chemical shifts Spectrum
13C
water-d2
Chemical shifts Spectrum
1H
Chemical shifts Spectrum
Chemical shifts
Location
Reference
200 MHz
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
50 MHz
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
chloroform-d1
400 MHz
supporting information
Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.
Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details
13C
chloroform-d1
100.5 MHz
supporting information
Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.
Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details
1H
24.84 °C
Matsumoto, Teruki; Urano, Yasuteru; Makino, Yukiko; Kikura-Hanajiri, Ruri; Kawahara, Nobuo; Goda, Yukihiro; Nagano, Tetsuo
Analytical Chemistry, 2008 , vol. 80, # 4 p. 1176 - 1181 Title/Abstract Full Text View citing articles Show Details
IR Spectroscopy (2) Description (IR Spectroscopy)
Solvent (IR Spectroscopy)
Comment (IR Spectroscopy)
Reference
Bands
Thompson,W.E. et al.
Journal of Pharmaceutical Sciences, 1965 , vol. 54, p. 1819 - 1821 Full Text View citing articles Show Details
Spectrum
KBr
4000 - 650 cm**(-1)
Chatten; Levi
Analytical Chemistry, 1959 , vol. 31, p. 1581,1582,1585 Full Text View citing articles Show Details
Mass Spectrometry (4) Description (Mass Spectrometry)
Location
Reference
time-of-flight mass spectra
Muramoto, Shin; Forbes, Thomas P.; Van Asten, Arian C.; Gillen, Greg
(TOFMS) spectrum
Analytical Chemistry, 2015 , vol. 87, # 10 p. 5444 - 5450 Title/Abstract Full Text View citing articles Show Details
high resolution mass spectrometry (HRMS) electrospray ionisation (ESI) spectrum
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
liquid chromatography mass spectrometry (LCMS) spectrum
Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.
Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details
DESI (desorption electrospray ionization) IT (ion trap) LCMS (Liquid chromatography mass spectrometry) Spectrum
Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao
International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (172) 1 of 172
Comment (Pharmacological Data)
Bioactivities present
Reference
E. R. Squibb and Sons, Inc.
Patent: US4602092 A1, 1986 ; Title/Abstract Full Text Show Details
Schmitt,J. et al.
Chimica Therapeutica, 1967 , vol. 2, p. 260 - 267 Full Text View citing articles Show Details
Halikas; James A.
Patent: US5102913 A1, 1992 ; Title/Abstract Full Text Show Details
Fowler
The Journal of organic chemistry, 1977 , vol. 42, # 15 p. 2637 - 2637 Title/Abstract Full Text View citing articles Show Details
SINSHEIMER; SMITH
Journal of pharmaceutical sciences, 1963 , vol. 52, p. 1080 - 1085 Title/Abstract Full Text View citing articles Show Details
Thompson,W.E. et al.
Journal of Pharmaceutical Sciences, 1965 , vol. 54, p. 1819 - 1821 Full Text View citing articles Show Details
HISAMITSU PHARMACEUTICAL CO., INC.
Patent: EP1541177 A1, 2005 ; Title/Abstract Full Text Show Details
CORTEX PHARMACEUTICALS, INC.; The Regents of the University of California
Patent: EP1026950 B1, 2006 ; Title/Abstract Full Text Show Details
MALLINCKRODT INC.
Patent: WO2006/73547 A1, 2006 ; Title/Abstract Full Text Show Details
Adamson et al.
Journal of the Chemical Society, 1949 , p. Spl. 144, 152 Full Text Show Details
Keenan
Journal of the American Pharmaceutical Association (1912-1977), 1949 , vol. 38, p. 314 Chem.Abstr., 1949 , p. 8611 Full Text Show Details
Freudenberg; Nikolai
Justus Liebigs Annalen der Chemie, 1934 , vol. 510, p. 223,227 Full Text Show Details
Rosenmund; Karg
Chemische Berichte, 1942 , vol. 75, p. 1850,1856 Full Text Show Details
Schmidt
Archiv der Pharmazie (Weinheim, Germany), 1914 , vol. 252, p. 121 Archiv der Pharmazie (Weinheim, Germany), 1915 , vol. 253, p. 52 Full Text Show Details
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Emde
Helvetica Chimica Acta, 1929 , vol. 12, p. 393 Full Text Show Details
Leithe
Chemische Berichte, 1932 , vol. 65, p. 660,665 Full Text Show Details
Temmler
Patent: DE767186 ; Full Text Show Details
Hauschild
Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, 1938 , vol. 191, p. 465 Full Text View citing articles Show Details
Chatten; Levi
Analytical Chemistry, 1959 , vol. 31, p. 1581,1582,1585 Full Text View citing articles Show Details
2 of 172
3 of 172
Comment (Pharmacological Data)
Bioactivities present
Reference
Chiang
Journal of the Chinese Chemical Society (Peking), 1950 , vol. 17, p. 106,112 Full Text Show Details
Buckley, Thomas F.; Rapoport, Henry
Journal of the American Chemical Society, 1981 , vol. 103, # 20 p. 6157 - 6163 Title/Abstract Full Text View citing articles Show Details
Glennon; Ablordeppey; Ismaiel; El-Ashmawy; Fischer; Howie
Journal of Medicinal Chemistry, 1994 , vol. 37, # 8 p. 1214 - 1219 Title/Abstract Full Text View citing articles Show Details
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi
Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details
Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton
Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details
Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu
Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details
Ohmori, T.; Abekawa, T.; Koyama, T.
Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details
Bronstein; Hong
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Shibata; Ono; Fukuhara; Watanabe
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details
Melega; Williams; Schmitz; DiStefano; Cho
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details
Albers; Sonsalla
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details
Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji
Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Farfel; Seiden
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details
Wu, Dafang; Victoria Otton, S.; Inaba, Tadanobu; Kalow, Werner; Sellers, Edward M.
Biochemical Pharmacology, 1997 , vol. 53, # 11 p. 1605 - 1612 Title/Abstract Full Text View citing articles Show Details
Kuribara, Hisashi
European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details
Cass, Wayne A.
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
Bioactivities present
4 of 172
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Rocher; Gardier
Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details
Tsutsumi, Hiroe; Katagi, Munehiro; Nishikawa, Mayumi; Tsuchihashi, Hitoshi; Kasuya, Fumiyo; Igarashi, Kazuo
Biological and Pharmaceutical Bulletin, 2004 , vol. 27, # 10 p. 1572 - 1575 Title/Abstract Full Text View citing articles Show Details
Morrow; Corrigan; Waldren
Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details
Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details
Sheridan, Robert D.; Turner, Simon R.; Cooper, Graham J.; Tattersall, John E.H.
European Journal of Pharmacology, 2005 , vol. 511, # 2-3 p. 99 - 107 Title/Abstract Full Text View citing articles Show Details
Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.
European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details
Suzuki, Tsutomu; Fukuoka, Yoshie; Mori, Tomohisa; Miyatake, Mayumi; Narita, Minoru
European Journal of Pharmacology, 2004 , vol. 498, # 1-3 p. 157 - 161 Title/Abstract Full Text View citing articles Show Details
Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details
Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.
European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details
Ishiguro, Yoshiki; Morgan, James P.
Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details
Suzuki, Tsutomu; Kishimoto, Yayoi; Misawa, Miwa
Life Sciences, 1996 , vol. 59, # 19 p. 1667 - 1674 Title/Abstract Full Text View citing articles Show Details
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
Bioactivities present
Reference
Peltier; Li; Lytle; Taylor; Emmett-Oglesby
Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details
Munzar, Patrik; Kutkat, Scott W; Miller, Cori R; Goldberg, Steven R
European Journal of Pharmacology, 2000 , vol. 408, # 2 p. 169 - 174 Title/Abstract Full Text View citing articles Show Details
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.
European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636
Title/Abstract Full Text View citing articles Show Details
Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru
European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details
Biosite Diagnostics Incorporated
Patent: US5470997 A1, 1995 ; Title/Abstract Full Text Show Details
Syntex (U.S.A.) Inc.
Patent: US5135863 A1, 1992 ; Title/Abstract Full Text Show Details
The Regents of the University of Minnesota
Patent: US5028611 A1, 1991 ; Title/Abstract Full Text Show Details
Matsumoto, Teruki; Urano, Yasuteru; Makino, Yukiko; Kikura-Hanajiri, Ruri; Kawahara, Nobuo; Goda, Yukihiro; Nagano, Tetsuo
Analytical Chemistry, 2008 , vol. 80, # 4 p. 1176 - 1181 Title/Abstract Full Text View citing articles Show Details
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
David, Gabrielle E.; Hibbert, D. Brynn; Frew, Russell D.; Hayman, Alan R.
Australian Journal of Chemistry, 2010 , vol. 63, # 1 p. 22 - 29 Title/Abstract Full Text View citing articles Show Details
Emcure Pharmaceuticals Limited
Patent: US2011/46416 A1, 2011 ; Title/Abstract Full Text Show Details
Moreno, Amira Y.; Mayorov, Alexander V.; Janda, Kim D.
Journal of the American Chemical Society, 2011 , vol. 133, # 17 p. 6587 - 6595 Title/Abstract Full Text View citing articles Show Details
5 of 172
Comment (Pharmacological Data)
Bioactivities present
Reference
Leis, Hans J.; Windischhofer, Werner
Rapid Communications in Mass Spectrometry, 2010 , vol. 24, # 22 p. 3320 - 3324 Title/Abstract Full Text View citing articles Show Details
Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao
International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details
Wood, Matthew R.; Lalancette, Roger A.
Acta Crystallographica Section C: Crystal Structure Communications, 2013 , vol. 69, # 4 p. 388 - 393 Title/Abstract Full Text View citing articles Show Details
Guharoy, Roy; Medicis, Joe; Choi, Se; Stalder, Bruce; Kusiowski, Kim; Allen, Andrea
Veterinary and Human Toxicology, 1999 , vol. 41, # 1 p. 28 - 30 Title/Abstract Full Text View citing articles Show Details
Itzhak, Yossef; Gandia, Carlos; Huang, Paul L.; Ali, Syed F.
Journal of Pharmacology and Experimental Therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Kuribara, Hisashi
European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 5 Title/Abstract Full Text View citing articles Show Details
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text Show Details
Ohmori; Abekawa; Koyama
Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1229 Title/Abstract Full Text Show Details
Witkin; Ricaurte; Katz
Journal of Pharmacology and Experimental Therapeutics, 1990 , vol. 253, # 2 p. 466 - 474 Title/Abstract Full Text View citing articles Show Details
Chahl
British journal of pharmacology, 1972 , vol. 45, # 3 p. 510 - 518
Title/Abstract Full Text Show Details
Campbell; Patil; LaPidus; Campbell; Tye
Title/Abstract Full Text Show Details
LaPidus; Patil; LaPidus; Tye
Title/Abstract Full Text Show Details
Type: Review, Lab: EFF_071212, Owner: EFFECT, Number: 000, Revision: 07.12.2012 00:00:00 2012 Full Text Show Details
Title/Abstract Full Text Show Details
CHANCE
The Journal of pharmacology and experimental therapeutics, 1946 , vol. 87, p. 214 - 219 Title/Abstract Full Text View citing articles Show Details
SINNIGER
Schweizerische medizinische Wochenschrift, 1954 , vol. 84, # 12 p. 351 - 355 Title/Abstract Full Text View citing articles Show Details
ALLES; FAIRCHILD; JENSEN
Proceedings of the Western Pharmacology Society, 1961 , vol. 4, p. 23 - 26 Title/Abstract Full Text View citing articles Show Details
Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.
Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details
Švorc, Ľubomír; Vojs, Marian; Michniak, Pavol; Marton, Marián; Rievaj, Miroslav; Bustin, Dušan
Journal of Electroanalytical Chemistry, 2014 , vol. 717-718, p. 34 - 40 Title/Abstract Full Text View citing articles Show Details
Pramanik, Chinmoy; Bapat, Kiran; Chaudhari, Ashok; Kulkarni, Mukund G.; Kolla, Rangarao; Sompalli, Srinivasarao; Tripathy, Narendra K.; Gurjar, Mukund K.
Organic Process Research and Development, 2014 , vol. 18, # 4 p. 495 - 500 Title/Abstract Full Text View citing articles Show Details
6 of 172
Comment (Pharmacological Data)
Bioactivities present
Reference
Kousik, Sharanya M.; Napier, T. Celeste; Ross, Ryan D.; Sumner, D. Rick; Carvey, Paul M.
Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 351, # 2 p. 432 - 439 Title/Abstract Full Text View citing articles Show Details
Mata, Mariana M.; Napier, T. Celeste; Graves, Steven M.; Mahmood, Fareeha; Raeisi, Shohreh; Baum, Linda L.
European Journal of Pharmacology, 2015 , vol. 752, p. 26 - 33 Title/Abstract Full Text View citing articles Show Details
Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian
European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details
Muramoto, Shin; Forbes, Thomas P.; Van Asten, Arian C.; Gillen, Greg
Analytical Chemistry, 2015 , vol. 87, # 10 p. 5444 - 5450 Title/Abstract Full Text View citing articles Show Details
Darvish, Mina; Qomi, Mahnaz; Akhgari, Maryam; Raoufi, Parviz
Biosciences Biotechnology Research Asia, 2015 , vol. 12, # 1 p. 587 - 597 Title/Abstract Full Text View citing articles Show Details
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus
Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details
Rodríguez, José E.; Campbell, Kendall M.
Primary Care - Clinics in Office Practice, 2016 , vol. 43, # 1 p. 61 - 67 Title/Abstract Full Text View citing articles Show Details
Tao, Yijie; Zhang, Kai; Zhang, Zhaoyang; Cheng, Haifeng; Jiao, Chunlin; Zhao, Yulei
Chemical Engineering Journal, 2016 , vol. 293, p. 34 - 43 Title/Abstract Full Text View citing articles Show Details
Kitanaka, Junichi; Kitanaka, Nobue; Scott Hall; Uhl, George R.; Takemura, Motohiko
Drug Target Insights, 2016 , vol. 10, p. 1 - 7 Title/Abstract Full Text View citing articles Show Details
Collins, Karen C.; Schlosburg, Joel E.; Bremer, Paul T.; Janda, Kim D.
Journal of Medicinal Chemistry, 2016 , vol. 59, # 8 p. 3878 - 3885 Title/Abstract Full Text View citing articles Show Details
Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu
Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details
Asadullin, Azat R.; Yuldashev, Vladimir L.; Galeeva, Elena Kh.; Achmetova, Elvina A.; Nikolaev, Ivan V.
International Journal of Environmental and Science Education, 2016 , vol. 11, # 8 p. 1913 - 1922 Title/Abstract Full Text View citing articles Show Details
Nožina, Miroslav; Kraus, Filip
Europe - Asia Studies, 2016 , vol. 68, # 3 p. 508 - 528 Title/Abstract Full Text View citing articles Show Details
De Jesús-Cortés, Héctor; Miller, Adam D.; Britt, Jeremiah K.; DeMarco, Anthony J.; De Jesús-Cortés, Mayralis; Stuebing, Emily; Naidoo, Jacinth; Vázquez-Rosa, Edwin; Morlock, Lorraine; Williams, Noelle S.; Ready, Joseph M.; Narayanan, Nandakumar S.; Pieper, Andrew A.
Parkinson's Disease, 2015 , vol. 1, art. no. 15010 Title/Abstract Full Text View citing articles Show Details
Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.
Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details
Tao, Yijie; Zhang, Kai; Zhang, Chaoyang; Cheng, Haifeng; Jiao, Chunlin; Zhao, Yulei
Materials Science in Semiconductor Processing, 2016 , vol. 56, p. 66 - 75 Title/Abstract Full Text View citing articles Show Details
Khorassani, Farah E.; Misher, Anne; Garris, Shauna
American Journal of Health-System Pharmacy, 2015 , vol. 72, # 9 p. 697 - 706 Title/Abstract Full Text View citing articles Show Details
Ramakrishna; Nagabhushana; Prasad, B. Daruka; Vidya; Sharma; Anantharaju; Prashantha; Choudhary, Nityanand
Journal of Luminescence, 2017 , vol. 181, p. 153 - 163 Title/Abstract Full Text Show Details
Donegani, Enrico; Paal, Peter; Küpper, Thomas; Hefti, Urs; Basnyat, Buddha; Carceller, Anna; Bouzat, Pierre; Van Der Spek, Rianne; Hillebrandt, David
High Altitude Medicine and Biology, 2016 , vol. 17, # 3 p. 157 - 184 Title/Abstract Full Text Show Details
7 of 172
Comment (Pharmacological Data)
Bioactivities present
Reference
Asadullin, Azat R.; Galeeva, Elena Kh.; Achmetova, Elvina A.; Nikolaev, Ivan V.
International Journal of Environmental and Science Education, 2016 , vol. 11, # 14 art. no. IJESE..001, p. 6697 - 6703 Title/Abstract Full Text Show Details
Goulding, David R.; White, Sally S.; McBride, Sandra J.; Fenton, Suzanne E.; Harry, G. Jean
NeuroToxicology, 2017 , vol. 58, p. 110 - 119 Title/Abstract Full Text Show Details
Hearne, Evelyn; Grund, Jean-Paul Cornelius; Van Hout, Marie Claire; McVeigh, Jim
Harm Reduction Journal, 2016 , vol. 13, # 1 art. no. 14 Title/Abstract Full Text Show Details
Weiß, Jennifer A.; Kadkhodaei, Kian; Schmid, Martin G.
Science and Justice, 2017 , vol. 57, # 1 p. 6 - 12 Title/Abstract Full Text Show Details
Florez, Diego Hernando Ângulo; dos Santos Moreira, Ana Maria; da Silva, Pedro Rafael; Brandão, Ricardo; Borges, Marcella Matos Cordeiro; de Santana, Fernando José Malagueño; Borges, Keyller Bastos
Drug and Alcohol Dependence, 2017 , vol. 173, p. 59 - 68 Title/Abstract Full Text Show Details
Brown, P.Leon; Shepard, Paul D.
Journal of Neurophysiology, 2016 , vol. 116, # 3 p. 1161 - 1174 Title/Abstract Full Text Show Details
CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.
Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details
8 of 172
9 of 172
10 of 172
11 of 172
12 of 172
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Sanchez, Ana B.; Varano, Giuseppe P.; De Rozieres, Cyrus M.; Maung, Ricky; Catalan, Irene C.; Dowling, Cari C.; Sejbuk, Natalia E.; Hoefer, Melanie M.; Kaul, Marcus
Antimicrobial Agents and Chemotherapy, 2016 , vol. 60, # 1 p. 168 - 179 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Mori, Tomohisa; Uzawa, Naoki; Iwase, Yoshiyuki; Masukawa, Daiki; Rahmadi, Mahardian; Hirayama, Shigeto; Hokazono, Mayuna; Higashiyama, Kimio; Shioda, Seiji; Suzuki, Tsutomu
Psychopharmacology, 2016 , vol. 233, # 12 p. 2343 - 2353 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Rice, Kenner C.; Gannon, Brenda M.; Fantegrossi, William E.; Gonzalez, Carmen; Paule, Merle G.; Ali, Syed F.
Neuroscience Letters, 2016 , vol. 629, p. 125 - 130 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Mata, Mariana M.; Napier, T. Celeste; Graves, Steven M.; Mahmood, Fareeha; Raeisi, Shohreh; Baum, Linda L.
European Journal of Pharmacology, 2015 , vol. 752, p. 26 - 33 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
13 of 172
14 of 172
15 of 172
16 of 172
Reference
Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.
Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Kousik, Sharanya M.; Napier, T. Celeste; Ross, Ryan D.; Sumner, D. Rick; Carvey, Paul M.
Journal of Pharmacology and Experimental Therapeutics, 2014 , vol. 351, # 2 p. 432 - 439 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Jiang, Wenda; Li, Ji; Zhang, Zhuang; Wang, Hongxin; Wang, Zhejian
European Journal of Pharmacology, 2014 , vol. 745, p. 243 - 248 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cytokine release; inhibition of
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
4 mg/kg
Kind of Dosing (Pharmacological Data)
dose administered 4 times; vehicle: saline
Method (Pharmacological Data)
mice treated with title comp.; 18 h later cytokine levels in plasma measured by mouse cytokine array kit
Results
title comp. reduced plasma interferon-γ level to 55percent of control and plasma interleukin-10 level to 50percent of control
Reference
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cytokine release; induction of
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
4 mg/kg
Kind of Dosing (Pharmacological Data)
dose administered 4 times; vehicle: saline
Method (Pharmacological Data)
mice treated with title comp.; 18 h later cytokine levels in plasma measured by mouse cytokine array kit
Further Details (Pharmacological Data)
MCP-1: monocyte chemotactic protein-1; TNF-α: tumor necrosis factor-α
Results
title comp. increased plasma interleukin-4, MCP-1, and TNF-α levels to 190percent, 130percent, and 120percent of control, resp.
Reference
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
17 of 172
18 of 172
19 of 172
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
dose administered 3 or 4 times with 2-h intervals; vehicle: saline
Method (Pharmacological Data)
mice treated with title comp.; rectal temperature recorded 30 min before or after each title comp. injection
Further Details (Pharmacological Data)
control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. or 2000 IU interferon-γ i.c.v. 30 min prior to 1st and 3rd title comp. injection
Results
title comp. induced hyperthermia; effect was attenuated by peripheral, but not central interferon-γ pretreatment; fig.
Reference
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
dose administered 3 or 4 times with 2-h intervals; vehicle: saline
Method (Pharmacological Data)
mice treated with title comp.; 3 days after the last injection integrity of dopaminergic terminals in striatum assessed by dopamine transporter immunostaining
Further Details (Pharmacological Data)
control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. or 2000 IU interferon-γ i.c.v. 30 min prior to 1st and 3rd title comp. injection or 1 h after the last title comp. injection
Results
title comp. induced degeneration of striatal dopaminergic nerve terminals; effect was attenuated by both peripheral and central interferon-γ pretreatment and by central interferon-γ post-treatment, but not by periferal post-treatment; fig.
Reference
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
20 of 172
Show next 20
21 of 172
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
dose administered 3 or 4 times with 2-h intervals; vehicle: saline
Method (Pharmacological Data)
mice treated with title comp.; 3 days after the last injection activated microglial cells and astrocytes were detected in striatum by CD11b and glial fibrillary acidic protein (GFAP) immunostaining, resp.
Further Details (Pharmacological Data)
control: vehicle; further investigations by administration of 20000 IU interferon-γ i.p. 30 min prior to 1st and 3rd title comp. injection
Results
title comp. induced accumulation of microglial cells and activated astrocytes; effect was not changed by peripheral interferon-γ pretreatment; fig.
Reference
Hozumi, Hiroaki; Asanuma, Masato; Miyazaki, Ikuko; Fukuoka, Saki; Kikkawa, Yuri; Kimoto, Naotaka; Kitamura, Yoshihisa; Sendo, Toshiaki; Kita, Taizo; Gomita, Yutaka
Toxicology Letters, 2008 , vol. 177, # 2 p. 123 - 129 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological Data)
double-lumen catheter implanted into monkeys who trained to get reinforcer (0.032 mg/kg/injection of cocaine) by responding (16 responses) to central key resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion
Further Details (Pharmacological Data)
control: saline (78.6 injections of cocaine/day during availability of 0.032 mg/kg/injection of cocaine; percent of cocaine-maintained responding; data obtained during last 3 days of treatment
Results
title comp. (at 0.056 mg/kg/h) sign. decreased 0.032 mg/kg/injection of cocaine self-administration to ca. 5percent of control (figure)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Hide facts Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological
double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion
Data)
22 of 172
23 of 172
24 of 172
Further Details (Pharmacological Data)
control: saline (97.2 food pellets/d); percent of food-maintained responding; data obtained during last 3 days of treatment
Comment (Pharmacological Data)
No effect
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological Data)
double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key; this resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion
Further Details (Pharmacological Data)
control: saline (95.3 food pellets/d); percent of food-maintained responding; data obtained during all 7 d of treatment to determine time course of title comp. effect
Results
title comp. at 0.056 mg/kg/h had slight effects on food-maintained responding during all 7 days of treatment (figure)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological Data)
double-lumen catheter implanted into monkeys trained to get reinforcer (0.01 mg/kg/injection of cocaine) by responding (16 responses) to central key; this resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion
Further Details (Pharmacological Data)
control: saline (79.2 injections of cocaine/day during availability of 0.01 mg/kg/injection of cocaine); percent of cocaine-maintained responding; data obtained during all 7 d of treatment to determine time course of title comp. effect
Results
during treatment with title comp. (0.056 mg/kg/h) maximal decreases in cocaine self-administration were achieved within 2 to 5 days, and decreases in cocaine self-administration generally sustained for duration of treatment (figure)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect
behavioural symptoms
(Pharmacological Data)
25 of 172
26 of 172
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.01 - 0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; each dose of title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological Data)
double-lumen catheter implanted into monkeys who trained to get reinforcer (25 food pellets/session) by responding (16 responses) to central key; this resulted in food delivery at 1-h sessions (4 sessions/day) performed during title comp. infusion
Further Details (Pharmacological Data)
control: saline (95.3 food pellets/d); percent of food-maintained responding; data obtained during last 3 d of 7-d treatment
Type (Pharmacological Data)
ED50
Value of Type (Pharmacological Data)
> 0.073 mg/kg
Results
effect of title comp. on food-maintained responding varied; it either did not affect food-maintained responding or decreased it (figure, table)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.01 - 0.056 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water; each dose of title comp. administered with infusion dose/h (one injection every 20 min from 10.30 AM to 9.30 AM the next morning) for 7 d
Method (Pharmacological Data)
double-lumen catheter implanted into monkeys who trained to get reinforcer (0.01 mg/kg/injection of cocaine) by responding (16 responses) to central key resulted in cocaine delivery at 1-h sessions (4 sessions/d) performed during title comp. infusion
Further Details (Pharmacological Data)
control: saline (79.2 injections of cocaine/day during availability of 0.01 mg/kg/injection of cocaine); percent of cocaine-maintained responding; data obtained during last 3 d of 7-d treatment
Type (Pharmacological Data)
ED50
Value of Type (Pharmacological Data)
0.024 mg/kg
Results
title comp. produced dose-dependent decreases in 0.01 mg/kg/injection cocaine self-administration (figure, table)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect
behavioural symptoms
(Pharmacological Data)
27 of 172
28 of 172
Species or TestSystem (Pharmacological Data)
Macaca mulatta, rhesus monkey
Sex
male
Route of Application
intramuscular
Concentration (Pharmacological Data)
0.03 - 0.3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water and was filter-sterilized using 0.22-μm Millipore filter
Method (Pharmacological Data)
monkeys trained to discriminate between saline and 0.4 mg/kg of cocaine i.m.; then increasing doses of title comp. administered cumulatively at beginning of time-out 15-min period; responding to title comp.-appropriate key assessed during 5 min
Further Details (Pharmacological Data)
control: saline (mean rate = 1.96 responses/s); percent of title comp.-appropriate responding for entire response period and response rate were determined
Type (Pharmacological Data)
ED50
Value of Type (Pharmacological Data)
0.10 mg/kg
Results
title comp. produced dose-dependent and complete substitution for cocaine training dose (0.4 mg/kg); dose that produced complete substitution either increased or decreased response rate (mean rate = 95.5percent of control) (figure, table)
Reference
Negus; Mello; Blough; Baumann; Rothman
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 320, # 2 p. 627 - 636 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
human embryonic kidney 293 cells
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological Data)
effect of title comp. on rTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing rTAAR1; rTAAR: rat trace amine-associated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
0.89 μmol/l
Results
title comp. dose-dependently stimulated cAMP production and was full agonist (86.20percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem
human embryonic kidney 293 cells
(Pharmacological Data)
29 of 172
30 of 172
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological Data)
effect of title comp. on mTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing mTAAR1; mTAAR: mouse trace amine-associated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
0.92 μmol/l
Results
title comp. dose-dependently stimulated cAMP production and was full agonist (91.76percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
human embryonic kidney 293 cells
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological Data)
effect of title comp. on h-rChTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing h-rChTAAR1; h-rChTAAR: human-rat chimera trace amineassociated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
4.44 μmol/l
Results
title comp. dose-dependently stimulated cAMP production (not saturated) and was full agonist (96.71percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
2 - 20 mg/kg
Kind of Dosing
title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
(Pharmacological Data)
31 of 172
32 of 172
Method (Pharmacological Data)
mice were with title comp. alone or coadministered with morphine; stereotyped behavior, locomotion, sedation and ataxia observed just before and after administration at 30-480 min and at 24 and 48 h
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied
Results
title comp. + morphine induced hyperlocomotion, Straub tail reaction, miosis, ataxia after 60-180 min and behavioral disruption after 120 min; fullerene, cooling attenuated title comp. effect; mepacrine showed ataxia, self-injurious behavior; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
2 - 20 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
Method (Pharmacological Data)
mice were administered title comp. alone or coadministered with morphine; toxicity and percent mortality observed just before and after administration at 30-480 min and at 24 and 48 h
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied
Results
coadmin. of title comp. and morphine showed tremors before death after 60-180 min and more than 80percent mice died within 24 h; fullerene, mepacrine and cooling attenuated the lethal effect of title comp. coadministered with morphine; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
colonic temperature; effect on
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
2 - 20 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
Method (Pharmacological Data)
mice were administered with title comp. alone or coadministered with morphine; colonic temp. immediately measured before and after administration at 30 to 480 min and at 24 and 48 h
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied
Results
title comp.+ morphine induced signif. hyperthermia within 30 min and normalized within 60 min; after ca. 120 min colonic temp. decreased; fullerene decreased colonic temp. post-dose; cooling normalized colonic temp.; mepacrine had no effect; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
33 of 172
34 of 172
35 of 172
Effect (Pharmacological Data)
oxidant
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
20 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
Method (Pharmacological Data)
mice were coadministered with title comp. and morphine; blood sampled from heart 60 min post-dose; centrifuged; oxidant effect determined by electron spin resonance analyzed using JEOL spin resonance apparatus
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied
Results
coadministered of title comp. and morphine increased hydroxyl radicals; title comp. effect was significantly and potently attenuated by fullerene and cooling while mepacrine slightly and nonsignificantly attenuated the effect; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cell morphology; effect on
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
20 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in saline containing 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
Method (Pharmacological Data)
mice were coadministered with title comp. and morphine; sacrificed after 4 h post-dose; kidney and liver collected; fixed; stained; effect of title comp. on cell morphology observed
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine and cooling on title comp. studied
Results
coadministration of title comp. and morphine showed apparent rupture of hepatic cells and changes in form of kidney cells; these effects were abolished by fullerene, mepacrine and cooling; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Concentration (Pharmacological Data)
20 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in saline containig 1percent Tween 80; administered at a dose of 0.1 ml/10 g body weight
36 of 172
37 of 172
38 of 172
Method (Pharmacological Data)
mice were coadministered with title comp. and morphine; sacrificed after 4 h post-dose; heart, kidney, liver and brain collected; fixed; stained; poly (ADP-ribose) polymerase positive cells determined by immunohistochemical analysis
Further Details (Pharmacological Data)
control: saline treated rats; further, effects of fullerene, mepacrine, benzamide and cooling on title comp. studied
Results
coadministration of title comp. and morphine signif. increased number of poly (ADP-ribose) polymerase cells in hepatic, cardiac and kidney cells and slightly in striatum; title comp. effect attenuated by fullerene, mepacrine, benzamide and cooling; fig.
Reference
Mori, Tomohisa; Ito, Shinobu; Namiki, Mizuho; Suzuki, Tadashi; Kobayashi, Shizuko; Matsubayashi, Kenji; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 236, # 3 p. 149 - 157 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neuroregulatoric
Species or TestSystem (Pharmacological Data)
limbic neuron/glia cells of newborn ICR mouse
Concentration (Pharmacological Data)
10 - 100 μmol/l
Method (Pharmacological Data)
co-cultures treated with title comp. for up to 3 days, then intensity of GFAP-like immunoreactivity measured with computer-assisted system
Further Details (Pharmacological Data)
control: normal medium; GFAP: glial fibrillary acidic protein
Results
title comp. caused robust activation of astrocytes even after 1 day of treatment and effect maintained 2 days after removal of title comp.; fig.
Reference
Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru
European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
limbic neuron/glia cells of newborn ICR mouse
Concentration (Pharmacological Data)
10 - 1000 μmol/l
Method (Pharmacological Data)
co-cultures treated with title comp. for 3 days, then cells stained with antibody to cleaved caspase-3
Further Details (Pharmacological Data)
control: normal medium
Results
100-1000 μM title comp. caused dose-dependent expression of cleaved caspase-3; fig.
Reference
Suzuki, Tsutomu; Shindo, Keiko; Miyatake, Mayumi; Kurokawa, Kazuhiro; Higashiyama, Kimio; Suzuki, Masami; Narita, Minoru
European Journal of Pharmacology, 2007 , vol. 574, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hyperthermic
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse with wild type DAT, SERT genes copies
Sex
male and female
Route of Application
intraperitoneal
Concentration
45 mg/kg
(Pharmacological Data)
39 of 172
40 of 172
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe
Further Details (Pharmacological Data)
fluoxetine (FLU) and nisoxetine (NIS) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT+/+ SERT+/+, DAT+/+ SERT +/-, DAT+/- SERT+/-, DAT+/- SERT+/+
Results
title comp. sign. increased body temp. of DAT+/+ SERT +/+, DAT+/- SERT +/+ and DAT+/+ SERT+/-, DAT+/- SERT+/- mice 30-60 and 15-60 min after admin. by maximally ca. 1.5, 2 and 2.5, 1.7 degree, resp. (FLU was hyperthermic, NIS had no effect) (figures)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
body temperature; effect on
Species or TestSystem (Pharmacological Data)
DAT single KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe
Further Details (Pharmacological Data)
nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT-/- SERT+/+, DAT-/- SERT +/-
Results
title comp. sign. increased body temp. of DAT-/- SERT +/+ mice 30-60 min after admin. and caused sign. hypothermia 15 min followed by sign. hyperthermia 45-60 min after admin. in DAT-/- SERT+/- mice (NIS, FLU were hypothermic) (figures)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hyperthermic
Species or TestSystem (Pharmacological Data)
SERT single KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe
Further Details (Pharmacological
nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotypes: DAT+/+ SERT-/-, DAT+/- SERT -/-
Data)
41 of 172
42 of 172
43 of 172
Results
title comp. sign. increased body temp. of SERT single KO mice 30-60 min after admin. by maximally ca. 2-2.5 degrees (NIS, FLU had no sign. effect) (figures)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hypothermic
Species or TestSystem (Pharmacological Data)
DAT/SERT double KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
body temperature (temp.) measured 15-60 min after title comp. admin. by digital thermometer and rectal probe
Further Details (Pharmacological Data)
nisoxetine (NIS) and fluoxetine (FLU) used for reference; DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-
Results
title comp. sign. decreased body temp. of DAT/SERT double KO mice 15-60 min after admin. by maximally ca. 2.2 degrees (NIS, FLU were hyperthermic) (figures)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
gene expression; induction of
Species or TestSystem (Pharmacological Data)
DAT/SERT double KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-; IL-1β: interleukin-1β
Comment (Pharmacological Data)
No effect
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect
toxicity
(Pharmacological Data)
44 of 172
Species or TestSystem (Pharmacological Data)
DAT/SERT double KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
119.6 mg/kg
Results
90-150 mg/kg title comp. induced 10.0-100percent lethality in treated animals (table)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
DAT single KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT+/-, DAT-/- SERT+/+
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
112.6 mg/kg
Results
45-150 mg/kg title comp. induced 9.1-100percent lethality in DAT-/- SERT+/+ mice, whereas in DAT-/- SERT+/- percent of lethality was substantially reduced (0 and 11.8percent at 45, 90 and 75 mg/kg, resp.) (table)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
45 of 172
46 of 172
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
SERT single KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT-/-
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
86.0 mg/kg
Results
45-150 mg/kg title comp. induced 4.3-94.7percent lethality in DAT+/- SERT-/- mice; table
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
SERT single KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT-/-
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
76.5 mg/kg
Results
45-150 mg/kg title comp. induced 9.5-95.5percent lethality in DAT+/+ SERT-/- mice; table
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128
Title/Abstract Full Text View citing articles Show Details
47 of 172
48 of 172
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 - 110 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT+/+
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
67.8 mg/kg
Results
15-110 mg/kg title comp. induced 5.0-100percent lethality in DAT+/+ SERT+/+ mice; table
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT+/+
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
73.3 mg/kg
Results
45-150 mg/kg title comp. induced 26.7-95.5percent lethality in DAT+/- SERT+/+ mice; table
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe,
Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
49 of 172
50 of 172
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 - 110 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/+ SERT+/-
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
80.5 mg/kg
Results
45-110 mg/kg title comp. induced 6.7-100percent lethality in DAT+/+ SERT+/- mice; table
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse with DAT, SERT wild type genes copies
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
15 - 150 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. percent of dead animals calculated
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT+/- SERT+/-
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
81.0 mg/kg
Results
45-150 mg/kg title comp. induced 13.3-100percent lethality in DAT+/- SERT+/- mice; table
51 of 172
52 of 172
53 of 172
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
gene expression; effect on
Species or TestSystem (Pharmacological Data)
DAT/SERT double KO C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining
Further Details (Pharmacological Data)
DAT, SERT: dopamine, serotonin transporters; genotype: DAT-/- SERT-/-; IL-1β: interleukin-1β
Comment (Pharmacological Data)
No effect
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
gene expression; induction of
Species or TestSystem (Pharmacological Data)
C57BL/6Jx129Sv/J mouse
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
45 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9percent saline solution
Method (Pharmacological Data)
60 min after title comp. admin. amount of IL-1β mRNA in hypothalamus, nucleus caudatus and accumbens, frontal cortex measured by RT-PCR; 1.2percent agarose gel electrophoresis; ethidium bromide staining
Further Details (Pharmacological Data)
IL-1β: interleukin-1β
Results
title comp. sign. increased hypothalamic IL-1β gene expression by 5-fold; no effect in other brain tissues (figures)
Reference
Numachi, Yohtaro; Ohara, Arihisa; Yamashita, Motoyasu; Fukushima, Setsu; Kobayashi, Hideaki; Hata, Harumi; Watanabe, Hidekazu; Hall, F. Scott; Lesch, Klaus-Peter; Murphy, Dennis L.; Uhl, George R.; Sora, Ichiro
European Journal of Pharmacology, 2007 , vol. 572, # 2-3 p. 120 - 128 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem
BALB/c mouse
(Pharmacological Data)
54 of 172
55 of 172
56 of 172
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
20 mg/kg
Method (Pharmacological Data)
title comp. administered in combination with morphine (20 mg/kg); mice survival monitored
Further Details (Pharmacological Data)
control: saline
Results
more than 90percent of mice were dead within 24 h after dosing; fig.
Reference
Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
2 - 20 mg/kg
Method (Pharmacological Data)
mice treated with title comp.; mouse striatum conc. of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3-MT) determined using HPLC
Results
title comp. at 20 mg/kg, but not at 2.0 mg/kg, decreased conc. of DA and DOPAC, but not HVA and 3MT; fig.
Reference
Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
oxidant
Species or TestSystem (Pharmacological Data)
BALB/c mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
20 mg/kg
Method (Pharmacological Data)
mice treated with title comp. alone or in combination with morphine (20 mg/kg); signal intensities of superoxide adducts (DMPO-AsA,OOH; DPPMPO-AsA,-OOH) in tissues (brain/heart/lung/liver/muscle) measured by ESP spin trap method
Further Details (Pharmacological Data)
DMPO: 5,5-dimethyl-1-pyrroline N-oxide; AsA: ascorbyl radical; DPPMPO: 5-diphenylphosphinoyl-5-methyl-4,5-dihydro-3H-pyrrole N-oxide; ESP: electron spin resonance; vehicle control
Results
title comp. induced high-intensity of free radical signal in brain (striatum) compared to title comp. plus morphine administration; in other tissues coadministration led to increased signal intensity compared to title comp.; fig.
Reference
Ito, Shinobu; Mori, Tomohisa; Kanazawa, Hideko; Sawaguchi, Toshiko
Toxicology, 2007 , vol. 240, # 1-2 p. 96 - 110 Title/Abstract Full Text View citing articles Show Details
Effect
drug interaction
(Pharmacological Data)
57 of 172
58 of 172
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
Ca. 0.5 - 10 μmol/kg
Method (Pharmacological Data)
rats trained to discriminate cocaine (29.4 μmol/kg, i.p.) from saline treated with title comp.; 5 or 15 min after rats tested in two-lever operant-conditioning chambers
Further Details (Pharmacological Data)
further studies: title comp. dosed with cocaine (ca. 3-30 μmol/kg)
Type (Pharmacological Data)
ED50
Value of Type (Pharmacological Data)
2.18 μmol/kg
Results
title comp. engendered dose-related increases in percent of responses on cocaine-appropriate lever; title comp. in combination with cocaine produced sign. greater effect
Reference
Li, Su-Min; Campbell, Bettye L.; Katz, Jonathan L.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 3 p. 1088 - 1096 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.3 - 1 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and administered as bolus injection
Method (Pharmacological Data)
rats administered with title comp.; blood collected every 15 min pre-dosing and at 15-min intervals for 90 min post-dosing; dialyzed; dialysates assayed for 5-hydroxytryptamine and 5-hydroxyindoleacetic acid using HPLC with electrochemical detection
Further Details (Pharmacological Data)
control: saline; ref.: fluoxetine
Results
title comp. elevated 5-hydroxytryptamine to 7- and 12-fold after 0.3 and 1.0 mg/kg, resp.; title comp. treatment did not affect plasma 5hydroxyindoleacetic acid levels; diagram
Reference
Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat blood
Sex
male
Concentration
0.3 - 33 μmol/l
(Pharmacological Data)
59 of 172
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline
Method (Pharmacological Data)
title comp. added to blood samples; microdialysis probes placed into blood samples; dialysate efflux collected for 15 min; assayed for 5hydroxytryptamine levels
Further Details (Pharmacological Data)
control: saline; ref.: fluoxetine
Results
title comp. increased plasma 5-hydroxytryptamine levels, producing 4- and 44-fold elevations when administered at concentrations of 3 and 33 μmol/l, resp.; diagram
Reference
Zolkowska, Dorota; Rothman, Richard B.; Baumann, Michael H.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 318, # 2 p. 604 - 610 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
rearing activity; reduction of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Method (Pharmacological Data)
Example 2 Synergy Between an Allosteric Potentiator of AMPA Receptors and Clozapine in an Animal Model of Schizophrenia Amphetamine induction of stereotypic behavior is a well-known and widely used animal model of schizophrenia. The logic for this has been based primarily on two related sets of findings: 1) Amphetamine abuse in humans is known to provoke psychotic symptoms including paranoid ideation, delusions, hallucinations, and stereotyped compulsive behaviors; and,2) Antipsychotic drugs that are effective in the treatment of human schizophrenia are also known to attenuate stereotypic behaviors induced in rats by amphetamines. Finding no. (2) indicates that amphetamine-induced stereotypic behaviors in rats are a useful model for screening potential anti-schizophrenic drugs. Both findings have been instrumental in validating the hypothesis that psychotic symptoms are due, in part, to hyperactive dopaminergic transmission since amphetamines enhance dopamine release and typical neuroleptic drugs are potent dopamine receptor antagonists. The experiments described below used enhanced locomotor and stereotypic rearing activity induced by amphetamines in rats as a model. Published authority for the use and reliability of this model is found in: Janssen, et al., "Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine- or apomorphine-induced 'Cheroing' and 'agitation' in rats" Arzneimittel-Forschung 17:841-854 (1967); Bentall, A.C.C. et al., "Blockade of amphetamine-induced locomotor activity and stereotypy in rats by spiroperidol but not by an atypical neuroleptic, thioridazine," Neuropharmacology 19:699-703 (1980): Niemegeers. C.J.E., et al., "A systematic study of the pharmacological activities of dopamine antagonists," Life Science 24:2201-2216 (1979); and Hornykiewicz, O., "Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence," Neuroscience 3:773-783 (1978). In the present experiments, male Sprague-Dawley rats (250-300 g; Charles River Laboratories) were given ad libitum food and water and maintained on a 12:12 hr light:dark cycle with lights on at 6:00 AM. Behavioral studies utilized a computerized Photobeam Activity System (San Diego Instruments, San Diego, CA), in which each of ten test cages (standard polycarbonate animal cage; 26 cm x 48 cm x 20 cm; W x L x H) were surrounded by two photobeam arrays that were placed to detect locomotor behavior with a lower array and rearing behavior with an upper array. Locomotor and rearing activities were continuously monitored by computer for all ten test cages. Test cages (with photobeam arrays) were placed in a partially darkened room with room ventilation as background noise. On the test day, naive rats were initially placed in the test cages and baseline behavioral activity in the novel environment was monitored during a 30-minute acclimation period. The rats were then injected (i.p.) with vehicle or drug(s) dissolved in vehicle and immediately returned to the test cage and monitored undisturbed for 90 minutes. Experimental groups (n = 10-12, except vehicle, n = 6) were 1) vehicle (saline or 1percent lactic acid, pH 5.0); 2) S-(+)-methamphetamine HCl (METH: 2.0 mg/kg); 3) METH (2 mg/kg) + CX516 (10 mg/kg); 4) METH (2 mg/kg) + clozapine (1.0 mg/kg); and 5) METH (2 mg/kg) + CX516 (10 mg/kg) + clozapine (1.0 mg/kg). Behavioral experiments were repeated at least twice for each condition. Photobeam breaks were summed by the computer into ten-minute periods for analysis. Group means and standard errors are reported in the figures: means and standard deviations were used for statistical analysis by unpaired, two-tailed t test assuming unequal variance. Activity measurements presented in Figures 1 and 2 show that CX516 synergistically enhanced the antagonistic activity of c
Results
test compound administration has rearing activity (see fig. 1-4)
Location
Page/Page column 21-22
Reference
CORTEX PHARMACEUTICALS, INC.; The Regents of the University of California
Patent: EP1026950 B1, 2006 ; Title/Abstract Full Text Show Details
60 of 172
Effect (Pharmacological Data)
action potential; effect on
Species or TestSystem (Pharmacological Data)
sheep cardiac Purkinje fiber
Sex
male
Concentration
0.05 - 5 μmol/l
(Pharmacological Data)
61 of 172
62 of 172
Kind of Dosing (Pharmacological Data)
formulated in DMSO; added cumulatively
Method (Pharmacological Data)
after 30 min. treatment with title comp. fibers placed to two-channel recording chamber with two silver stimulation electrodes; 1 Hz; square-wave constant voltage pulses ca. 0.05 ms; cardiac action potentials (AP) monitored
Further Details (Pharmacological Data)
analysed parameters: AP duration at 50 percent or 90 percent repolarisation, maximum rate of rise in AP upstroke, upstroke amplitude, diastolic membrane potential; further investigation with dl-sotalol, human ether-a-go-go related gene/K(1+) current blocker
Comment (Pharmacological Data)
No effect
Reference
Sheridan, Robert D.; Turner, Simon R.; Cooper, Graham J.; Tattersall, John E.H.
European Journal of Pharmacology, 2005 , vol. 511, # 2-3 p. 99 - 107 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
title comp. administration; for up to 48 h after last injection prostaglandin E2 level in striatum determined by enzyme immunoassay
Further Details (Pharmacological Data)
control: vehicle
Comment (Pharmacological Data)
No effect
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein expression; induction of
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
title comp. administration; at 3 - 48 h after last injection COX-1 and COX-2 protein levels in striatum were determined by immunoblotting with specific antibodies
Further Details
COX: cyclooxygenase; control: vehicle
(Pharmacological Data)
63 of 172
64 of 172
65 of 172
Results
title comp. increased COX-2 level by 50 percent at 3 h after injection, and it remained high for up to 48 h with maximum of 390 percent of control at 24 h; title comp. had no effect on COX-1 level
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein expression; induction of
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs1tm1Unc mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
wild-type mice and mice with null mutation of COX-1 were used; title comp. administration; at 24 h after last injection COX-2 protein level in striatum were determined by immunoblotting with specific antibodies
Further Details (Pharmacological Data)
COX: cyclooxygenase; control: vehicle
Results
title comp. increased COX-2 level by up to 320 percent of control in wild-type mice; in COX-1-null mice COX-2 level also was elevated by title comp.
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein expression; induction of
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs2tm1Smi mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
wild-type mice and mice with null mutation of COX-2 were used; title comp. administration; at 24 h after last injection COX-1 and COX-2 protein levels in striatum were determined by immunoblotting with specific antibodies
Further Details (Pharmacological Data)
COX: cyclooxygenase; control: vehicle
Results
title comp. increased COX-2 level by up to 320 percent of control in wild-type mice; in COX-2-null mice COX-1 level also was not affected by title comp.
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
tm1Unc
66 of 172
67 of 172
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs1
mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
wild-type mice and mice with null mutation of COX-1 were used; title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection
Further Details (Pharmacological Data)
COX: cyclooxygenase; control: vehicle
Results
title comp. reduced dopamine level in striatum to ca. 30 percent of control both in wild-type and COX-1-null mice
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs2tm1Smi mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
wild-type mice and mice with null mutation of COX-2 were used; title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection
Further Details (Pharmacological Data)
COX: cyclooxygenase; control: vehicle
Results
title comp. reduced dopamine level in striatum to ca. 30 percent of control in wild-type mice and to 81 percent of control in COX-2-null mice
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Data)
68 of 172
69 of 172
Method (Pharmacological Data)
title comp. administration; at 48 h after last injection dopamine level in striatum were determined by high-performance liquid chromatography with electrochemical detection
Further Details (Pharmacological Data)
control: vehicle; further investigations using inhibitors of cyclooxygenase 2 (rofecoxib, NS-398), cyclooxygenase 1 (SC-560), cyclooxygenases 1 and 2 (ketoprofen), and cyclooxygenase 3 (antipyrine)
Results
title comp. reduced dopamine level in striatum to ca. 30 percent of control; neither of cyclooxygenase inhibitors changed this effect
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated
Further Details (Pharmacological Data)
AUC: area under curve; control: vehicle; further investigations using inhibitors of cyclooxygenase 2 (rofecoxib, NS-398), cyclooxygenase 1 (SC-560), cyclooxygenases 1 and 2 (ketoprofen), and cyclooxygenase 3 (antipyrine)
Results
title comp. increased body temperature by ca. 1 deg C at time period of 1 - 6 h after first injection with AUC = 2514 vs AUC = 2160 in control; cyclooxygenase inhibitors had variable effects and did not show clear inhibition of title comp. effect
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hypothermic
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs1tm1Unc mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
mice were with null mutation of cyclooxygenase 1; body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated
Further Details (Pharmacological Data)
AUC: area under curve; control: vehicle
Results
title comp. decreased body temperature by 1 - 2 deg C at time period of 1 - 3 h after first injection; later body temperature became slightly higher than in control; AUC = 2232 in title comp.-treated mice vs AUC = 2160 in control
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
70 of 172
71 of 172
72 of 172
Effect (Pharmacological Data)
hypothermic
Species or TestSystem (Pharmacological Data)
B6;129P2-Ptgs2tm1Smi mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dose was administered in 4 injections with 2-h intervals; dissolved in saline
Method (Pharmacological Data)
mice were with null mutation of cyclooxygenase 2; body temperature was monitored by telemetry from 1 h before title comp. first injection till 2 h after fourth injection; AUC value for this time period was calculated
Further Details (Pharmacological Data)
AUC: area under curve; control: vehicle
Results
title comp. decreased body temperature by 1 - 2 deg C at time period of 1 - 3 h after first injection; later body temperature became slightly higher than in control; AUC = 2142 in title comp.-treated mice vs AUC = 2160 in control
Reference
Thomas, David M.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 313, # 2 p. 870 - 876 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
mouse
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in 0.9 percent NaCl; title comp. in dose 1 mg/kg administered repeatedly on days 1, 3, 5, and again in dose 0.5 mg/kg on day 18 (challenge session)
Method (Pharmacological Data)
wild-type, heterozygous and nociceptin receptor knockout mice; sensitization and challenge with title comp.; locomotor activity monitored for 60 min after injection during sensitization and challenge sessions
Results
locomotor sensitization to title comp. and locomotion on challenge day occurred independently on null mutation of nociceptive receptor gene
Reference
Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.
European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
gene expression; induction of
Species or TestSystem (Pharmacological Data)
mouse
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in 0.9 percent NaCl; title comp. in dose 1 mg/kg administered repeatedly on 1, 3, and 5 day and again on day 18 in dose 0.5 mg/kg (challenge session)
Method (Pharmacological Data)
wild-type, heterozygous and nociceptin receptor knockout mice; sensitization and challenge with title comp.; 90 min after treatment immunohistochemical analysis of s-fos expression in 36 brain regions performed
73 of 172
74 of 172
75 of 172
Further Details (Pharmacological Data)
c-fos: marker of neural activation; NAC: nucleus accumbens core; VCP: ventromedial caudate putamen
Results
treatment with title comp. increased c-fos expression in a third of brain regions, challenge increased expression in almost half of brain regions (table); in NAC and VCP accentuated c-fos expression in nociceptin receptor knockout mice
Reference
Okabe, Chinami; Takeshima, Hiroshi; Murphy, Niall P.
European Journal of Pharmacology, 2005 , vol. 507, # 1-3 p. 57 - 67 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
0.5 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline
Method (Pharmacological Data)
microdialysis probe implanted into substantia nigra; then rats were injected with title comp.; dialysis samples were collected every 30 min for 180 min after injection; conc. of neurotensin in samples was determined using solid-phase radioimmunoassay
Further Details (Pharmacological Data)
further investigations with D1 and D2 receptor antagonists SCH 23390 and eticlopride, resp.
Results
title comp. induced neurotensin release in the substantia nigra only at conc. 0.5 mg/kg with involvement of D1 and D2 dopamine receptors (figure)
Reference
Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.
European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
0.5 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline
Method (Pharmacological Data)
microdialysis probe implanted into globus pallidus; then rats were injected with title comp.; dialysis samples were collected every 30 min for 180 min after injection; conc. of neurotensin in samples was determined using solid-phase radioimmunoassay
Further Details (Pharmacological Data)
radioimmunoassay: protein G-neurotensin antiserum was incubated with samples, then washed and <125>I-neurotensin added; radioactivity counted after <125>I-neurotensin removal; data from treated rats were sorted to "responder" and "non-responder"
Results
title comp. at 0.5 mg/kg induced sign. neurotensin release only in distinct population of treated group ("responder"); 10 mg/kg had no effect in all treated rats (figure)
Reference
Frankel, Paul S.; Hoonakker, Amanda J.; Hanson, Glen R.; Bush, Lloyd; Keefe, Kristen A.; Alburges, Mario E.
European Journal of Pharmacology, 2005 , vol. 522, # 1-3 p. 47 - 54 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
uptake; inhibition of
76 of 172
77 of 172
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 90 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed
Further Details (Pharmacological Data)
control: saline
Results
title comp. caused 65 percent decrease in vesicular dopamine uptake
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 90 rat sacrificed 7 days after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed
Further Details (Pharmacological Data)
control: saline
Results
title comp. decreased vesicular dopamine uptake in dose dependent manner with approximately 75 percent decrease at 10 mg/kg (figure)
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
78 of 172
79 of 172
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 40 rat sacrificed 7 days after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed
Further Details (Pharmacological Data)
control: saline
Comment (Pharmacological Data)
No effect
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 90 rat sacrificed 7 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle pellet prepared, sonicated; dopamine content in supernatant assayed using HPLC system with electrochemical detection
Further Details (Pharmacological Data)
control: saline; HPLC: high-performance liquid chromatography
Results
title comp. decreased dopamine tissue content in dose-dependent manner with about 40 percent decrease at 5 mg/kg (figure)
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 40 rat sacrificed 7 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle pellet prepared, sonicated; dopamine content in supernatant assayed using HPLC system with electrochemical detection
Further Details (Pharmacological Data)
control: saline; HPLC: high-performance liquid chromatography
80 of 172
81 of 172
82 of 172
Comment (Pharmacological Data)
No effect
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 90 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; deuterated title comp. added as internal standard; title comp. conc. detected by liquid chromatography/tandem mass spectrometry
Further Details (Pharmacological Data)
control: saline
Results
title comp. conc. found to be 4.3 ng/mg tissue
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 - 15 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 40 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; deuterated title comp. added as internal standard; title comp. conc. detected by liquid chromatography/tandem mass spectrometry
Further Details (Pharmacological Data)
control: saline
Results
title comp. conc. found to be 5.0 and 10.7 ng/mg tissue after administration of 10 and 15 mg/kg, resp.
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
83 of 172
84 of 172
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
rectal temperatures of postnatal 90 day rat measured every 1 h beginning 30 min before first title comp. dose and containing until 30 min after last dose
Further Details (Pharmacological Data)
control: saline
Results
title comp. increased rectal temperature to approximately 40 deg C versus 37.5 deg C in control (figure)
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 - 15 mg/kg
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
rectal temperatures of postnatal 40 day rat measured every 1 h beginning 30 min before first title comp. dose and containing until 30 min after last dose
Further Details (Pharmacological Data)
control: saline
Results
title comp. increased rectal temperature to approximately 40 deg C versus 37.5 deg C in control (figure)
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
uptake; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 - 15 mg/kg
85 of 172
86 of 172
Kind of Dosing (Pharmacological Data)
dose for free base; four injections with 2-h intervals
Method (Pharmacological Data)
postnatal day 40 rat sacrificed 1 h after title comp. last dose; striatal tissue removed, homogenized; synaptic vesicle-enriched fraction prepared; <3H>dopamine uptake concurrently assayed
Further Details (Pharmacological Data)
control: saline
Results
both doses of title comp. caused 45 percent decrease in vesicular dopamine uptake
Reference
Truong, Jannine G.; Wilkins, Diana G.; Baudys, Jakub; Crouch, Dennis J.; Johnson-Davis, Kamisha L.; Gibb, James W.; Hanson, Glen R.; Fleckenstein, Annette E.
Journal of Pharmacology and Experimental Therapeutics, 2005 , vol. 314, # 3 p. 1087 - 1092 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Saimiri sciureus, squirrel monkey
Sex
male
Route of Application
intramuscular
Concentration (Pharmacological Data)
0.01 - 0.3 mg/kg
Kind of Dosing (Pharmacological Data)
training dose 0.3 mg/kg
Method (Pharmacological Data)
monkeys trained to discriminate injections of title comp. from saline were treated with title comp. in cumulative manner; title comp.associated lever responding and response rates calculated; substitution of title comp. evaluated
Further Details (Pharmacological Data)
monkeys trained under 10-response fixed ratio schedule of stimulus termination in chambers equipped with colored stimulus lights and two response levers (shock stimuli occurred every 10 s during illumination of stimulus lights); control: saline
Type (Pharmacological Data)
ED50
Value of Type (Pharmacological Data)
0.10 mg/kg
Results
title comp. at 0.3 mg/kg produced full substitution, whereas 0.1 mg/kg produced varying degrees of title comp.-lever responding (range 15-57 percent); ED50 range 0.05-0.15 mg/kg; response rates significantly increased by title comp. (0.1, 0.3 mg/kg) vs saline
Reference
Czoty, Paul W.; Ramanathan, Chinnasamy R.; Mutschler, Nicole H.; Makriyannis, Alexandros; Bergman, Jack
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 2 p. 720 - 727 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Fisher 344 rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.125 - 1 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline
Method (Pharmacological
rats trained to discriminate title comp. from saline after 2-week treatment with 2.0 mg/kg title comp.; training began under FR 1 reinforcement schedule, FR increased to 10; title comp. given 15 min before each session; 6 months withdrawal
Data)
87 of 172
88 of 172
89 of 172
Further Details (Pharmacological Data)
FR: fixed-ratio; 15-min sessions conducted once a day; saline as a control; generalization test with 1.25-10 mg/kg cocaine
Results
title comp. produced a dose-related increase in title comp.-appropriated responses (figure); it founded cross-sensitization with cocaine in title comp.-sensitized rats; sensitization lasted for at least 6 months
Reference
Suzuki, Tsutomu; Fukuoka, Yoshie; Mori, Tomohisa; Miyatake, Mayumi; Narita, Minoru
European Journal of Pharmacology, 2004 , vol. 498, # 1-3 p. 157 - 161 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
four injections with 2-h interval between
Method (Pharmacological Data)
20-25 g mice; 48 h after last dose decapitated, slices from striatum and substantia nigra labeled with HRP-conjugated ILB4; microglial activity quantified by stereological analysis under light microscope; DA amount in striatal slices determd. by HPLC
Further Details (Pharmacological Data)
HRP: horseradish peroxidase; ILB4: isolectin B4 from Griffonia simplicifolia; DA: dopamine; further investigations on mechanism of action using hyperthermia, D1/D2 receptor agonists and DA transporter antagonists
Results
title comp. activates striatal microglia in dose-dependent manner, coincident with DA nerve ending damage (graph); neither microglial activation nor DA cell body damage in substantia nigra; microglial activation suggested as early step in neurotoxicity
Reference
Thomas, David M.; Walker, Paul D.; Benjamins, Joyce A.; Geddes, Timothy J.; Kuhn, Donald M.
Journal of Pharmacology and Experimental Therapeutics, 2004 , vol. 311, # 1 p. 1 - 7 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
embryotoxic
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21 of pregnancy
Method (Pharmacological Data)
pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, 14 or 56; heart removed; upper side of ventricle fixed, cut and stained with hematoxylin-eosin; junction between ventricular and intraventricular septum observed
Results
title comp. treatment induced eosinophilic changes with large and picnotic nuclei, hypertrophy and disarray at postnatal day 0, by postnatal day 14 these lesions disappeared and normal cardiomyocytes formed myocardium (figure)
Reference
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hormone release; inhibition of
90 of 172
91 of 172
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in 0.9 percent saline
Method (Pharmacological Data)
pregnant rats treated with title comp. during 16 days; blood collected; plasma conc. of T3, T4, testosterone and progesterone determined
Further Details (Pharmacological Data)
control: saline
Results
title comp. treatment significantly decreased T4 and progesterone plasma levels and had no effect on T3 and testosterone plasma levels (figure)
Reference
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
mRNA expression; effect on
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21 of pregnancy
Method (Pharmacological Data)
pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, 14 or 56; heart removed; mRNA expression of αand β-myosin heavy chain (MHC) observed in ventricular muscles by quantitative reverse transcription-PCR
Further Details (Pharmacological Data)
PCR: polymerase chain reaction
Results
title comp. increased α-MHC mRNA expression at postnatal day 0 and 5; title comp. had no significant effect on rapid decrease of β-MHC mRNA expression after birth (figure)
Reference
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
embryotoxic
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
92 of 172
93 of 172
94 of 172
Kind of Dosing (Pharmacological Data)
title comp. dissolved in 0.9 percent saline; administered from day 0 to day 21
Method (Pharmacological Data)
pregnant rats treated with title comp.; neonates sacrificed on postnatal day 0, 2, 5, 9, or 14; neonate body weight, heart weight and heart weight/body weight ratio evaluated
Results
title comp. treatment increased heart weight (significant effect at postnatal day 0) (table)
Reference
Inoue, Hiromasa; Nakatome, Masato; Terada, Masaru; Mizuno, Mizuki; Ono, Reiko; Iino, Morio; Ino, Yukiko; Ogura, Yoshiaki; Kuroki, Hisanaga; Matoba, Ryoji
Life Sciences, 2004 , vol. 74, # 12 p. 1529 - 1540 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
mRNA expression; effect on
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Method (Pharmacological Data)
title comp. administered once daily for 5 d followed by 21-d abstinence period; after abstinence period total RNA isolated from tissues; OCTs mRNA expression determined by RT-PCR
Further Details (Pharmacological Data)
RT-PCR: reverse transcriptase-polymerase chain reaction; OCT: organic cation transporter
Results
in title comp.-treated rats expression of OCT3 mRNA was decreased in kidney, brain, and lung compared to untreated control; expression of other OCT mRNAs was not affected
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Endpoint of Effect (Pharmacological Data)
locomotor activity
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.8 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with title comp.; locomotor activity evaluated using photosensor for 2 h every 10 min
Further Details (Pharmacological Data)
behavioral sensitization: treatment with 5 mg/kg of title comp. once a day i.p. for 5 d followed by 21-d abstinence period
Results
significant enhance of locomotor activity in sensitized rats vs. control at 0 - 1 h, but not 1 - 2 h after title comp. administration
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect
pharmacokinetics
(Pharmacological Data)
95 of 172
96 of 172
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
5 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with bolus injection of title comp.; plasma samples collected for up to 3 h; concentration of title comp. evaluated by high performance liquid chromatography
Further Details (Pharmacological Data)
sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; AUC: area under plasma conc.-time curve; Vd: steady-state volume of distribution
Results
significant increase in plasma title comp. conc. in sensitized rats vs control at all time points except 3 h after administration; increase in AUC, decrease in systemic clearance and Vd, and prolongation of t1/2 (57.1 vs 47.4 min) in sensitized rats
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
5 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with bolus injection of title comp.; brain dialysate samples collected for up to 3 h; concentration of title comp. evaluated by high-performance liquid chromatography
Further Details (Pharmacological Data)
sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period
Results
concentration of title comp. in brain dialysate was significantly increased in sensitized rats vs control at all time points
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
0.8 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with injection of title comp.; penetration through blood-brain barrier estimated as AUCbrain/AUCplasma; conc.-time curve for title comp. in each rat analyzed individually by noncompartmental method
Further Details
sensitization: treatment with 5 mg/kg of title comp. i.p. for 5 d followed by 21-d abstinence period; AUC: area under the curve;
97 of 172
98 of 172
99 of 172
(Pharmacological Data)
AUCbrain/AUCplasma: ratio of AUC of unbound title comp. in plasma to AUC in brain extracellular area
Results
significant increase in AUCbrain and AUCbrain/AUCplasma in sensitized rats at 0 - 1 h, but not at 1 - 2 h after administration; increase in AUCplasma at 0 - 2 h
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
5 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with bolus injection of title comp.; 2 h later plasma and tissue samples collected; title comp. conc. determined by high-performance liquid chromatography
Further Details (Pharmacological Data)
sensitization: by treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period
Results
relative magnitude of accumulation, compared to plasma: kidney (43 times) > lung > liver > brain > heart > muscle (7 times) in control rats; tissue/plasma ratios in sensitized rats were significantly decreased in lung and heart
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Kind of Dosing (Pharmacological Data)
bolus injection of 1.09 mg/kg followed by constant-rate infusion of 834 μg/h/kg at a flow rate 2 ml/h
Method (Pharmacological Data)
sensitized and control rats treated with title comp. for 60 min; plasma title comp. conc. determined by high performance liquid chromatography
Further Details (Pharmacological Data)
sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; further invest. using tetraethylammonium, cimetidine, π-aminohippuric acid, and carnitine; Css: conc. of title comp. at steady-state
Results
Css in sensitized rats was significantly higher than in control (200.1 vs 148 ng/ml, resp.); in both groups Css was increased by tetraethylammonium and cimetidine, but not carnitine and p-aminohippuric acid
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Wistar rat
100 of 172
101 of 172
Sex
male
Route of Application
intravenous
Kind of Dosing (Pharmacological Data)
loading dose of 1.09 mg/kg followed by constant-rate infusion of 834 μg/h/kg at a flow rate 2 ml/h
Method (Pharmacological Data)
sensitized and control rats treated with title comp. for 60 min; plasma and urine samples collected; title comp. conc. determined by highperformance chromatography; renal clearance determined (CLR)
Further Details (Pharmacological Data)
sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period; further investigations with tetraethylammonium, cimetidine, π-aminohippuric acid, and carnitine or with urine alkalization (pH 8)
Results
CLR in sensitized rats was lower than in control (10.3 vs 12.2 μl/min, resp.); in both groups CLR was decreased by tetraethylammonium and cimetidine, but not carnitine, p-aminohippuric acid and urine alkalization
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein binding
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
5 mg/kg
Method (Pharmacological Data)
sensitized and control rats were treated with bolus injection of title comp.; title comp. plasma protein binding determined by ultrafiltration
Further Details (Pharmacological Data)
behavioral sensitization: treatment with 5 mg/kg of title comp. i.p. once a day for 5 d followed by 21-d abstinence period
Results
no significant difference in plasma protein binding between sensitized rats vs control observed (unbound fraction 0.48 and 0.46, resp.)
Reference
Kitaichi, Kiyoyuki; Morishita, Yuki; Doi, Yuko; Ueyama, Jun; Matsushima, Miyoko; Zhao, Ying-Lan; Takagi, Kenzo; Hasegawa, Takaaki
European Journal of Pharmacology, 2003 , vol. 464, # 1 p. 39 - 48 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
once daily; dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
Method (Pharmacological Data)
title comp. administered for 5 consecutive days (test d 2-6) and on test d 11; after injections, locomotor activity counted for 30 min (within 5-min intervals) and then for 23 h 30 min (within 30-min intervals)
Further Details (Pharmacological Data)
control: saline
102 of 172
103 of 172
104 of 172
Results
title comp. significantly increased locomotor activity for about 12 h (figure); effect increased at every 5-min interval up to 30 min (figure); effect reached maximal on test d 4 and plateaued thereafter, indicating behavioral sensetization (figures)
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
once daily; dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
Method (Pharmacological Data)
title comp. injected daily on d 2-6 and d 11 (RA) or only on d 11 (SA); 30 min after last injection, animals decapitated; striata and regions of thalami and hypothalami isolated; contents of L-DOPA, DOPAC, 5-HT and 5-hydroxytryptophan determined by HPLC
Further Details (Pharmacological Data)
RA, SA: single, repeated administration, resp.; control: saline; HPLC: high-performance liquid chromatography; L-DOPA: Ldihydroxyphenylalanine; DOPAC: 3,4-dihydroxyphenylacetic acid; 5-HT: 5-hydroxytryptamine
Results
title comp. reduced L-DOPA and 5-HT level in striatum+accumbens (both SA and RA) but not in thalamus+hypothalamus, reduced DOPAC level (RA only) in striatum+accumbens and thalamus+hypothalamus, had no effect on 5-hydroxytryptophan content (table)
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
Method (Pharmacological Data)
title comp. injected daily on test 2-6 and 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; contents of 5-HIAA, norepinephrine and MHPG determined by HPLC
Further Details (Pharmacological Data)
control: saline; HPLC: high-performance liquid chromatography; 5-HIAA: 5-hydroxyindolacetic acid; MHPG: 3-methoxy-4hydroxyphenylglycol
Results
both single and repeated treatment with title comp. reduced 5-HIAA acid content in thalamus+hypothalamus but not in striatum+accumbens, had no effect on content of norepinephrine and its metabolite MHPG (table)
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological
ICR mouse
Data)
105 of 172
106 of 172
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
Method (Pharmacological Data)
title comp. injected daily on test d 2-6 and d 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; centrifuged; washed; content of dopamine determined by HPLC
Further Details (Pharmacological Data)
control: saline; HPLC: high-performance liquid chromatography
Results
title comp. did not change dopamine content in thalamus+hypothalamus (at both single and repeated treatment) but increased content of dopamine in striatum+accumbens after single administration but not after repeated treatment (table)
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
Method (Pharmacological Data)
title comp. injected daily on test d 2-6 and d 11 or only on d 11; 30 min after last injection animals decapitated; striata and regions of thalami and hypothalami isolated; homogenized; contents of 3-MT and HVA determined by HPLC
Further Details (Pharmacological Data)
control: saline; HPLC: high-performance liquid chromatography; 3-MT: 3-methoxytyramine; HVA: homovanilic acid
Comment (Pharmacological Data)
No effect
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
ICR mouse
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline; administered in volume of 0.1 ml/10 g of body weight
107 of 172
108 of 172
109 of 172
Method (Pharmacological Data)
title comp. injected daily on 1-6 and 11 days; body weight measured
Further Details (Pharmacological Data)
control: saline
Comment (Pharmacological Data)
No effect
Reference
Kitanaka, Nobue; Kitanaka, Junichi; Takemura, Motohiko
European Journal of Pharmacology, 2003 , vol. 474, # 1 p. 63 - 70 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
dopamine uptake; inhibition of
Species or TestSystem (Pharmacological Data)
CF-1 mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in 0.9 percent saline; administered as four injections with 2-h intervals
Method (Pharmacological Data)
title comp. administered; 1-24 h later striatal synaptic vesicles obtained; vesicular <3H>dopamine uptake measured by incubation of vesicles (ca. 2.5 μg protein) with 30 nmol/l <3H>dopamine at 30 deg C, 3 min, pH 7.5; radioactivity on filters counted
Further Details (Pharmacological Data)
further investigation with SCH23390 and eticlopride (dopamine D1 and D2 receptor antagonists, resp.); furtherinvestigation in 28.5 or 4 deg C environment
Results
title comp. rapidly decreased vesicular <3H>dopamine uptake; effect was sign. attenuated by eticlopride at 23 deg C and less at 28.5 deg C; SCH23390 had no effect; at 28.5 deg C 80 percent decrease, at 4 deg C 35 percent decrease of <3H>dopamine uptake, resp.
Reference
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
hyperthermic
Species or TestSystem (Pharmacological Data)
CF-1 mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in 0.9 percent saline; administered as four injections with 2-h intervals
Method (Pharmacological Data)
title comp. administered in 6 or 28.5 deg C environment; body temperature measured
Results
title comp. caused hyperthermia (38.5 - 40.5 deg C) in mice at 28.5 deg C environment but failed to induce hyperthermia at 6 deg C
Reference
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological
binding; inhibition of
Data)
110 of 172
111 of 172
Species or TestSystem (Pharmacological Data)
CF-1 mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in 0.9 percent saline; administered as four injections with 2-h intervals
Method (Pharmacological Data)
title comp. administered; 1 or 24 h later striatal synaptic vesicles obtained; <3H>DTB binding measured by incubation of vesicles (ca. 6 μg protein) with 2 nmol/l <3H>DTB at 25 deg C for 10 min; radioactivity bound to filters counted
Further Details (Pharmacological Data)
<H3>DTB: <3H>dihydrotetrabenazine, ligand of vesicular monoamine transporter-2 (VMAT-2)
Results
title comp. rapidly decreased vesicular <3H>DTB binding
Reference
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
protein expression; effect on
Species or TestSystem (Pharmacological Data)
CF-1 mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in 0.9 percent saline; administered as four injections with 2-h intervals
Method (Pharmacological Data)
title comp. administered; 1 h later striatal subcellular fractions obtained; VMAT-2 immunoreactivity assayed in separate fractions (S3, P3) by Western blotting using specific antibodies
Further Details (Pharmacological Data)
VMAT-2: vesicular monoamine transporter-2; S3: vesicular fraction; P3: membrane-associated fraction
Results
title comp. caused subcellular redistribution of VMAT-2 immunoreactivity (decrease in S3 and increase in P3 fractions)
Reference
Ugarte, Yvette V.; Rau, Kristi S.; Riddle, Evan L.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2003 , vol. 472, # 3 p. 165 - 171 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
4 times 10 mg/kg title comp. inj. at 2-h intervals
Method
rats (14/10 h light/dark cycle; 24 deg C) without/with pretreatment with 15 mg/kg s.c. title comp. on two consecutive days weekly for six
112 of 172
113 of 172
114 of 172
(Pharmacological Data)
consecutive weeks; 1 week later, at postnatal day 90 challenged with 'binge' treatment
Further Details (Pharmacological Data)
striatal <3H>dopamine (DA) uptake determined; title comp. effect without/with pretreatment on DA uptake sstudied
Results
long-term DA deficits without pretreatment; response blocked by pretreatment; title comp.-induced hyperthermia also attenuated by pretreatment (graph)
Reference
Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; binding activity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
4 times 10 mg/kg title comp. inj. at 2-h intervals
Method (Pharmacological Data)
rats (14/10 h light/dark cycle; 24 deg C) without/with pretreatment with 15 mg/kg s.c. title comp. on two consecutive days weekly for six consecutive weeks; 1 week later, at postnatal day 90 challenged with 'binge' treatment
Further Details (Pharmacological Data)
striatal <3H>WIN35428 (WIN) binding determined; title comp. effect without/with pretreatment on WIN binding sstudied
Results
long-term decrease of transporter ligand binding without pretreatment; response blocked by pretreatment (graph)
Reference
Riddle, Evan L.; Kokoshka, Jerry M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.
European Journal of Pharmacology, 2002 , vol. 435, # 2-3 p. 181 - 185 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.1 - 3 mg/kg
Kind of Dosing (Pharmacological Data)
daily dose; each dose was separated by at least 2 days of saline treatment; injected in volume of 1 ml/kg
Method (Pharmacological Data)
title comp. was administered; locomotor activity was tested; distance traveled was measured
Further Details (Pharmacological Data)
control: saline
Results
title comp. increased locomotor activity in dose-dependent manner; females were more sensitive to this effect than were males
Reference
Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.
European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem
Sprague-Dawley rat
(Pharmacological Data)
115 of 172
116 of 172
Sex
male and female
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
<= 3 mg/kg
Kind of Dosing (Pharmacological Data)
single dose; each dose was separated by at least 2 days of saline treatment; injected in volume of 1 ml/kg
Method (Pharmacological Data)
title comp. was administered; rat was placed on one side of chamber; place preference (time spent on title comp. paired side) was monitored
Further Details (Pharmacological Data)
control: saline
Results
preference for title comp. paired side was dose-dependent; no differences between males and females were found
Reference
Schindler, Charles W.; Bross, Joshua G.; Thorndike, Eric B.
European Journal of Pharmacology, 2002 , vol. 442, # 3 p. 231 - 235 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
secretion stimulant
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
7.5 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in 0.9 percent NaCl
Method (Pharmacological Data)
adult rats (aged ca. 55 days, 240-300 g) housed at constant temperature, food and water provided ad libitum; extracellular glutamate and 5-HT levels in the ventral hippocampus determined by in vivo microdialysis
Results
title comp. markedly increased extracellular 5-HT (ca. 250 percent) and glutamate levels (77 percent over control values)
Reference
Rocher; Gardier
Naunyn-Schmiedeberg's Archives of Pharmacology, 2001 , vol. 363, # 4 p. 422 - 428 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
female
Route of Application
subcutaneous
Concentration (Pharmacological Data)
40 mg/kg
Kind of Dosing (Pharmacological Data)
administered twice daily
Method (Pharmacological Data)
pregnant mice were treated with title comp. from gestation day 7 through 18; 21 days postparturition striatal monoamine and metabolite levels were determined to assess neurotoxic effectiveness; high-performance liquid chromatography
Further Details
saline control; determined monoamines and metabolites: dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA),
117 of 172
118 of 172
119 of 172
(Pharmacological Data)
5-hydroxytryptamine (5-HT), 3-methoxytyramine (3-MT), 5-hydroxyindoleacetic acid (5-HIAA)
Results
title comp. produced long-lasting depletion of striatal dopaminergic markers, but did not affect 3-MT, 5-HT, or 5-HIAA levels (table)
Reference
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
male and female
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 20 mg/kg
Method (Pharmacological Data)
3-month old offsprings, exposed in utero to saline or title comp. were challenged twice (spaced 2 h apart) with title comp.; 7 days later brain monoamine and metabolite levels were determined to assess neurotoxic effectiveness; HPLC
Further Details (Pharmacological Data)
saline control; determined monoamines and metabolites: dopamine (DA), dihydroxyphenyacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5-HT), 3-methoxytyramine (3-MT), 5-hydroxyindoleacetic acid (5-HIAA)
Results
title comp. depleted dopaminergic markers in striatum, brainstem, cortex and cerebellum, but did not affect serotonergic markers; effect of title comp. was greater in males and was enhanced by prenatal exposure to title comp. (table, figure)
Reference
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
male and female
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 20 mg/kg
Method (Pharmacological Data)
3-month old offsprings, exposed in utero to saline or title comp. were challenged twice (spaced 2 h apart) with title comp.; rectal temperature was measured during administration of title comp. and over 5 - 6 h following last injection
Further Details (Pharmacological Data)
saline control; pregnant females received title comp. (40 mg/kg s.c.) from gestational day 7 through 18 twice a day
Results
title comp. caused hyperthermic responses in males regardless of prenatal treatment; title comp. had no effect in females (table)
Reference
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
C57BL/6 mouse
Sex
male
Route of Application
subcutaneous
120 of 172
121 of 172
122 of 172
Concentration (Pharmacological Data)
10 mg/kg
Method (Pharmacological Data)
15-week-old mice were given 2 injections of title comp. (2 h apart); 1 week later striatal level of DA and DAT binding site density and affinity were determined to assess neurotoxic effectiveness
Further Details (Pharmacological Data)
saline control; DA level was determined by HPLC; DAT binding was assessed in saturation studies using 125I-RTI-121; DA: dopamine; DAT: dopamine transporter
Results
title comp. reduced DA level and DAT without change in affininty of transporter (table)
Reference
Heller, Alfred; Bubula, Nancy; Lew, Robert; Heller, Barbara; Won, Lisa
Journal of Pharmacology and Experimental Therapeutics, 2001 , vol. 298, # 2 p. 769 - 779 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
start: 8 weeks old; DRL 72-s schedule training for 12 weeks before title comp. treatment; 1-REG or 3-REG group; data (response, reinforcement rates, PkA, PkL measures) collected at 26-28, 33-35, 40-42, 62 weeks
Further Details (Pharmacological Data)
baseline data: 19-21 weeks, saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens; PkA: peak area; PkL: peak location
Results
title comp. decreased PkA at 26-28 weeks (1-REG), 40-42 weeks (1-REG, 3-REG), increased responses rate at 26-28 weeks (1-REG) (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter synthesis; effect on
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
start: 8 weeks old; DRL 72-s schedule training for 12 weeks before title comp. treatment; 1-REG or 3-REG group; at 70 weeks old 10 brain regions assayed for tissue conc. of dopamine and serotonin by reversed phase HPLC
Further Details (Pharmacological Data)
DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: 3 regimens; PkA/PkL: peak area/location
Results
title comp. decreased serotonin in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG), increased serotonin and dopamine in septum (3-REG) (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological
behavioural symptoms
Data)
123 of 172
124 of 172
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
title comp. treatment at 23 weeks old, 1-REG or 3-REG group; first DRL 72-s schedule training at 60 weeks for 10 weeks; data (response, reinforcement rates, PkA, PkL measures) collected across 3-week periods
Further Details (Pharmacological Data)
saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens; PkA: peak area; PkL: peak location
Comment (Pharmacological Data)
No effect
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter synthesis; effect on
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
title comp. treatment at 23 weeks old, 1-REG or 3-REG group; first DRL 72-s schedule training at 60 weeks for 10 weeks; at 70 weeks old 10 brain regions assayed for dopamine and serotonin by reversed phase HPLC
Further Details (Pharmacological Data)
saline control; DRL: differential reinforcement of low-rate; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens
Results
title comp. decreased serotonin conc. in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG) and increased it in striatum (3-REG) (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
at 23 weeks old title comp. injected (1-REG/3-REG); at 70 weeks frontal, somatosensory, occipital cortex, hippocampus, amygdala, n. accumbens+olfactory tuberie, striatum, septum, hypothalamus, ventral midbrain: dopamine, serotonin by reversed phase HPLC
125 of 172
126 of 172
127 of 172
Further Details (Pharmacological Data)
saline control; 1-REG: group received of one regimen of title comp.; 3-REG: group received 3 regimens
Results
title comp. decreased serotonin conc. in somatosensory cortex, occipital cortex and hippocampus (1-REG, 3-REG) (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time at 2-h intervals
Method (Pharmacological Data)
dopamine and serotonin tissue conc. determined 2 weeks after title comp. injection in 10 brain regions by reversed phase HPLC
Results
title comp. decreased dopamine in striatum and serotonin in striatum, nucleus accumbens+olfactory tubercle, somatosensory cortex and hippocampus (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pyrogenic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological Data)
15 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
at 22 weeks old temperature-sensitive transmitter implanted into abdominal region; 1 week later title comp. injected (1-REG/2-REG/3REG); average core temperature analysed across treatment period (1000 min)
Further Details (Pharmacological Data)
saline control; 1-REG: group received of one regimen of title comp.; 2-REG/3-REG: group received 2/3 regimens
Results
individual injection of title comp. increased core body temperature; this pattern was apparent throughout individual regimens and in all cases of multiple regimens (figure, table)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter release; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Concentration (Pharmacological
15 mg/kg
Data)
128 of 172
129 of 172
130 of 172
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline; dose per injection; injectable volume of 1 ml/kg; administered four time per regimen at 2-h intervals; regimens separated by 7-wk intervals
Method (Pharmacological Data)
at 23 weeks old title comp. injected (1-REG/2-REG/3-REG); 6 weeks later last treatment dopamine and serotonin analysed in 10 brain regions by reversed phase HPLC
Further Details (Pharmacological Data)
saline control; 1-REG: group received of one regimen of title comp. (15 mg/kg/injection*4, at 2-h intervals); 2-REG/3-REG: group received 2/3 regimens separated by 7 weeks
Results
title comp. (1-REG, 2-REG, 3-REG) decreased serotonin in frontal cortex, somatosensory cortex, occipital cortex, hippocampus, amygdala and striatum; it also decreased dopamine in striatum and septum (figure)
Reference
Sabol; Richards; Yung
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 294, # 3 p. 850 - 863 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 10-80 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. time-dependently reduced <3H>DA uptake (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
1E-07 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. concentration-dependently reduced <3H>DA uptake (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect
transport; inhibition of
(Pharmacological Data)
131 of 172
132 of 172
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting; Eadie-Hofstee plot constructed
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. reduced <3H>DA uptake by reducing maximum number of <3H>DA transporters, without significantly altering transporter affinity (noncompetitive inhibition) (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
loaded with unlabeled DA, synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in absence or presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. reduced <3H>DA uptake by 57.4percent in absence of external DA, and smaller reduction, 16.7percent in presence of external DA (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 34, 37, and 40 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
133 of 172
134 of 172
135 of 172
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. temperature-dependently decreased <3H>DA uptake; at 34, 37, and 40 deg C uptakes of <3H>DA were 81.1, 63.8, and 32.4percent of control values, respectively (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; in presence of DA transporter blockers (bupropion, methylphenidate, and cocaine, all at 10 μmol/l) and protein kinase C inhibitors (chelerythrine and bisindolylmaleimide, at 0.1-1 μmol/l); DA: dopamine
Results
title comp. significantly reduced <3H>DA uptake; effect blocked in presence of all DA transporter inhibitors tested, but not protein kinase C inhibitors (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
40 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
animals treated with title comp. 1 h before decapitation; striatal synaptosomes prepared and exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. significantly reduced <3H>DA uptake by 58.3percent (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; binding activity
Species or TestSystem
Sprague-Dawley rat striatal synaptosomes
(Pharmacological Data)
136 of 172
137 of 172
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>WIN35,428 in presence of unlabeled WIN35,428 for 5 min; changes in specific binding of radioligand determined by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; reference comp.: 1-methyl-4-phenyl-pyridinium (MPP(1+)), at 10 μmol/l
Comment (Pharmacological Data)
No effect
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
receptor; binding activity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
40 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
animals treated with title comp. 1 h before decapitation; striatal synaptosomes prepared and exposed to 30 nmol/l <3H>WIN35,428 in presence of unlabeled WIN35,428 for 5 min; changes in specific binding of radioligand determined
Further Details (Pharmacological Data)
control: vehicle
Comment (Pharmacological Data)
No effect
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>glutamate in presence of unlabeled glutamate for 5 min; changes in <3H>glutamate uptake assayed by scintillation counting
Data)
138 of 172
139 of 172
140 of 172
Further Details (Pharmacological Data)
control: vehicle
Comment (Pharmacological Data)
No effect
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
10 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
synaptosomes preexposed to title comp. for 60 min at 37 deg C, washed and then exposed to <3H>DA in presence of unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting
Further Details (Pharmacological Data)
control: vehicle; reference comp.: amphetamine (AMPH), fenfluramine, 6-hydroxydopamine (6-OHDA), and 1-methyl-4-phenyl-pyridinium (MPP(1+)), all at 10 μmol/l; DA: dopamine
Results
similar to DA neurotoxins AMPH, MPP(1+) and 6-OHDA, but not fenfluramine (selective serotonin neurotoxin), title comp. reduced <3H>DA uptake (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transport; inhibition of
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat striatal synaptosomes
Sex
male
Concentration (Pharmacological Data)
0.1 μmol/l
Kind of Dosing (Pharmacological Data)
dissolved in saline
Method (Pharmacological Data)
after pretreatment with title comp. for 1 h and washing, synaptosomes exposed to <3H>DA in presence of title comp. and unlabeled DA for 5 min; changes in <3H>DA uptake assayed by scintillation counting; Eadie-Hofstee plot constructed
Further Details (Pharmacological Data)
control: vehicle; DA: dopamine
Results
title comp. reduced <3H>DA uptake by reducing affinity of <3H>DA transporter, without significantly altering maximum number of <3H>DA transporters (competitive inhibition) (figure)
Reference
Kim, Saejeong; Westphalen, Robert; Callahan, Brian; Hatzidimitriou, George; Yuan, Jie; Ricaurte, George A.
Journal of Pharmacology and Experimental Therapeutics, 2000 , vol. 293, # 2 p. 625 - 633 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
releasing hormones
Species or TestSystem
Sprague-Dawley rats
(Pharmacological Data)
141 of 172
142 of 172
143 of 172
144 of 172
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
1 - 2.5 mg/kg
Method (Pharmacological Data)
dialysis probe was inserted into caudate-putamen via previously implanted cannula and was perfused, after stable baseline levels were obtained for DA, DOPAC, HVA, 5-HIAA, title comp. was administered and dialysate samples were collected for 90 min
Further Details (Pharmacological Data)
dialysate samples were analyzed by HPLC with electrochemical detector; dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA)
Results
extracellular conc. of DA and its metabolites were increased; areas under microdialysate DA conc. versus time curve (AUC 0-60 min) of 9.586 and 25.939 nM/l*min at 1.0 and 2.5 mg/kg doses, resp.; diagrams are given
Reference
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rats
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2.5 mg/kg
Method (Pharmacological Data)
animals were sacrified by decapitation at 10-60 min after title comp. administration, caudate-putamen, cortex, and cerebellum were rapidly dissected, fozen in liquid nitrogen, and stored at -70 deg C until analyzed
Further Details (Pharmacological Data)
tissue sample was homogenized and centrifuged, supernatant was alkalinized (Na2CO3) and extracted with isopropanol-dichloromethane mixture and processed for GC/MS analysis
Results
area under tissue conc. versus time curve (AUC) of title comp. from 0 to 60 min after administration was 760 nmol/g*min
Reference
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
treatment of male Sprague-Dawley rat with 0.5 mg/kg, significantly, but transiently increased dopamine release to ca. 250 and 180percent in nucleus accumbens and corpus striatum, resp. after 2 h effects disappeared
Reference
Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi
Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
treatment of male Sprague-Dawley rat with 0.5 mg/kg, decreased 3,4-dihydroxyphenylacetic acid, homovanillic acid in nucleus accumbens, did not influence in corpus striatum; no effect on 5-hydroxy-3-indoleacetic acid, increased 3-methoxytyramine levels
Reference
Fukuchi, Isao; Asahi, Toshio; Kawashima, Kazutaka; Kawashima, Yumiko; Yamamura, Michio; Matsuoka, Yuzo; Kinoshita, Kiyoshi
Arzneimittel-Forschung/Drug Research, 1998 , vol. 48, # 4 p. 353 - 359 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
mice
Route of
intraperitoneal
Application
145 of 172
146 of 172
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. added 3 times, every 3 h
Method (Pharmacological Data)
nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice divided into 2 subgroups, one treated with title comp., animals sacrified 72 h after the last injection, brain removed, dopamine and its metabolites determined by HPLC
Further Details (Pharmacological Data)
nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice; DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: homovanillic acid, DA: dopamine
Results
no signif. change in tissue content of DA, DOPAC and HVA in nNOS(-/-) mice; in nNOS(+/-) mice 35 percent decrease in DA concn. obsd.; decreases in DA/DOPAC/HVA concn. in B6/SV129, C57BL/6 and SV129 mices 45/37/35 percent, 68/61/45 percent and 37/35/39 percent, resp.
Reference
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
mice
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. added 3 times, every 3 h
Method (Pharmacological Data)
nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice treated with title comp., animals sacrified 72 h after the last injection, brain removed, striatal tissue homogenized, centrifuged, <3H>mazindol binding measured
Further Details (Pharmacological Data)
nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice
Results
admin. of title comp. to B6/SV129, C57BL/6 and SV129 mice resulted in 60, 66 and 49 percent decreases, resp., to nNOS(-/-) and nNOS(+/-) only 12 and 32 percent decreases, resp. in <3H>mazindol binding sites
Reference
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
mice
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. added 3 times, every 3 h
Method (Pharmacological Data)
nNOS(-/-), nNOS(+/-), B6/SV129, C57BL/6 and SV129 strains of mice treated with title comp., body temp. measured before the first injection of title comp. and every 30 min therafter, for a total periosd of 120 min
Further Details (Pharmacological Data)
nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice
147 of 172
148 of 172
149 of 172
Results
30 and 60 min after the admin. of the first dose of title comp. to nNOS(+/-), B6/SV129, C57BL/6 and SV129 mice, a marked increase in body temp. obsd., no signif. effect obsd. on nNOS(-/-) mice
Reference
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
mice
Route of Application
intraperitoneal
Kind of Dosing (Pharmacological Data)
title comp. added in a following way: 1 mg/kg, 3 times 5 mg/kg in 3-h intervals
Method (Pharmacological Data)
nNOS(-/-), B6/SV129 and C57BL/6 strains of mice treated with title comp. in a programmed way, locomotor activity measured 68-72 h after the last injection
Further Details (Pharmacological Data)
nNOS(-/-): homozygote neuronal nitric oxide synthase; nNOS(+/-): heterozygote neuronal nitric oxide synthase knockout mice
Results
on d 1, admin. of 1 mg/kg title comp. caused a marked increase in locomotor activity in all the 3 groups tested, on d 4 the loc. activity of nNOS(-/-) mice was similar in intensity to that on d 1; for the 2 others a signif. sensitized response obsd.
Reference
Itzhak; Gandia; Huang; Ali
The Journal of pharmacology and experimental therapeutics, 1998 , vol. 284, # 3 p. 1040 - 1047 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
enzyme; inhib. of
Species or TestSystem (Pharmacological Data)
human liver microsomes
Method (Pharmacological Data)
effect on activity of enzyme CYP2D6 studied; 0.5 to 5.0 μmol/l dextromethorphan incubated in 0.2 mol/l phosphate buffer with (μmol/l): 0.1 NADP, 1 glucose-6-phosphate, 0.5 MgCl2 and 0.2 U glucose-6-phosphate dehydrogenase with/without title compound
Further Details (Pharmacological Data)
reaction started by adding microsomal protein; incubation at 37 deg C for 30 min; stopped with 70 percent perchloric acid; centrifuged; supernatant assayed for dextrorphan by HPLC
Results
competitive inhibitory effect; apparent inhibition constant (Ki) = 25 μmol/l
Reference
Wu, Dafang; Victoria Otton, S.; Inaba, Tadanobu; Kalow, Werner; Sellers, Edward M.
Biochemical Pharmacology, 1997 , vol. 53, # 11 p. 1605 - 1612 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Fischer-344 rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 mg/kg
Kind of Dosing (Pharmacological Data)
dissolved in saline, administered four times 1 day at 2-hr intervals
Method (Pharmacological Data)
rats (210-280 g) used; in vivo electrochemistry and microdialysis used to examine potassium- and amphetamine-evoked release of DA in the striatum (S) and nucleus accumbens (NAc); animals killed, S and NAc dissected, monoamine content analyzed by HPLC
Further Details
DA = dopamine
(Pharmacological Data)
150 of 172
151 of 172
152 of 172
Results
title comp. treatment resulted in dramatic decreases in DA basal levels, in potassium- and amphetamine-evoked DA release and overflow in S, NAc not significantly affected; post-mortem levels of tissue DA decreased by 41 to 67 percent in S and 25 to 31 percent in NAc
Reference
Cass, Wayne A.
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 280, # 1 p. 105 - 113 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
inotropic pos.
Species or TestSystem (Pharmacological Data)
ferret right ventricle papillary muscle
Sex
male
Concentration (Pharmacological Data)
1E-08 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. dissolved in deionized water
Method (Pharmacological Data)
papillary muscles bathed in physiological soln.; aequorin loaded; title comp. added; intracellular calcium <Ca(2+)>i and developed tension measured by multichannel analyzer
Further Details (Pharmacological Data)
aequorin: bioluminescent calcium indicators; PIE: positive ionotropic effect; control: without title comp.; MTR: maximal tension response; effect of propranolol, atropine in the presence of title comp. also studied
Results
title comp. showed PIE in dose-dependent manner with increased <Ca(2+)>i with threshold of 1E-7 mol/l and a MTR and <Ca(2+)>i at 1E-5 mol/l; signif. decrease in developed tension with further decrease in <Ca(2+)>i at 1E-3 mol/l observed; diagram
Reference
Ishiguro, Yoshiki; Morgan, James P.
Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
inotropic neg.
Species or TestSystem (Pharmacological Data)
ferret right ventricle papillary muscle
Sex
male
Concentration (Pharmacological Data)
1E-08 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. dissolved in deionized water
Method (Pharmacological Data)
reserpine pretreated test system bathed in physiological soln.; title comp. added; intracellular calcium <Ca(2+)>i and developed tension measured using multichannel analyzer
Further Details (Pharmacological Data)
NIE: negative inotropic effect; PIE: positive ionotropic effect; control: without title comp.; ferrets injected with reserpine (1 mg/kg, i.m.) for the depletion of catecholamines
Results
title comp. at higher conc. (>1E-5 mol/l) manifested NIE with decreased calcium signal; title comp. failed to show signif. PIE; diagram
Reference
Ishiguro, Yoshiki; Morgan, James P.
Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
inotropic neg.
Species or TestSystem (Pharmacological Data)
ferret papillary right ventricle muscle
Sex
male
153 of 172
154 of 172
Concentration (Pharmacological Data)
0.0002 mol/l
Kind of Dosing (Pharmacological Data)
title comp. dissolved in deionized water
Method (Pharmacological Data)
test system bathed in physiological soln.; treated with calcium/histamine/isoproterenol with/without title comp.; tension response measured; dose-response curve to histamine, calcium, isoproterenol with/without title comp. plotted
Further Details (Pharmacological Data)
NIE: negative inotropic effect; inotropic agents: isoproterenol (1E-9 - 1E-5 mmol/l); histamine (1E-8 - 1E-4 mmol/l); calcium (0.7 - 8 mmol/l); MEC: minimally effective concentration
Results
title comp. did not shift dose-response curves to calcium or histamine signif., but signif. altered isoproterenol by shifting MEC without affecting the conc. at which maximal effect was obtained; diagram
Reference
Ishiguro, Yoshiki; Morgan, James P.
Journal of Cardiovascular Pharmacology, 1997 , vol. 30, # 6 p. 744 - 749 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
ddY mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 mg/kg
Method (Pharmacological Data)
title compd. dissolved in isotonic saline; behavioural symptoms (linear locomotion, circling, rearing and grooming) measured in Animex II apparatus, evaluated by PC
Results
marked behavioural sensitization
Reference
Toyoshi, Tohru; Ukai, Makoto; Kameyama, Tsutomu
Biological and Pharmaceutical Bulletin, 1996 , vol. 19, # 3 p. 369 - 374 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
HSD Wistar rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
0.1 - 1 mg/kg
Kind of Dosing (Pharmacological Data)
30 min before measurement
Method (Pharmacological Data)
rats treated with title comp.; killed; release of biogenic amines from brain samples <striatum, substantia nigra, tuberculum olfactorium (dopamine), lobus coeruleus (noradrenaline) and raphe (serotonin)> measured
Further Details (Pharmacological Data)
compared with the activity of desmethylimipramine (DMI, 0.25 - 5.0 mg/kg), (-)- and (+)deprenyl (0.01 - 0.25 mg/kg) ()methamphetamine (0.1 - 1.0 mg/kg)
Comment (Pharmacological Data)
No effect
Reference
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details
155 of 172
156 of 172
157 of 172
Effect (Pharmacological Data)
drug interaction
Species or TestSystem (Pharmacological Data)
dd mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10.8 μmol/kg
Method (Pharmacological Data)
6 week-old mice; ambulation activity generated by slight tilt of cage; effect of title comp. on ambulation activity after pretreatment (5 times at 3 d intervals) with 1.4-47.2 μmol/kg s.c. CMMA
Further Details (Pharmacological Data)
CMMA (= N-cyanomethylmethamphetamine HCl) accelerated ambulation activity
Results
cross-sensitization between title comp. and MAP (activity counts were significantly higher in 14.2-47.2 μmol/kg-pretreated mice, 1.4 and 4.7 μmol/kg pretreatment had no effect); graphical representations
Reference
Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji
Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
dd mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10.8 μmol/kg
Kind of Dosing (Pharmacological Data)
5 repeated admin. at 3 d intervals
Method (Pharmacological Data)
6-week-old mice; ambulation activity generated by slight tilt of cage and measured for 3 h after administration
Results
accelerated ambulation (ca. 2.0 times higher activity counts in 5th admin. than in 1st, respectively); graphical representations
Reference
Kuribara, Hisashi; Sekine, Hitoshi; Nakahara, Yuji
Pharmacology and Toxicology, 1996 , vol. 78, # 6 p. 374 - 380 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
dd mouse
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2 mg/kg
Kind of Dosing (Pharmacological Data)
single dose repeated three times at 3, 6, 12, 24 or 48 h, then 2 times at intervals of 3 days
Method
25-28 g, 6-week-old mice (T=23 deg C; R.H.=55 percent; 12 h light/dark cycle); after treatment ambulatory activity (AA) of mice
158 of 172
159 of 172
160 of 172
(Pharmacological Data)
measured with an ambulometer for 3 h
Further Details (Pharmacological Data)
effect of interdose interval on ambulatory sensitization (increase of AA on repeated doses) studied
Results
interdose interval of 24 h or longer is required for induction of ambulatory sensitization (graph)
Reference
Kuribara, Hisashi
European Journal of Pharmacology, 1996 , vol. 316, # 1 p. 1 - 6 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
drug dependence
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
1 - 4 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline
Method (Pharmacological Data)
IM induced in rat paw by formalin (2.5 percent, 50 μl), λ-carrageenan (1 percent, 100 μl) or vehicle (100 μl); title comp. admin.; conditioned in SB at first, fifth, or fourteenth day after IM induction; after conditioning TS in each compartment measured by IBS
Further Details (Pharmacological Data)
control: vehicle (saline, 1 ml/kg, i.p.); conditioning sessions conducted once daily for 50 min; IM: inflammation; SB: shuttlebox; IBS: infrared beam sensor; TS: time spent
Results
title comp. produced a dose-related place preference; it showed significant conditioning at 1, 2 and 4 mg/kg; no effect in presence of induced inflammation; diagram
Reference
Suzuki, Tsutomu; Kishimoto, Yayoi; Misawa, Miwa
Life Sciences, 1996 , vol. 59, # 19 p. 1667 - 1674 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
effect on cocaine self-administration
Species or TestSystem (Pharmacological Data)
Fischer F-344 rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
3.2 mg/kg
Kind of Dosing (Pharmacological Data)
chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline
Method (Pharmacological Data)
Fischer F-344 rats (270 g) were implanted with indwelling jugular catheters and were trained to self-adm. cocaine under a progressiveratio (PR) schedule of reinforcement; 0.028-0.25 mg/inj. of cocaine
Further Details (Pharmacological Data)
the number of reinforcers obtained was measured
Results
chronic treatment shifted the dose-response curve for breaking points significantly to the right
Reference
Peltier; Li; Lytle; Taylor; Emmett-Oglesby
Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological
effect on cocaine self-administration
Data)
161 of 172
162 of 172
Species or TestSystem (Pharmacological Data)
Fischer F-344 rat
Sex
male
Concentration (Pharmacological Data)
0.32 - 3.2 mg/kg
Kind of Dosing (Pharmacological Data)
chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline
Method (Pharmacological Data)
Fischer F-344 rats (270 g) were implanted with an indwelling catheter inserted into the right external jugular; after 5 days were given opportunity to FR2 self-administer cocaine (0.125-0.5 mg/infusion)
Further Details (Pharmacological Data)
interreinforcer time (min) measured; FR2 = fixed-ratio 2 schedule of reinforcement
Results
chronic treatment shifted the cocaine self-administration curve to the right (diagram, table given)
Reference
Peltier; Li; Lytle; Taylor; Emmett-Oglesby
Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
effect on the discrimination of cocaine
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
0.32 - 3.2 mg/kg
Kind of Dosing (Pharmacological Data)
chronic adm. 0.32, 1.0 and 3.2 mg/kg/12 hr for 7 days; dissolved in 0.9 percent saline
Method (Pharmacological Data)
Sprague-Dawley rats (330 g) trained to discriminate 10 mg/kg (i.p.) of cocaine from saline with food as a reinforcer, using a cumulative dose testing procedure (1.0-17.8 mg/kg of cocaine)
Further Details (Pharmacological Data)
cocain-lever responding ( percent) determined
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
16.67 mg/kg
Results
chronic adm. of title comp. resulted in cross-tolerance to the discriminative stimulus effects in cocaine; ED50 = 3.84 mg/kg (base-line) (table, diagram given)
Reference
Peltier; Li; Lytle; Taylor; Emmett-Oglesby
Journal of Pharmacology and Experimental Therapeutics, 1996 , vol. 277, # 1 p. 212 - 218 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
human
Sex
male and female
Route of Application
intravenous
163 of 172
164 of 172
Concentration (Pharmacological Data)
30 mg
Kind of Dosing (Pharmacological Data)
ethanol (or placebo) in 6 drinks of fruit juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl
Exposure Period (Pharmacological Data)
48 h
Method (Pharmacological Data)
8 users (7 men and 1 woman) of title comp. and ethanol, 24-38 year; double-blind, double-placebo, Latin-square design; subjective and neuropsychological effects of drug combination with ethanol
Further Details (Pharmacological Data)
title comp. and amphetamine in plasma and urine by GC for 48 h; urine collected 48 h; data analyzed by repeated-measures ANOVA
Results
pharmacokinetics not altered by concurrent adm. of etahanol with the exception of lowering the apperent volume of distribution for the title comp. at steady state
Reference
Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton
Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
sympathomimetic
Species or TestSystem (Pharmacological Data)
human
Sex
male and female
Route of Application
intravenous
Concentration (Pharmacological Data)
30 mg
Kind of Dosing (Pharmacological Data)
ethanol (or placebo) in 6 drinks of fruit juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl
Exposure Period (Pharmacological Data)
48 h
Method (Pharmacological Data)
8 users (7 men and 1 woman) of title comp. and ethanol 24-38 year; double-blind, double-placebo, Latin-square design; subjective and neuropsychological effects of drug combination with ethanol
Further Details (Pharmacological Data)
title comp. and amphetamine in plasma and urine by GC for 48 h; urine collected 48 h; data analyzed by repeated-measures ANOVA
Results
title comp. alone increased alertness, relaxation, stimulation, euphoria, sensory awareness; no change in these subjective effects on concurrent adm. of ethanol
Reference
Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton
Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cardiovascular
Species or TestSystem (Pharmacological Data)
human
Sex
male and female
Route of Application
intravenous
Concentration (Pharmacological Data)
30 mg
Kind of Dosing (Pharmacological
ethanol (or placebo) in 6 drinks of friut juice over 30 min; title comp. (or placebo) 60 min after the first drink in 0.9 percent NaCl
Data)
165 of 172
166 of 172
167 of 172
Exposure Period (Pharmacological Data)
420 min
Method (Pharmacological Data)
8 users (7 men and 1 woman) of title comp. and ethanol, 24-38 year; double-blind, double-placebo, Latin-square design; systolic and diastolic blood pressure, heart rate, rate pressure product; breath ethanol concn. by IR
Results
increased systolic blood-pressure; minimal change in heart rate; concurrent adm. of ethanol increased heart rate, decreased systolic blood pressure; increase in rate pressure product, cardiac work index and myocardial oxygen consumption
Reference
Mendelson, John; Jones, Reese T.; Upton, Robert; Jacob III, Peyton
Clinical Pharmacology and Therapeutics, 1995 , vol. 57, # 5 p. 559 - 568 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Wistar-King rat
Sex
male
Route of Application
subcutaneous
Kind of Dosing (Pharmacological Data)
1 mg/kg for 10 days, then 7-8 day withdrawal, then single 0.5 mg/kg
Method (Pharmacological Data)
animals weighing 200-250 g housed individually, 12 h dark/light cycle, 24 deg C, 50 percent humidity, free access to standard diet and water
Results
significantly enhanced motor activity
Reference
Ohmori, T.; Abekawa, T.; Koyama, T.
Life Sciences, 1995 , vol. 56, # 14 p. 1223 - 1230 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
Fischer-344 rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
10 mg/kg
Method (Pharmacological Data)
effect of title comp. on rectal temperature measured by YSI tele-thermometer
Results
title comp. caused significant increase in body temperature at 2.5 h after inj. which was gradually declined and returned to basal level at ca. 5 h
Reference
Bronstein; Hong
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
toxicity
Endpoint of Effect (Pharmacological Data)
death
Species or TestSystem (Pharmacological Data)
rat
Sex
male
168 of 172
169 of 172
Route of Application
subcutaneous
Concentration (Pharmacological Data)
5 - 40 mg/kg
Method (Pharmacological Data)
Fischer-344 and Sprague-Dawley rats; number of deaths determined in the 48 h following administration
Further Details (Pharmacological Data)
LD50 refers to Srague-Dawley rats
Type (Pharmacological Data)
LD50
Value of Type (Pharmacological Data)
10.4 mg/kg
Results
title comp. produced dose-dependent lethality in both strains of rats (no lethality at 5 mg/kg, 100 percent lethality at 20 mg/kg or greater); majority of death occurred within 3-4 h
Reference
Bronstein; Hong
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 943 - 950 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
sensitization
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.5 - 5 mg/kg
Kind of Dosing (Pharmacological Data)
daily inj. at 14:00 for 6, 13 or 20 consecutive days
Method (Pharmacological Data)
rats weighing 200 to 250 g; housed individually; 12 h light-dark cycle; T: 23 deg C; food and water ad libitum; title comp. inj. withdrawn on day 7, 14 or 21; locomotor activity measured from 14:00 to 17:00 on the withdrawal day
Further Details (Pharmacological Data)
DA, dopamine; NMDA, N-methyl-D-aspartate
Results
daily inj. of title comp. for 6 consec. days was sufficient to produce an increase of anticipatory activity in a dose-dependent manner (0.5 to 2 mg/kg, but moderate at 5 mg/kg); DA, NMDA and sigma receptor mechanisms are involved in the effect
Reference
Shibata; Ono; Fukuhara; Watanabe
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 2 p. 688 - 694 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
1 - 5 mg/kg
Kind of Dosing (Pharmacological Data)
in 0.9 percent saline
170 of 172
171 of 172
Method (Pharmacological Data)
femoral vein of rats (300-325g) was cannulated; dialysate samples were collected for 90 min postdrug injection; blood samples were collected before sacrifice 5,10,20,30,40 and 60 min; HPLC; brain tissues were analysis with GC/MS
Further Details (Pharmacological Data)
determination of plasma or striatum content of title comp. vs. time; determination of striatum/plasma content ratio vs. time; determination of drug-induced dopamine efflux profiles
Results
title comp. and D-amphetamine on the strital dopamine system were equipotent and pharmacokinetic (and pharmacodynamic) profiles of each drug were similar
Metabolite (Pharmacological Data)
3,4-dihydroxyphenylacetate [Reaxys RN: 2211017] ; 5-Hydroxyindole-3-acetic acid [Reaxys RN: 168797] ; Homovanillic acid [Reaxys RN: 2213447]
Reference
Melega; Williams; Schmitz; DiStefano; Cho
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 274, # 1 p. 90 - 96 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Swiss Webster mice
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
5 - 10 mg/kg
Kind of Dosing (Pharmacological Data)
10, 10, 5 and 5 mg/kg (four injection i.p.) at 2-hr intervals
Method (Pharmacological Data)
mice received four injections of title comp. at 2-h intervals, other groups injected with saline (control); colonic temp. recorded 30 min before the first injection of title comp. and 1 h after each title comp. injection
Further Details (Pharmacological Data)
mice sacrificed 7 days later, both neostriata removed and assayed for dopamine (DA) and for its metabolites by HPLC-electrochemical detection; neostriatal tyrosine hydroxylase (TH) activity measured by a radioenzymatic technique
Results
striatal TH activity and DA content were decreased by 57 and 68 percent seven days, after treatment with title comp. (TH activity 43 percent title comp.; 100 percent saline treatment)
Reference
Albers; Sonsalla
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 275, # 3 p. 1104 - 1114 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neurotoxicity
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
4 doses spaced 1 h apart
Method (Pharmacological Data)
in vivo; effect on brain 5-HT, 5-HIAA and DA level assayed; rats weighed 225-250 g; kept in individual cages at 20-22 deg C under 12 h light/dark cycle with free access to food and water; rats killed 72 h after treatment; brain removed
Further Details (Pharmacological Data)
striatum and hippocampus dissected; 5-HT, 5-HIAA and DA levels in striatum and hippocampus measured by HPLC; 5-HT: serotonin; 5HIAA: 5-hydroxyindole acetic acid; DA: dopamine
Results
in hippocampus title comp. decreased 5-HT/5-HIAA levels to 42/59 percent of control; title comp. decreased also striatal DA level
Reference
Farfel; Seiden
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details
172 of 172
Effect (Pharmacological Data)
hyperthermic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
10 mg/kg
Kind of Dosing (Pharmacological Data)
4 doses given with 1 h intervals
Method (Pharmacological Data)
in vivo; effect on body temp. assayed; rats weighed 225-250 g; kept in individual cages at 20-22 deg C under 12 h light/dark cycle with free access to food and water; rats implanted with temp.-sensitive radiotransmitter into intraperitoneal cavity
Further Details (Pharmacological Data)
body temp. measured for at least 4 h after treatment
Results
title comp. increased core body temp. to 3.6 deg C above base-line at 300 min after the first dose of title cmop. and body temp. returned to base-line level by the next day; graphical representation
Reference
Farfel; Seiden
Journal of Pharmacology and Experimental Therapeutics, 1995 , vol. 272, # 2 p. 868 - 875 Title/Abstract Full Text View citing articles Show Details
Ecotoxicology (1) 1 of 1
Effect (Ecotoxicology)
toxicity to invertebrates
Species or TestSystem (Ecotoxicology)
Daphnia pulex Leydig
Concentration (Ecotoxicology)
1 - 1000 mg/l
Method (Ecotoxicology)
Daphnia incub. with title comp. in freshwater (17-21 deg C; 24 h; in a darkbox); number of Daphnia immobile counted; mean mortalities calculated; EC50 determined using regression analysis
Type (Ecotoxicology)
EC50
Value of Type (Ecotoxicology)
109.5 mg/l
Reference
Morrow; Corrigan; Waldren
Planta Medica, 2001 , vol. 67, # 9 p. 843 - 846 Title/Abstract Full Text View citing articles Show Details
Other Data Use (5) Use Pattern
Location
Reference
Pharmaceuticals
Page/Page column title page; 26
CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.
Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details
attention deficit hyperactive disorder (ADHD)
Page/Page column title page; 26
CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.
Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details
treatment of attention deficit disorder (ADD)
Page/Page column title page; 26
CONCERT PHARMACEUTICALS, INC.; TUNG, Roger D.; GRAHAM, Philip B.
Patent: WO2017/20016 A1, 2017 ; Title/Abstract Full Text Show Details
Drug
HISAMITSU PHARMACEUTICAL CO., INC.
Patent: EP1541177 A1, 2005 ;
Title/Abstract Full Text Show Details
a stimulan-antihypnotic agent
HISAMITSU PHARMACEUTICAL CO., INC.
Patent: EP1541177 A1, 2005 ;
Title/Abstract Full Text Show Details
Chemical Name: (R)-2-N-methylamino-1-phenylpropane hydrochloride Reaxys Registry Number: 5617071
CAS Registry Number: 826-10-8 Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697
InChI Key: TWXDDNPPQUTEOV-SBSPUUFOSA-N
42
1 prep out of 3 reactions.
Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-2-N-methylamino-1-phenylpropane hydrochloride, (R)-N-methyl-1-phenylpropan-2-amine hydrochloride, (R)-(-)-methamphetamine hydrochloride, (-)-methamphetamine hydrochloride, methamphetamine hydrochloride, Methamphtamine hydrochloride, (R)-(-)-methamphetamine HCl Identification Substance Label (6) Label
Reference
ent-4
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
I
Colucid Pharmaceuticals, Inc.
Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details
R-(-)-METH; - METH
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Merck Index 6015
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
MERCK 6015
Knoll, Joseph; Miklya, Ildiko
Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details
(R)-4a*HCl
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (3) Melting Point
Solvent (Melting Point)
Reference
165 - 166 °C
ethanol diethyl ether
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
Identification Physical Data (6) Bioactivity (12)
15
171 - 173 °C
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
170 - 171 °C
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Optical Rotatory Power (3) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
1g/100ml
water
17.51 deg
589 nm
[alpha]
0.52 g/100ml
H2O
-16.3 deg
[alpha]
-14.8 deg
Location
Reference
25 °C
supporting information
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
589 nm
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
589 nm
22 °C
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Bioactivity Pharmacological Data (12) 1 of 12
Comment (Pharmacological Data)
Bioactivities present
Reference
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Takashashi; Chida; Higashiyama; Onishi
Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 11 p. 4662 - 4670 Title/Abstract Full Text View citing articles Show Details
Nomura; Yotsumoto; Oki
Journal of Pharmacy and Pharmacology, 1981 , vol. 33, # 4 p. 264 - 266 Title/Abstract Full Text View citing articles Show Details
Chafetz; Desai; Sukonik
Journal of Pharmaceutical Sciences, 1994 , vol. 83, # 9 p. 1250 - 1252 Title/Abstract Full Text View citing articles Show Details
Noggle, F. Taylor; DeRuiter, Jack; Clark, C. Randall
Analytical Chemistry, 1986 , vol. 58, # 8 p. 1643 - 1648 Title/Abstract Full Text View citing articles Show Details
Knoll, Joseph; Miklya, Ildiko
Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Colucid Pharmaceuticals, Inc.
Patent: US2010/256229 A1, 2010 ; Title/Abstract Full Text Show Details
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text Show Details
Knoll, Joseph; Miklya, Ildiko
Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text Show Details
Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.
Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details
Lalwani, Komal G.; Sudalai, Arumugam
Tetrahedron Letters, 2015 , vol. 56, # 46 p. 6488 - 6490 Title/Abstract Full Text View citing articles Show Details
Cheong, Jae Hoon; Choi, Mee Jung; Jang, Choon-Gon; Lee, Yong Sup; Lee, Sooyeun; Kim, Hee Jin; Seo, Joung-Wook; Yoon, Seong Shoon
Psychopharmacology, 2017 , vol. 234, # 5 p. 857 - 867 Title/Abstract Full Text Show Details
2 of 12
3 of 12
4 of 12
5 of 12
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Cheong, Jae Hoon; Choi, Mee Jung; Jang, Choon-Gon; Lee, Yong Sup; Lee, Sooyeun; Kim, Hee Jin; Seo, Joung-Wook; Yoon, Seong Shoon
Psychopharmacology, 2017 , vol. 234, # 5 p. 857 - 867 Title/Abstract Full Text Show Details
Comment (Pharmacological Data)
physiological behaviour discussed
Reference
Reese, Edmund A.; Norimatsu, Yohei; Grandy, Madeline S.; Suchland, Katherine L.; Bunzow, James R.; Grandy, David K.
Journal of Medicinal Chemistry, 2014 , vol. 57, # 2 p. 378 - 390 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
human embryonic kidney 293 cells
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological Data)
effect of title comp. on rTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing rTAAR1; rTAAR: rat trace amine-associated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
1.19 μmol/l
Results
title comp. dose-dependently stimulated cAMP production and was partial agonist (75.05percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
human embryonic kidney 293 cells
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological
effect of title comp. on mTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Data)
6 of 12
7 of 12
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing mTAAR1; mTAAR: mouse trace amine-associated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
2.44 μmol/l
Results
title comp. dose-dependently stimulated cAMP production and was full agonist (91.33percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
agonist
Species or TestSystem (Pharmacological Data)
human embryonic kidney 293 cells
Concentration (Pharmacological Data)
Ca. 5E-09 - 0.001 mol/l
Kind of Dosing (Pharmacological Data)
title comp. was dissolved in water
Method (Pharmacological Data)
effect of title comp. on h-rChTAAR1 studied by measuring cAMP production; cells incubated with title comp. for 1 h at 37 deg C, lysed; cAMP production determined using <3H>cAMP and cAMP-binding protein; radioactivity counted
Further Details (Pharmacological Data)
data normalized to maximal level produced in response to PEA; cells expressing h-rChTAAR1; h-rChTAAR: human-rat chimera trace amineassociated receptor; PEA: β-phenylethylamine
Type (Pharmacological Data)
EC50
Value of Type (Pharmacological Data)
9.83 μmol/l
Results
title comp. dose-dependently stimulated cAMP production and was full agonist (91.55percent PEAmax) (table, figure)
Reference
Reese; Bunzow; Arttamangkul; Sonders; Grandy, David K.
Journal of Pharmacology and Experimental Therapeutics, 2007 , vol. 321, # 1 p. 178 - 186 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
pharmacokinetics
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rats
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
2.5 - 20 mg/kg
Method (Pharmacological Data)
animals were sacrified by decapitation at 10-60 min after title comp. administration, caudate-putamen, cortex, and cerebellum were dissected, fozen in liquid N2, and stored at -70 deg C; plasma samples were obtained from trunk blood
Further Details (Pharmacological Data)
tissue sample was homogenized, centrifuged, alkalinized (Na2CO3) and extracted with i-PrOH-CH2Cl2 mixture and processed for GC/MS analysis; plasma sample was alkalinized and extracted similarly, derivatized with (CF3CO)2O in MeCN and analyzed by GC/MS
Results
area under tissue conc. versus time curve (AUC) of title comp. in caudate putamen from 0 to 60 min after dose of 2.5 and 20 mg/g were 795 and 4875 nmol/g*min, resp.; diagram is given
Reference
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
8 of 12
9 of 12
10 of 12
Effect (Pharmacological Data)
biotransformation
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rats
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
20 mg/kg
Method (Pharmacological Data)
animals were sacrified by decapitation at 5-50 min after title comp. administration, caudate-putamen, cortex, and cerebellum were rapidly dissected, fozen in liquid nitrogen, and stored at -70 deg C until analyzed
Further Details (Pharmacological Data)
tissue sample was homogenized and centrifuged, supernatant was alkalinized (Na2CO3) and extracted with isopropanol-dichloromethane mixture and processed for GC/MS analysis
Results
relative to striatal levels of title comp., l-amphetamine caudate-putamen levels ranged from 5 to 10 percent, whereas p-hydroxy-lmethamphetamine levels were less than 0.25 percent; diagrams are given
Metabolite (Pharmacological Data)
l-amphetamine [Reaxys RN: 2432739] ; (-)-p-Hydroxymethamphetamine [Reaxys RN: 3197900]
Reference
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
releasing hormones
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rats
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
20 mg/kg
Method (Pharmacological Data)
dialysis probe was inserted into caudate-putamen via previously implanted cannula and was perfused, after stable baseline levels were obtained for DA, DOPAC, HVA, 5-HIAA, title comp. was administered and dialysate samples were collected for 90 min
Further Details (Pharmacological Data)
dialysate samples were analyzed by HPLC with electrochemical detector; dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA)
Results
extracellular conc. of DA and its metabolites were increased; area under microdialysate DA conc. versus time curve (AUC 0-60 min) of 21.120 nM*l/min; diagrams are given
Reference
Melega, William P.; Cho, Arthur K.; Schmitz, Debra; Kuczenski, Ronald; Segal, David S.
Journal of Pharmacology and Experimental Therapeutics, 1999 , vol. 288, # 2 p. 752 - 758 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
transmitter releasing
Species or TestSystem (Pharmacological Data)
HSD Wistar rat
Sex
male
Route of Application
subcutaneous
Concentration
0.1 - 1 mg/kg
(Pharmacological Data)
11 of 12
12 of 12
Kind of Dosing (Pharmacological Data)
30 min before measurement
Method (Pharmacological Data)
rats treated with title comp.; killed; release of biogenic amines from brain samples <striatum, substantia nigra, tuberculum olfactorium (dopamine), lobus coeruleus (noradrenaline) and raphe (serotonin)> measured
Further Details (Pharmacological Data)
compared with the activity of desmethylimipramine (DMI, 0.25 - 5.0 mg/kg), (-)- and (+)deprenyl (0.01 - 0.25 mg/kg) (+)methamphetamine (0.1 - 1.0 mg/kg)
Results
title comp. enhanced activity of noradrenergic and dopaminergic neurons (table III)
Reference
Knoll; Miklya; Marko; Kelemen
Life Sciences, 1996 , vol. 58, # 10 p. 817 - 827 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
neuroregulatoric
Species or TestSystem (Pharmacological Data)
Wistar rat
Sex
male
Route of Application
subcutaneous
Concentration (Pharmacological Data)
0.05 mg/kg
Exposure Period (Pharmacological Data)
21 d
Method (Pharmacological Data)
after treatment, sexualy highly active rats decapitated, brain samples removed, held in Krebs solution (37 deg C, 5 percent CO2); 2x20 min incubation in Krebs-solution
Further Details (Pharmacological Data)
dopamine (D) released from striatum (ST), substantia nigra (SN), tuberculum olfactorum (TO); noradrenaline (NA) from locus coeruleus (LC), serotonin (5-HT) from raphe (R) determined by HPLC
Results
significant enhancement of resting release of catecholamines (D, NA); decrease of S
Reference
Knoll, Joseph; Miklya, Ildiko
Life Sciences, 1995 , vol. 56, # 8 p. 611 - 620 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
locomotor stimulating action (rat)
Reference
Nomura; Yotsumoto; Oki
Journal of Pharmacy and Pharmacology, 1981 , vol. 33, # 4 p. 264 - 266 Title/Abstract Full Text View citing articles Show Details
Chemical Name: (+)-methamphetamine hydrochloride Reaxys Registry Number: 6489321
Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*HCl Molecular Weight: 185.697
InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N
43
Synthesize | Hide Details Find similar
no reactions.
Identification Spectra (2) Bioactivity (9)
5
Chemical Names and Synonyms (+)-methamphetamine hydrochloride, (+)-Metamfetamin Hydrochlorid, methamphetamine hydrochloride Identification Substance Label (2) Label
Reference
METH
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
1-HCl
Neugebauer
Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details
Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
Chemical shifts
1H
dimethylsulfoxide-d6
Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique
Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 1638 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
dimethylsulfoxide-d6
Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique
Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 1638 Title/Abstract Full Text View citing articles Show Details
Reference
Bioactivity Pharmacological Data (9) 1 of 9
2 of 9
Comment (Pharmacological Data)
Bioactivities present
Reference
Ueno; Kitagawa; Kohei; Furukawa; Kushiku
Arzneimittel-Forschung/Drug Research, 1986 , vol. 36, # 3 A p. 560 - 567 Title/Abstract Full Text View citing articles Show Details
Neugebauer
Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details
Kim; Kang; Rheu; Cho; Oh
Planta Medica, 1995 , vol. 61, # 1 p. 22 - 25 Title/Abstract Full Text View citing articles Show Details
Reviriego, Felipe; Navarro, Pilar; Domenech, Antonio; Garcia-Espana, Enrique
Journal of the Chemical Society, Perkin Transactions 2, 2002 , # 9 p. 1634 - 1638 Title/Abstract Full Text View citing articles Show Details
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cardiovascular
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing
title comp. was administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10
3 of 9
4 of 9
(Pharmacological Data)
days
Method (Pharmacological Data)
rats were administered with title comp.; mean arterial blood pressure and heart rate (HR) recorded for 1 h after each dosing
Further Details (Pharmacological Data)
control: normal saline
Results
pressor response elicited by first three doses of title comp. in second/third binges were signif. larger than those elicited by corresponding doses in first binge; HR responses elicited by title comp. were similar within and among three binges; table
Reference
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cardiovascular
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. was administered in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days
Method (Pharmacological Data)
rats were administered with title comp.; acetylcholine, sodium nitroprusside (SN) and isoproterenol admin. i.v. before each binge and 10 days after last binge; mean arterial blood pressure and heart rate (HR) recorded
Further Details (Pharmacological Data)
control: normal saline
Results
10 days after last title comp. binge, depressor responses elicited by SN, isoproterenol, acetylcholine were signif. smaller than those elicited before each binge; no signif. differences in magnitude of HR elicited by SN/isoproterenol/acetylcholine; fig.
Reference
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
cardiovascular
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days
Method (Pharmacological Data)
rats were administered with title comp.; 5-hydroxytryptamine (5-HT) or phenylephrine administered i.v. before each binge and 10 days after last binge; mean arterial blood pressure and heart rate (HR) recorded
Further Details (Pharmacological Data)
control: normal saline
Results
title comp. treatment did not affect HR responses elicited by 5-HT although they were markedly reduced 10 days after last binge; no signif. differences in either mean arterial blood pressure or heart rate responses elicited by phenylephrine; diagram
Reference
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
5 of 9
6 of 9
7 of 9
8 of 9
9 of 9
Effect (Pharmacological Data)
cardiovascular
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intravenous
Concentration (Pharmacological Data)
3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. administered over 10 to 15 s in three binges (b.i.d. for 4 days) and each binge separated by non-treatment period of 10 days
Method (Pharmacological Data)
rats were administered with title comp.; 1 day after each binge, 4 rats were sacrificed; hearts removed; histological studies performed
Further Details (Pharmacological Data)
control: saline
Results
hearts from title comp.-treated rats showed focal inflammatory infiltrates with abundant monocytes and occasional necrotic foci; no pathologic fibrosis observed; photo, table
Reference
Varner, Kurt J.; Ogden, Brian A.; Delcarpio, Joseph; Meleg-Smith, Suzanne
Journal of Pharmacology and Experimental Therapeutics, 2002 , vol. 301, # 1 p. 152 - 159 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
application to albumen of embryonated hen's eggs: application on first day of incubation: LD 50: 12.7 mg at 12. day and 10.4 mg at 17. day of incubation; application on sixth day of incubation: LD 50: 7.0 mg at 12. and 6.4 mg at 17. day of incubation
Reference
Neugebauer
Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
in vivo ambulation-accelerating activity in male mice
Reference
Kim; Kang; Rheu; Cho; Oh
Planta Medica, 1995 , vol. 61, # 1 p. 22 - 25 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
metabolism after application to the albumen of embryonated hen's eggs: application of 4 to 16 mg at the first or sixth day of incubation; analysis between the 8. and 18. day of incubation
Reference
Neugebauer
Pharmazie, 1995 , vol. 50, # 3 p. 201 - 206 Title/Abstract Full Text View citing articles Show Details
Comment (Pharmacological Data)
influence on locomotor activity (5 mg/kg s.c.) and chewing behaviour in rats (16 mg/kg i.v.)
Reference
Ueno; Kitagawa; Kohei; Furukawa; Kushiku
Arzneimittel-Forschung/Drug Research, 1986 , vol. 36, # 3 A p. 560 - 567 Title/Abstract Full Text View citing articles Show Details
Chemical Name: d-methamphetamine hydrochloride
44
Reaxys Registry Number: 8159451
Type of Substance: isocyclic Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H15N*ClH Molecular Weight: 185.697
InChI Key: TWXDDNPPQUTEOV-UHFFFAOYSA-N
no reactions.
Identification Bioactivity (6)
2
Synthesize | Hide Details Find similar Chemical Names and Synonyms d-methamphetamine hydrochloride, d-metamphetamine hydrochloride Identification Substance Label (1) Label
Reference
d-MP hydrochloride
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (6) 1 of 6
2 of 6
Comment (Pharmacological Data)
Bioactivities present
Reference
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Ohno; Watanabe
European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat CYP2C13 isozymes
Sex
male
Concentration (Pharmacological Data)
1 mmol/l
Exposure Period (Pharmacological Data)
10 min
Method (Pharmacological Data)
in vitro; rats 340-350 g; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine
Further Details (Pharmacological Data)
substrate specificity, P450 enzyme activity of deamination
Results
10.3 nmol P450/mg protein; metabolic product, nmol/min/nmol P450: formaldehyde 4.52
Reference
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72
Title/Abstract Full Text View citing articles Show Details
3 of 6
4 of 6
5 of 6
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat CYP2C11 isozymes
Sex
male
Concentration (Pharmacological Data)
1 mmol/l
Exposure Period (Pharmacological Data)
10 min
Method (Pharmacological Data)
in vitro; rats 340-350 g; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine
Further Details (Pharmacological Data)
substrate specificity, P450 enzyme activity of deamination
Results
12.3 nmol P450/mg protein; metabolic products, nmol/min/nmol P450: formaldehyde 6.46, phenylacetone 0.42
Reference
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
New Zealand White rabbit CYP2C3 isozymes
Sex
male
Concentration (Pharmacological Data)
1 mmol/l
Exposure Period (Pharmacological Data)
10 min
Method (Pharmacological Data)
in vitro; rabbits ca. 3 kg; title comp. incubated 37 deg C, pH 7.4 with 0.1 nmol test subst., 0.8 unit NADPH-P450 reductase, 15 μg dilauroylphosphatidylcholine
Further Details (Pharmacological Data)
substrate specificity, P450 enzyme activity of deamination
Results
15.3 nmol P450/mg protein; metabolic products, nmol/min/mg P450: formaldehyde 11.68, phenylacetone 2.14
Reference
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
metabolic
Species or TestSystem (Pharmacological Data)
New Zealand White rabbit liver microsomes
Sex
male
Exposure Period (Pharmacological Data)
10 min
Method (Pharmacological
in vitro; rabbits ca. 3 kg; varying conc. title comp. incubated 37 deg C, pH 7.4 with 0.5-1.0 protein of microsomes, NADP; colorimetric and HPLC analysis
Data)
6 of 6
Further Details (Pharmacological Data)
substrate specificity, kinetic parameters of deamination
Results
metabolic products: formaldehyde: Km = 0.148 mM, Vmax = 10.6 nmol/min/mg protein; phenylacetone: Km = 0.045 mM, Vmax = 1.06 nmol/min/mg protein
Reference
Yamada, Hideyuki; Shiiyama, Sachiko; Soejima-Ohkuma, Toyomi; Honda, Shin-Ichiro; Kumagai, Yoshito; Cho, Arthur K.; Oguri, Kazuta; Yoshimura, Hidetoshi
Journal of Toxicological Sciences, 1997 , vol. 22, # 1 p. 65 - 72 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
sensitization
Species or TestSystem (Pharmacological Data)
ddY strain mice
Sex
male
Route of Application
intraperitoneal
Kind of Dosing (Pharmacological Data)
chronic: 7 consecutive days 1/d title comp. 1.0 mg/kg, preceded or not by L-NA (10-30), L-NAME (30-100), D-NAME (100), MK-801 (0.2) (all i.p.mg/kg), on day 10: challenge, then test
Exposure Period (Pharmacological Data)
10 d
Method (Pharmacological Data)
25-30 g mice; open-field activity tested 20 min after title comp. challenge (a) acute: 1.0 mg/kg with/without L-NA or L-NAME or D-NAME or MK-801 i.p.; (b) chronic: challenge dose 0.5 mg/kg on day 10 after pretreatment, see kind of dosing
Further Details (Pharmacological Data)
locomotor activation by title comp. and effect of NO-synthase inhibitors NG-nitro-L-arginine (L-NA), its methyl ester (L-NAME), or of NMDA receptor antagonist MK-801; D-NAME = NG-nitro-D-arginine methyl ester
Results
significant increase of locomotor activity by title comp., almost completely blocked by 30 mg/kg L-NA or 100 mg/kg L-NAME both in acute and chronic regimen, by 0.2 mg/kg MK-801 only in chronic regimen; D-NAME had no antagonizing effect
Reference
Ohno; Watanabe
European Journal of Pharmacology, 1995 , vol. 275, # 1 p. 39 - 44 Title/Abstract Full Text View citing articles Show Details
Reaxys Registry Number: 20232066
Molecular Formula: C10H15N*ClH Linear Structure Formula: C10H14(2)HN*ClH
1 prep out of 1 reactions.
1
Chemical Name: acetonitrile ice
no reactions.
1
Molecular Weight: 186.689
InChI Key: TWXDDNPPQUTEOV-XUBZWTSNSA-N
45
Synthesize Find similar
46
Reaxys Registry Number: 30265482
Molecular Formula: C2H3N*C10H15N Linear Structure Formula: C2H3N*C10H15N Molecular Weight: 190.288
InChI Key: XGNXOMUXFOZOSD-FVGYRXGTSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms acetonitrile ice Chemical Name: DL-[13C6]-methamphetamine hydrochloride
2 prep out of 2 reactions.
Reaxys Registry Number: 26969006
CAS Registry Number: 1419916-80-5 Molecular Formula: C10H15N*ClH Linear Structure Formula: C4(13)C6H15N*ClH
Identification Physical Data (1) Spectra (4)
2
Molecular Weight: 191.631
InChI Key: TWXDDNPPQUTEOV-XLGVMALESA-N
47
Synthesize | Hide Details Find similar Chemical Names and Synonyms DL-[13C6]-methamphetamine hydrochloride, DL-[13C6]-methamphetamine hydrochloride Identification Substance Label (1) Label
Reference
1b
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (1) Melting Point
Reference
133.5 - 134.1 °C
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Coupling Nuclei
Solvents (NMR Spectroscopy)
Frequency (NMR Spectroscopy)
Chemical shifts
1H
1H
water-d2
400 MHz
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
water-d2
100 MHz
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
Mass Spectrometry (2)
Reference
Description (Mass Spectrometry)
Reference
electron impact (EI) spectrum
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
high resolution mass spectrometry (HRMS) spectrum
Karlsen, Morten; Liu, Huiling; Berg, Thomas; Johansen, Jon Eigill; Hoff, Bard Helge
Journal of Labelled Compounds and Radiopharmaceuticals, 2014 , vol. 57, # 5 p. 378 - 387 Title/Abstract Full Text View citing articles Show Details
Chemical Name: formamide ice
no reactions.
1
no reactions.
1
no reactions.
3
Reaxys Registry Number: 30250298
Molecular Formula: CH3NO*C10H15N Linear Structure Formula: CH3NO*C10H15N Molecular Weight: 194.277
InChI Key: XVHFCTKZOSOGDK-FVGYRXGTSA-N
48
Synthesize | Hide Details Find similar Chemical Names and Synonyms formamide ice Chemical Name: methamphetamine ethanol Reaxys Registry Number: 29844919
Molecular Formula: C2H6O*C10H15N Linear Structure Formula: C2H6O*C10H15N Molecular Weight: 195.305
InChI Key: MMYWFWOYXAXTQT-UHFFFAOYSA-N
49
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine ethanol Chemical Name: ice ethyl alcohol Reaxys Registry Number: 29867953
Molecular Formula: C2H6O*C10H15N Linear Structure Formula: C2H6O*C10H15N Molecular Weight: 195.305
InChI Key: MMYWFWOYXAXTQT-FVGYRXGTSA-N
50
Synthesize | Hide Details Find similar Chemical Names and Synonyms
ice ethyl alcohol, ethanol ice, ice ethanol Chemical Name: water methanol ice
no reactions.
1
no reactions.
1
no reactions.
1
no reactions.
1
Reaxys Registry Number: 30655327
Molecular Formula: CH4O*C10H15N*H2O Linear Structure Formula: CH4O*C10H15N*H2O Molecular Weight: 199.293
InChI Key: ZNSBDMQCKXEGEI-WWPIYYJJSA-N
51
Synthesize | Hide Details Find similar Chemical Names and Synonyms water methanol ice Chemical Name: acrylonitrile ice Reaxys Registry Number: 30639273
Molecular Formula: C3H3N*C10H15N Linear Structure Formula: C3H3N*C10H15N Molecular Weight: 202.299
InChI Key: GWXHFJDEYQWKPF-FVGYRXGTSA-N
52
Synthesize | Hide Details Find similar Chemical Names and Synonyms acrylonitrile ice Chemical Name: methamphetamine hydrochloride water Reaxys Registry Number: 30656215
Molecular Formula: C10H15N*ClH*H2O Linear Structure Formula: C10H15N*ClH*H2O Molecular Weight: 203.712
InChI Key: ISNOBPWHINYYAZ-UHFFFAOYSA-N
53
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine hydrochloride water Chemical Name: acrolein ice Reaxys Registry Number: 30671867
Molecular Formula: C3H4O*C10H15N
Linear Structure Formula: C3H4O*C10H15N Molecular Weight: 205.3
InChI Key: ITQWMQLXSRJPKZ-FVGYRXGTSA-N
54
Synthesize | Hide Details Find similar Chemical Names and Synonyms acrolein ice Chemical Name: dry ice acetone
no reactions.
2
no reactions.
1
no reactions.
Spectra (2)
2
Reaxys Registry Number: 30426731
Molecular Formula: C3H6O*C10H15N Linear Structure Formula: C3H6O*C10H15N Molecular Weight: 207.316
InChI Key: HJNNWPJYYQQRKA-FVGYRXGTSA-N
55
Synthesize | Hide Details Find similar Chemical Names and Synonyms dry ice acetone, acetone ice Chemical Name: Sodium chloride ice Reaxys Registry Number: 30432865
Molecular Formula: C10H15N*Cl*Na Linear Structure Formula: C10H15N*Cl(1-)*Na(1+)
Molecular Weight: 207.679
InChI Key: GHYPUHAATGFZBQ-WWPIYYJJSA-M
56
Synthesize | Hide Details Find similar Chemical Names and Synonyms Sodium chloride ice Chemical Name: ice acetic acid Reaxys Registry Number: 22269336
CAS Registry Number: 1246496-41-2 Molecular Formula: C2H4O2*C10H15N Linear Structure Formula: C2H4O2*C10H15N Molecular Weight: 209.288
InChI Key: CLVYMGAXECNXBV-FVGYRXGTSA-N
57
Synthesize | Hide Details Find similar Chemical Names and Synonyms ice acetic acid Spectra Mass Spectrometry (2) Description (Mass Spectrometry)
Reference
CID (collision-induced dissociation) Tandem mass spectrometry Spectrum
Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao
International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details
DESI (desorption electrospray ionization) IT (ion trap) LCMS (Liquid chromatography mass spectrometry) Spectrum
Sun, Xiaobo; Miao, Zhixin; Yuan, Zongqian; Harrington, Peter De B.; Colla, Jennifer; Chen, Hao
International Journal of Mass Spectrometry, 2011 , vol. 301, # 1-3 p. 102 - 108 Title/Abstract Full Text View citing articles Show Details
Chemical Name: urea ice
no reactions.
1
no reactions.
1
Reaxys Registry Number: 29844013
Molecular Formula: CH4N2O*C10H15N Linear Structure Formula: CH4N2O*C10H15N Molecular Weight: 209.291
InChI Key: GYKPPPOGKMGVKS-FVGYRXGTSA-N
58
Synthesize | Hide Details Find similar Chemical Names and Synonyms urea ice Chemical Name: dry ice propanol
59
Reaxys Registry Number: 30705902
Molecular Formula: C3H8O*C10H15N Linear Structure Formula: C3H8O*C10H15N Molecular Weight: 209.332
InChI Key: XUIIOIDMDMXGNO-FVGYRXGTSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms dry ice propanol Chemical Name: ethanethiol ice
no reactions.
1
no reactions.
Physical Data (1)
1
no reactions.
1
Reaxys Registry Number: 30676805
Molecular Formula: C2H6S*C10H15N Linear Structure Formula: C2H6S*C10H15N Molecular Weight: 211.371
InChI Key: JRAWJVFUPHBRAF-FVGYRXGTSA-N
60
Synthesize | Hide Details Find similar Chemical Names and Synonyms ethanethiol ice Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; nitrate Reaxys Registry Number: 6099506
Type of Substance: isocyclic Molecular Formula: C10H15N*HNO3
Linear Structure Formula: C10H15N*HNO3
Molecular Weight: 212.249
InChI Key: YZCCVMSXIRFRPB-SBSPUUFOSA-N
61
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; nitrate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Nitrat Physical Data Melting Point (1) Melting Point
Reference
73 - 74 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: ice nitrate
62
Reaxys Registry Number: 30784604
Molecular Formula: C10H15N*HNO3
Linear Structure Formula: C10H15N*HNO3
Molecular Weight: 212.249
InChI Key: YZCCVMSXIRFRPB-FVGYRXGTSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms ice nitrate Chemical Name: Meth methanol
no reactions.
1
no reactions.
2
no reactions.
1
Reaxys Registry Number: 30212679
Molecular Formula: CH4O*C10H15N*ClH Linear Structure Formula: CH4O*C10H15N*ClH Molecular Weight: 217.739
InChI Key: YIVHWUCCLFAUKP-WWPIYYJJSA-N
63
Synthesize | Hide Details Find similar Chemical Names and Synonyms Meth methanol Chemical Name: ice ether Reaxys Registry Number: 30264149
Molecular Formula: C4H10O*C10H15N Linear Structure Formula: C4H10O*C10H15N Molecular Weight: 223.359
InChI Key: BJYJORMDDZABNX-FVGYRXGTSA-N
64
Synthesize | Hide Details Find similar Chemical Names and Synonyms ice ether Chemical Name: silicate ice Reaxys Registry Number: 30053862
Molecular Formula: C10H15N*H2O3Si Linear Structure Formula: C10H15N*H2O3Si Molecular Weight: 227.335
InChI Key: QGFYPZNTXZCRCF-FVGYRXGTSA-N
65
Synthesize | Hide Details Find similar Chemical Names and Synonyms silicate ice Chemical Name: pyrimidine ice
no reactions.
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 30839666
Molecular Formula: C4H4N2*C10H15N Linear Structure Formula: C4H4N2*C10H15N Molecular Weight: 229.325
InChI Key: XROJWYNTLKGLPF-FVGYRXGTSA-N
66
Synthesize | Hide Details Find similar Chemical Names and Synonyms pyrimidine ice Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide Reaxys Registry Number: 6118175
Type of Substance: isocyclic Molecular Formula: BrH*C10H15N Linear Structure Formula: C10H15N*BrH Molecular Weight: 230.148
InChI Key: GPMZKGCPEDRJPV-FVGYRXGTSA-N
67
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Hydrobromid Physical Data Melting Point (1) Melting Point
Reference
151 - 153 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161
Full Text Show Details
Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide
no reactions.
Physical Data (1)
1
no reactions.
2
1 prep out of 1 reactions.
Physical Data (2) Spectra (2)
1
Reaxys Registry Number: 6118176
Type of Substance: isocyclic Molecular Formula: BrH*C10H15N Linear Structure Formula: C10H15N*BrH Molecular Weight: 230.148
InChI Key: GPMZKGCPEDRJPV-SBSPUUFOSA-N
68
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; hydrobromide, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Hydrobromid Physical Data Melting Point (1) Melting Point
Reference
151 - 153 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: hexane dry ice Reaxys Registry Number: 30235479
Molecular Formula: C6H14*C10H15N Linear Structure Formula: C6H14*C10H15N Molecular Weight: 235.413
InChI Key: SYLZFKYURFEYGI-FVGYRXGTSA-N
69
Synthesize | Hide Details Find similar Chemical Names and Synonyms hexane dry ice, hexane ice Chemical Name: methamphetamine oxalate Reaxys Registry Number: 20382304
CAS Registry Number: 175166-06-0 Molecular Formula: C2H2O4*C10H15N Linear Structure Formula: C2H2O4*C10H15N Molecular Weight: 239.271
InChI Key: QBHXOBRIGUCDQX-UHFFFAOYSA-N
70
Synthesize | Hide Details
Find similar Chemical Names and Synonyms methamphetamine oxalate, N,α-dimethyl-2-phenylethylamine oxalate Physical Data Melting Point (1) Melting Point
Reference
149 - 151 °C
Schulze, Matthias
Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details
Crystal Property Description (1) Colour & Other Properties
Reference
white
Schulze, Matthias
Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details
Spectra NMR Spectroscopy (2) Description (NMR Spectroscopy)
Nucleus (NMR Spectroscopy)
Solvents (NMR Spectroscopy)
Frequency (NMR Spectroscopy)
Chemical shifts
1H
dimethylsulfoxide-d6
300 MHz
Schulze, Matthias
Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details
Chemical shifts
13C
dimethylsulfoxide-d6
75 MHz
Schulze, Matthias
Synthetic Communications, 2010 , vol. 40, # 10 p. 1461 - 1476 Title/Abstract Full Text View citing articles Show Details
Chemical Name: phenol ice
Reference
no reactions.
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 30418382
Molecular Formula: C6H6O*C10H15N Linear Structure Formula: C6H6O*C10H15N Molecular Weight: 243.349
InChI Key: NPDCNQZQKBYOOQ-FVGYRXGTSA-N
71
Synthesize | Hide Details Find similar Chemical Names and Synonyms phenol ice Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phosphate
Reaxys Registry Number: 6099766
CAS Registry Number: 942068-47-5 Type of Substance: isocyclic Molecular Formula: C10H15N*H3O4P Linear Structure Formula: C10H15N*H3O4P Molecular Weight: 247.231
InChI Key: LERYZJIMAXSLFC-FVGYRXGTSA-N
72
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phosphate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Phosphat Physical Data Melting Point (1) Melting Point
Solvent (Melting Point)
Reference
197 °C
methanol
Temmler-Werke
Patent: DE871155 , 1938 ; Full Text Show Details
Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; sulfate
no reactions.
Physical Data (1)
1
no reactions.
Identification Bioactivity (7)
1
Reaxys Registry Number: 6099911
CAS Registry Number: 17086-30-5, 20189-61-1, 28297-73-6, 2829774-7, 58670-90-9 Type of Substance: isocyclic Molecular Formula: C10H15N*H2O4S Linear Structure Formula: C10H15N*H2O4S Molecular Weight: 247.315
InChI Key: SOBAVQRLBCJNQT-SBSPUUFOSA-N
73
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; sulfate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Sulfat Physical Data Melting Point (1) Melting Point
Reference
122 - 124 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methamphetamine sulfate
Reaxys Registry Number: 10472660
Type of Substance: isocyclic Molecular Formula: C10H15N*H2O4S Linear Structure Formula: C10H15N*H2O4S Molecular Weight: 247.315
InChI Key: SOBAVQRLBCJNQT-FVGYRXGTSA-N
74
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine sulfate Identification Substance Label (1) Label
Reference
MAP
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Bioactivity Pharmacological Data (7) 1 of 7
2 of 7
Comment (Pharmacological Data)
Bioactivities present
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.3 - 3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 1-1.3 sec schedule; title comp. admin.; after 10 min, effect on number of responses emitted and interresponse times (IRTs) collected as performance indicators during every session
Further Details (Pharmacological Data)
control: saline; illumination of house light in the ceiling, stimulus light above the right lever, signaled the beginning of the sessions; RF: relative frequency; RD: response durations; RDI: response distribution; UW: upward; LW: leftward; CU: curve
Results
title comp. at 0.3 mg/kg, RF of RD increased, as dose increased, RF of RD that were too short, too long to produce the reinforcer increased (progressive flattening of RDI) and CU shifted UW, LW; at higher doses CU did not reach asymptote; diagram
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
3 of 7
4 of 7
5 of 7
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.3 - 3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 4-5.2 sec schedule; title comp. admin.; after 10 min, effect on number of responses emitted and interresponse times (IRTs) collected as performance indicators during every session
Further Details (Pharmacological Data)
control: saline; illumination of house light in the ceiling, stimulus light above the right lever, signaled the beginning of the sessions; UW: upward; CU: curve; CFC: cumulative frequency curves; FQ: frequency; SD: short duration; RES: response
Results
title comp. shifted CFC to UW, left without any change in asymptote; at 1.0 mg/kg, increased in FQ of RES of SD; at 1.7 mg/kg, large increased in short RES occurred; at higher doses, more than 50 percent of RES are short causing CU to shifted UW, left; diagram
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.3 - 3 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 10-13 sec schedule; title comp. admin.; after 10 min, effect on number of responses (RES) emitted and interresponse times (IRTs) collected as performance indicators during every session
Further Details (Pharmacological Data)
control: saline; illumination of house light in ceiling, stimulus light above the right lever, signaled the beginning of sessions; UW: upward; LW: leftward; CFD: cumulative frequency distributions; SRD: short RES duration; AS: asymptotic
Results
title comp. at lower doses shifted CFD to UW, LW (little change in AS portion); increased in relative frequency of SRD, CF shifted LW, more pronounced at higher doses; at 1.7 mg/kg, >50 percent of RES occurred; at 3.0 mg/kg, 67 percent of all RES <1 sec; diagram
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration
0.3 - 5.6 mg/kg
(Pharmacological Data)
6 of 7
7 of 7
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 1-1.3 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied
Further Details (Pharmacological Data)
control: saline; MRD: mean response duration; AC: accuracy
Results
title comp. at 1.0 and 3.0 caused dose-dependent decreased in AC with increasing time duration; had no effect on MRD; had no effect on response rates until dose levels reached that eliminated responding (but at 5.60 mg/kg signif. decreased); table
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.3 - 5.6 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 4-5.2 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied
Further Details (Pharmacological Data)
control: saline; MRD: mean response duration; AC: accuracy
Results
title comp. at 1.0 and 3.0 caused dose-dependent decreased in AC with increasing time duration; large decreased occurred in MRD (5fold); no signif. effect on response rate up to 3 mg/kg (but signif. decrease at 5.6 mg/kg); table
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Effect (Pharmacological Data)
behavioural symptoms
Species or TestSystem (Pharmacological Data)
Sprague-Dawley rat
Sex
male
Route of Application
intraperitoneal
Concentration (Pharmacological Data)
0.3 - 5.6 mg/kg
Kind of Dosing (Pharmacological Data)
title comp. dissolved in saline and admin. in a volume of 1 ml/kg
Method (Pharmacological Data)
rats trained under the temporal response differentiation (TRD) 10-13 sec schedule; title comp. admin.; after 10 min, effect on accuracy, mean interresponse time and response rate studied
Further Details (Pharmacological Data)
control: saline; MRD: mean response duration; AC: accuracy
Results
title comp. at all doses caused dose-dependent decreased in AC with increasing time duration; large decreased occurred in MRD (10-fold); no signif. effect on response rate up to 4.20 mg/kg (but signif. decrease at 5.6 mg/kg); table
Reference
Mcclure; Wenger; Mcmillan
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 281, # 3 p. 1357 - 1367 Title/Abstract Full Text View citing articles Show Details
Chemical Name: ice water, ethyl acetate Reaxys Registry Number: 19666566
Molecular Formula: C4H8O2*C10H15N*H2O Linear Structure Formula: C4H8O2*C10H15N*H2O Molecular Weight: 255.357
InChI Key: OWYKDZCKPRLYNA-WWPIYYJJSA-N
75
0 prep out of 1 reactions.
1
no reactions.
Identification
1
no reactions.
5
Synthesize | Hide Details Find similar Chemical Names and Synonyms ice water, ethyl acetate Chemical Name: meth acrylamide Reaxys Registry Number: 15408256
Molecular Formula: C3H5NO*C10H15N*ClH Linear Structure Formula: C3H5NO*C10H15N*ClH Molecular Weight: 256.776
InChI Key: UOBXUAKQDYKZMZ-WWPIYYJJSA-N
76
Synthesize | Hide Details Find similar Chemical Names and Synonyms meth acrylamide Identification Patent-Specific Data (1) Location in Patent
Reference
Claim
GelTex Pharmaceuticals, Inc.
Patent: US6271264 B1, 2001 ; Title/Abstract Full Text Show Details
Chemical Name: meth acrylic acid
77
Reaxys Registry Number: 30173792
Molecular Formula: C3H4O2*C10H15N*ClH Linear Structure Formula: C3H4O2*C10H15N*ClH Molecular Weight: 257.76
InChI Key: GKLKPLBCJLADSQ-WWPIYYJJSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms meth acrylic acid, meth acrylate Chemical Name: SMA ice
no reactions.
1
no reactions.
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 30655984
Molecular Formula: C2H2ClO2*C10H15N*Na Linear Structure Formula: C2H2ClO2(1-)*C10H15N*Na(1+)
Molecular Weight: 265.715
InChI Key: MOMAUAKHRDBPQK-WWPIYYJJSA-M
78
Synthesize | Hide Details Find similar Chemical Names and Synonyms SMA ice Chemical Name: ICE V Reaxys Registry Number: 30311961
Molecular Formula: C5H11NO2*C10H15N Linear Structure Formula: C5H11NO2*C10H15N Molecular Weight: 266.384
InChI Key: SMCCTKZYRJBKFZ-AGAVTAENSA-N
79
Synthesize | Hide Details Find similar Chemical Names and Synonyms ICE V Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; benzoate Reaxys Registry Number: 6101798
Type of Substance: isocyclic Molecular Formula: C7H6O2*C10H15N Linear Structure Formula: C10H15N*C7H6O2
Molecular Weight: 271.359
InChI Key: NGCJUVZJTGXSGE-SBSPUUFOSA-N
80
Synthesize | Hide Details Find similar Chemical Names and Synonyms
methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Benzoat Physical Data Melting Point (1) Melting Point
Reference
85 - 87 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate
no reactions.
Physical Data (1)
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 6121025
Type of Substance: isocyclic Molecular Formula: C2H2Cl2O2*C10H15N Linear Structure Formula: C10H15N*C2H2Cl2O2
Molecular Weight: 278.178
InChI Key: BVGQWEAQESJUOG-FVGYRXGTSA-N
81
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Dichloracetat Physical Data Melting Point (1) Melting Point
Reference
77 - 79 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate Reaxys Registry Number: 6121026
Type of Substance: isocyclic Molecular Formula: C2H2Cl2O2*C10H15N Linear Structure Formula: C10H15N*C2H2Cl2O2
Molecular Weight: 278.178
InChI Key: BVGQWEAQESJUOG-SBSPUUFOSA-N
82
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; dichloroacetate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Dichloracetat Physical Data Melting Point (1) Melting Point
Reference
76 - 77 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: caprine ice
no reactions.
1
no reactions.
31
no reactions.
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 30710813
Molecular Formula: C6H13NO2*C10H15N Linear Structure Formula: C6H13NO2*C10H15N Molecular Weight: 280.411
InChI Key: YCOHMYYFNVQFGV-LMECJBHSSA-N
83
Synthesize | Hide Details Find similar Chemical Names and Synonyms caprine ice Chemical Name: IDA ICE Reaxys Registry Number: 29628165
Molecular Formula: C4H7NO4*C10H15N Linear Structure Formula: C4H7NO4*C10H15N Molecular Weight: 282.34
InChI Key: VJOFJHXTHDLKJN-FVGYRXGTSA-N
84
Synthesize | Hide Details Find similar Chemical Names and Synonyms IDA ICE Chemical Name: methamphetamine amphetamine Reaxys Registry Number: 29844906
Molecular Formula: C9H13N*C10H15N Linear Structure Formula: C9H13N*C10H15N Molecular Weight: 284.445
InChI Key: GEIDWHRAKJQHQQ-UHFFFAOYSA-N
85
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine amphetamine Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 2-methyl benzoate Reaxys Registry Number: 6102388
Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2
Molecular Weight: 285.386
InChI Key: QVGKMZIGUIAKJJ-SBSPUUFOSA-N
86
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 2-methyl benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; 2-Methyl-benzoat Physical Data Melting Point (1) Melting Point
Reference
70 - 71 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate
no reactions.
Reaxys Registry Number: 6121353
Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2
Molecular Weight: 285.386
InChI Key: GBTLMZBLFVVCKS-FVGYRXGTSA-N
87
Physical Data (1)
1
Physical Data (1)
1
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; 4-Methyl-benzoat Physical Data Melting Point (1) Melting Point
Reference
85 - 87 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate
88
Reaxys Registry Number: 6121354
Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2
Molecular Weight: 285.386
InChI Key: GBTLMZBLFVVCKS-SBSPUUFOSA-N
no reactions.
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; 4-methyl benzoate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; 4-Methyl-benzoat Physical Data Melting Point (1) Melting Point
Reference
85 - 86 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate
no reactions.
Physical Data (1)
1
no reactions.
Physical Data (1)
1
Reaxys Registry Number: 6121427
Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2
Molecular Weight: 285.386
InChI Key: XFAAKZRQUDXEEI-FVGYRXGTSA-N
89
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Phenylacetat Physical Data Melting Point (1) Melting Point
Reference
81 - 82 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate
90
Reaxys Registry Number: 6121428
Type of Substance: isocyclic Molecular Formula: C8H8O2*C10H15N Linear Structure Formula: C10H15N*C8H8O2
Molecular Weight: 285.386
InChI Key: XFAAKZRQUDXEEI-SBSPUUFOSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; phenyl acetate, Methyl-((R)-1-methyl-2-phenyl-aethyl)-amin; Phenylacetat Physical Data Melting Point (1) Melting Point
Reference
80 - 81 °C
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
Chemical Name: ethyl meth acrylate
no reactions.
1
no reactions.
1
Reaxys Registry Number: 30297758
Molecular Formula: C5H8O2*C10H15N*ClH Linear Structure Formula: C5H8O2*C10H15N*ClH Molecular Weight: 285.814
InChI Key: SREKFPXANIMQBH-WWPIYYJJSA-N
91
Synthesize | Hide Details Find similar Chemical Names and Synonyms ethyl meth acrylate Chemical Name: isophorone ice Reaxys Registry Number: 30616718
Molecular Formula: C9H14O*C10H15N Linear Structure Formula: C9H14O*C10H15N Molecular Weight: 287.445
InChI Key: JSKWQGNPDQRXPR-FVGYRXGTSA-N
92
Synthesize | Hide Details Find similar Chemical Names and Synonyms
isophorone ice Chemical Name: methamphetamine depen
no reactions.
1
no reactions.
Identification Physical Data (7)
3
Reaxys Registry Number: 30138018
Molecular Formula: C5H11NO2S*C10H15N Linear Structure Formula: C5H11NO2S*C10H15N Molecular Weight: 298.45
InChI Key: AMIDPTMDMUWREW-SCKZZFMESA-N
93
Synthesize | Hide Details Find similar Chemical Names and Synonyms methamphetamine depen Chemical Name: (S)-methamphetamine (2R,3R)-tartrate Reaxys Registry Number: 5488465
CAS Registry Number: 7487-70-9, 32359-31-2, 62265-33-2, 6544027-9, 90027-30-8, 93777-08-3, 140166-94-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-FVGYRXGTSA-N
94
Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-methamphetamine (2R,3R)-tartrate, methyl-((S)-1-methyl-2-phenyl-ethyl)-amine; Dg-hydrogentartrate, Methyl-((S)-1-methyl-2-phenyl-aethyl)amin; Dg-Hydrogentartrat, Methyl-((S)-1-methyl-2-phenyl-aethyl)-amin; Lg-Hydrogentartrat Identification Substance Label (1) Label
Reference
(S)-4*(2R,3R)-8
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (4) Melting Point
Solvent (Melting Point)
Reference
113.85 °C
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
115 - 117 °C
ethanol
Walton
Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details
164 - 165 °C
H2O
Walton
Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details
118 - 119 °C
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Enthalpy of Fusion (1) Enthalpy of Fusion
Reference
35900 Jmol-1
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (2) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
c=3
H2O
24.7 deg
589 nm
16 °C
Walton
Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details
[alpha]
c=0.8
H2O
-3.2 deg
589 nm
16 °C
Walton
Journal of the Society of Chemical Industry, London, 1945 , vol. 64, p. 219 Full Text Show Details
Chemical Name: (R)-methamphetamine (2R,3R)-tartrate
Reference
no reactions.
Reaxys Registry Number: 5488466
CAS Registry Number: 7487-70-9, 32359-31-2, 62265-33-2, 6544027-9, 90027-30-8, 93777-08-3, 140166-94-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-SBSPUUFOSA-N
95
Identification Physical Data (5)
Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-methamphetamine (2R,3R)-tartrate, methyl-((R)-1-methyl-2-phenyl-ethyl)-amine; Lg-hydrogentartrate, Methyl-((R)-1-methyl-2-phenyl-aethyl)amin; Lg-Hydrogentartrat Identification Substance Label (1) Label
Reference
(R)-4*(2R,3R)-8
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (3) Melting Point
Solvent (Melting Point)
Reference
163.85 °C
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
3
164 - 166 °C
ethanol
Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
165 - 166 °C
Ogata
Yakugaku Zasshi, 1919 , # 451 p. 751 Chem.Abstr., 1920 , vol. 14, p. 745 Full Text Show Details
Enthalpy of Fusion (1) Enthalpy of Fusion
Reference
50000 Jmol-1
Kozma, David; Pokol, Gyoergy; Acs, Maria
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1992 , # 3 p. 435 - 440 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
[alpha]
H2O
5.15 deg
589 nm
Chemical Name: (S)-(+)-N-methylamphetamine (RR)-tartrate Reaxys Registry Number: 6081392
CAS Registry Number: 179805-09-5 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-WGTXBUCSSA-N
96
Reference Chiang; Li
Journal of the Chinese Chemical Society (Peking), 1951 , vol. 18, p. 161 Full Text Show Details
1 prep out of 1 reactions.
Identification Physical Data (9)
Synthesize | Hide Details Find similar Chemical Names and Synonyms (S)-(+)-N-methylamphetamine (RR)-tartrate Identification Substance Label (1) Label
Reference
SMERTA
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Related Structure (1) Related Structure
Reference
The author investigated the configuration
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (1)
1
Melting Point
Solvent (Melting Point)
Comment (Melting Point)
114 - 115 °C
ethanol
Decomposition
Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Density (1) Density
Type (Density)
Reference
1.292 g·cm-3
crystallographic
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Crystal Phase (1) Description (Crystal Phase) Crystal structure determination
Comment (Crystal Phase)
Reference
β=93.9 grad, a=14.38 Angstroem, b=6.85 Angstroem, c=7.83 Angstroem, n=2. Temperature: 30 C. Method of determination: X-ray Diffraction
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (19721999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Crystal System (1) Crystal System
Reference
monoclinic
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Enthalpy of Fusion (1) Enthalpy of Fusion
Reference
70000 Jmol-1
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Interatomic Distances and Angles (1) Description
Reference
Interatomic distances and angles
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
5 g/100ml
H2O
22.1 deg
589 nm
20 °C
Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Solubility (MCS) (1) Saturation in pure solvent
Temperature (Solubility (MCS))
Solvent (Solubility (MCS))
Comment (Solubility (MCS))
20 °C
ethanol
Solubility: 4.10 p(g/100g solution)
Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886
Title/Abstract Full Text View citing articles Show Details
Space Group (1) Space Group
Reference
4
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Chemical Name: (R)-(-)-N-methylamphetamine (RR)-tartrate Reaxys Registry Number: 6081393
CAS Registry Number: 170591-59-0 Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-VXLLBCKSSA-N
97
1 prep out of 1 reactions.
Identification Physical Data (9)
Synthesize | Hide Details Find similar Chemical Names and Synonyms (R)-(-)-N-methylamphetamine (RR)-tartrate Identification Substance Label (1) Label
Reference
RMERTA
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Related Structure (1) Related Structure
Reference
The author investigated the configuration
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (1) Melting Point
Solvent (Melting Point)
Reference
163 - 164 °C
ethanol
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Density (1) Density
Type (Density)
Reference
1.331 g·cm-3
crystallographic
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Crystal Phase (1) Description (Crystal
Comment (Crystal Phase)
Reference
1
Phase) Crystal structure determination
β=91.4 grad, a=14.04 Angstroem, b=6.9 Angstroem, c=7.72 Angstroem, n=2. Temperature: 30 C. Method of determination: X-ray Diffraction
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (19721999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Crystal System (1) Crystal System
Reference
monoclinic
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Enthalpy of Fusion (1) Enthalpy of Fusion
Reference
48800 Jmol-1
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Interatomic Distances and Angles (1) Description
Reference
Interatomic distances and angles
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
5 g/100ml
H2O
4.77 deg
589 nm
20 °C
Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Solubility (MCS) (1) Saturation in pure solvent
Temperature (Solubility (MCS))
Solvent (Solubility (MCS))
Comment (Solubility (MCS))
20 °C
ethanol
Solubility: 0.16 p(g/100g solution)
Reference Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Space Group (1) Space Group
Reference
4
Fogassy, Elemer; Acs, Maria; Faigl, Ferenc; Simon, Kalman; Rohonczy, Janos; Ecsery, Zoltan
Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1986 , p. 1881 - 1886 Title/Abstract Full Text View citing articles Show Details
Reaxys Registry Number: 6835793
Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-LREBCSMRSA-N
no reactions.
Identification Physical Data (4)
1
98
Synthesize | Hide Details Find similar
Identification Substance Label (1) Label
Reference
III-R,R-XIII
Kozma, David; Acs, Maria; Fogassy, Elemer
Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (2) Melting Point
Reference
113.85 °C
Kozma, David; Acs, Maria; Fogassy, Elemer
Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details
163.85 °C
Kozma, David; Acs, Maria; Fogassy, Elemer
Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details
Enthalpy of Fusion (2) Enthalpy of Fusion
Reference
35880 Jmol-1
Kozma, David; Acs, Maria; Fogassy, Elemer
Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details
49040 Jmol-1
Kozma, David; Acs, Maria; Fogassy, Elemer
Tetrahedron, 1994 , vol. 50, # 23 p. 6907 - 6912 Title/Abstract Full Text View citing articles Show Details
Reaxys Registry Number: 7454315
Type of Substance: isocyclic Molecular Formula: C4H6O6*C10H15N Linear Structure Formula: C10H15N*C4H6O6
Molecular Weight: 299.324
InChI Key: SOSGXQJCXKXQCB-KZKMUFAMSA-N
99
Synthesize | Hide Details Find similar
1 prep out of 1 reactions.
Identification Physical Data (2)
1
Identification Substance Label (1) Label
Reference
(R)-4 salt
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
Physical Data Melting Point (1) Melting Point
Solvent (Melting Point)
Reference
162 - 164 °C
H2O
Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Concentration (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
Temperature (Optical Rotatory Power)
[alpha]
0.8 g/100ml
H2O
4.4 deg
589 nm
20 °C
Reference Crock, Piero Dalla; Ferraccioli, Raffaella; Rosa, Concetta L.A.
Gazzetta Chimica Italiana, 1996 , vol. 126, # 2 p. 107 - 109 Title/Abstract Full Text View citing articles Show Details